



Section One

A GLOBAL PERSPECTIVE





Section One A Global Perspective

The Global State of Tobacco Harm Reduction 2024: A Situation Report

©Knowledge-Action-Change 2024

The Global State of Tobacco Harm Reduction 2024: A Situation Report

ISBN: 978-1-7398231-0-8

Executive Editor and Lead Author: Harry Shapiro

Co-Authors: Tomasz Jerzyński, Giorgi Mzhavanadze and Oliver Porritt

Editor: Ruth Goldsmith

Report and website production coordination: Grzegorz Król

Report design and layout: WEDA sc; Urszula Biskupska

Print: WEDA sc.

Project Manager: David MacKintosh

The full report is available to download in PDF and to read online in HTML at the Global State of Tobacco Harm Reduction website, https://gsthr.org.

Knowledge·Action·Change, 8 Northumberland Avenue, London, WC2N 5BY

© Knowledge Action Change 2024

Citation: The Global State of Tobacco Harm Reduction 2024: A Situation Report. London: Knowledge·Action·Change, 2024.

The conception, design, analysis, and writing of The Global State of Tobacco Harm Reduction 2024: A Situation Report was undertaken independently and exclusively by Knowledge-Action-Change.

This report was funded with a grant from Global Action to End Smoking (formerly known as Foundation for Smoke-Free World), an independent, U.S. nonprofit 501(c) (3) grant making organization, accelerating science-based efforts worldwide to end the smoking epidemic. Global Action played no role in designing, implementing, data analysis, or interpretation of the report nor did Global Action edit or approve any presentations or publications from the report. The contents, selection, and presentation of facts, as well as any opinions expressed, are the sole responsibility of the authors and should not be regarded as reflecting the positions of Global Action to End Smoking.

Contents

Section One

A global perspective	
Chapter One: The global smoking epidemic and the role of tobacco harm reduction	.8
Chapter Two: The evidence for tobacco harm reduction	17
Chapter Three: Global progress towards tobacco harm reduction	30
Chapter Four: Global regulation and control	57
Chapter Five: The challenges to tobacco harm reduction	34
Chapter Six: Conclusions	98
Regional and national insights	
Section Two Latin AmericaBook	: 2
Section Three Eastern Europe and Central AsiaBook	: 3
Section Four Japan Book	: 4
Section Five Aotearoa New ZealandBook	c 5
Section Six NorwayBook	: 6
Section Seven	

United Kingdom.....Book 7

Introduction

Key concepts



Tobacco harm reduction (THR) is a potentially life-saving public health intervention for millions of people worldwide who currently use high-risk tobacco products. It offers people the chance to switch to a range of **safer nicotine products (SNP)** that pose significantly fewer risks to health.

Most people know that using tobacco is harmful to health, and that people use tobacco to consume **nicotine**. It is less well known that nicotine itself does not cause the severe illnesses associated with high-risk tobacco use. Nicotine is a comparatively low-risk drug, but its effects encourage repeated use. This is one of the reasons people find it hard to stop smoking, even when they know it is bad for their health.

The most dangerous way of using nicotine is by burning a cigarette and inhaling the smoke. Burning tobacco releases tar and gases containing thousands of toxins, many of which pose a risk of severe illness, leading to premature death in half of all smokers.

SNP are non-combustible: none of them burn tobacco and some do not contain any tobacco at all. They include **nicotine vapes (e-cigarettes)**, tobacco-free **nicotine pouches**, Swedish-style **snus** (an oral tobacco), many US smokeless (chewing) tobaccos and **heated tobacco products (HTP)**. Many of these products have only been developed in the last 10 - 15 years.

In public health, **harm reduction** reduces health risks by providing people with safer alternative products and/or encouraging less risky behaviours, rather than by banning those products or behaviours. It emerged in the fight against HIV/AIDS in the 1980s and has since developed into a range of evidence-based, humane and cost-effective practices that save countless lives every year.

Harm reduction is a political and social justice issue as well as a public health one. International treaties make it clear that health is a universal right, and the UN has accepted that harm reduction for people who use drugs is part of the right to health. The 1.1 billion people worldwide who smoke have the same right to health as anyone else.

The Global State of Tobacco Harm Reduction

The Global State of Tobacco Harm Reduction (GSTHR) is a multi-component project that provides information and resources on THR for specialist and non-specialist audiences. The GSTHR aims:

- to generate and communicate information and evidence about THR;
- \Rightarrow to map the global, regional and national availability, use of and regulatory responses to SNP;
- to provide high quality policy-focused information, critical analyses and resources on THR;
- to foster local development and implementation of THR.

The GSTHR website (https://gsthr.org) provides researchers, academics, policymakers and media with a unique tool to deepen their understanding of THR. Powered by the world's largest THR database, the free-to-access online resource supplies data on the use, availability and regulation of SNP, as well as smoking prevalence and mortality, across over 200 countries and regions.

The GSTHR's publications, including biennial reports such as this, thematic reports and briefing papers, are available in up to 13 languages, making THR concepts accessible to a global audience. The previous biennial reports (2018, 2020, 2022) document the history, development and potential future of THR, otherwise largely overlooked. These three reports therefore provide a valuable insight into the scientific, policy and social evolution of THR, and are a valued resource to those operating and studying this subject area.

All GSTHR publications can be accessed at https://gsthr.org

The previous GSTHR biennial reports

The first GSTHR report, *No Fire, No Smoke* (2018), set out the importance of THR in the context of the global smoking epidemic. It documented the growing interest from existing nicotine consumers, the supporting evidence for THR relative to smoking, the range of SNP available and the regulation and controls to which they were subject. *No Fire, No Smoke* offered a baseline for the use and regulation of SNP as of 2018.

As global use of SNP increased, it became evident that there was rapidly developing and well-resourced opposition to their use. This reflected both the barriers faced by new innovations across many fields, as well as elements of traditional tobacco control which opposed THR in principle. Delineating this opposition was a key focus of the second report, *Burning Issues* (2020), published in English, Chinese, French, Spanish and Russian.

The Right Side of History (2022), the third in the series, was published in English, Chinese and French. The report draws on interviews with consumers, THR advocates, and people both from the tobacco industry and tobacco control. Documenting the failed experiments of the tobacco industry to make a 'safer cigarette', and the technological revolution of the first commercially viable vaping products, The Right Side of History is the only global report to track the development of SNP over time.

The fourth GSTHR report

This publication, the fourth in the series, takes a new approach, offering a status or situation report for THR in 2024. We assess global progress towards acceptance of the principles of THR, changes in the uptake of SNP, and changes in policy and regulation.

The extent to which SNP are replacing and substituting for combustible tobacco products and risky oral tobaccos is the central theme. Our analysis considers what is driving these changes, how different regulatory environments have developed, and the complex interplay between products, consumers, and policy and regulation.

The report is the result of collaborative work by the GSTHR cluster, supported by the K·A·C technical team. It draws on multiple publicly available sources of information including market data, regulatory regimes, data on the epidemiology of smoking and use of SNP, and the extensive country-based information held in the online GSTHR database. It also draws on information from an extensive network of colleagues globally, built up through the GSTHR's external engagement work. Other sources include academic journals, tobacco policy papers and research, market analyses, government websites, international tobacco control monitoring, mainstream and specialist journalism and social media commentary.

We are also grateful for the time and expertise offered by key individuals who provided information through conversations, email exchanges and the supply of documents.



2018



2020



2022



Report overview

The Global State of Tobacco Harm Reduction 2024: A situation report is a multi-component publication, grouped into two parts, A global perspective and Regional and national insights. The extent to which SNP are replacing and substituting for combustible and risky oral tobacco products is the unifying theme.

A global perspective uses the latest evidence and new data projections to report on the current global THR situation and its potential to rapidly reduce the burden of disease and mortality associated with risky tobacco use. Measuring changes in SNP uptake, policy and regulation, it considers how these factors interrelate to support or undermine progress.

Chapter One: The global smoking epidemic and the role of tobacco harm reduction

After two decades of the WHO FCTC, smoking remains the leading cause of non-communicable diseases, disproportionately impacting people living in low- and middle-income countries as well as vulnerable groups elsewhere. THR using SNP could change this.

Chapter Two: The evidence for tobacco harm reduction

THR's path from concept to real-world application, via creative disruption and consumer-led development. We explore the latest large-scale scientific studies on SNP for smoking cessation and comparisons with NRT, and hear from consumers who successfully quit by switching.

Chapter Three: Global progress towards tobacco harm reduction

Are SNP reducing or replacing smoking yet? A look at current evidence, from population-wide studies to seismic shocks on the markets. Are tobacco companies really intent on change? New GSTHR modelling reveals the global number of vapers – and projects lives saved by SNP.

Chapter Four: Global regulation and control

A focus on FCTC COP meetings considers how the WHO's position on SNP developed. But despite the WHO urging prohibition, the global regulatory picture is varied. We reveal what percentage of the world's population can legally access SNP. GSTHR analysis of regulation and a deep dive into tax policies seek best practice options to facilitate THR.

Chapter Five: The challenges to tobacco harm reduction

Obstacles to THR are manifold, and include outright opposition from numerous sources. This fuels media reporting and underpins negative beliefs about SNP among health professionals, the wider public and adults who smoke. They are the ones with the most to lose.

Chapter Six: Conclusions

What does this report tell us about how we can facilitate THR and hasten the end of smoking as fast as possible?



Latin America

Latin America hosts several tobacco-producing nations - and large populations mean high numbers of people who smoke. Consumers can purchase SNP in most countries, but often from unregulated sources. Responses to SNP are shaped by outside influences, despite the efforts of active consumers.

Eastern Europe and Central Asia

With relatively late implementation of tobacco control measures in the post-Soviet era, high rates of smoking and risky oral product use persist across the region. SNP uptake is comparatively low, and recognition of THR virtually non-existent. The current trend towards heavy restrictions or prohibition of SNP risks undermining the potential of THR in the region even further.

Cigarette sales halved: heated tobacco products and the Japanese experience


Pro-consumer laws and an endorsement for vaping: why smoking is disappearing in Aotearoa New Zealand

How snus is replacing smoking in Norway: a revolution led by consumers and product innovation

A smokefree UK? How research, policy and vapes have cut smoking rates

Chapter One: The global smoking epidemic and the role of tobacco harm reduction

Statistics on the health impacts of smoking are alarming. There are currently over one billion smokers worldwide, resulting in 8.9 million deaths from smoking-related diseases every year (7.69m from smoking; 1.30m from secondhand smoke). The annual death toll has increased by nearly two million deaths since 1990, likely as a consequence of population growth.





one billion people could die from smoking by the end of this century

smoking is responsible for around one in six non-communicable disease deaths

millions of people have not quit smoking [and] are still at risk of serious disease and death The twentieth century saw an estimated 100 million deaths from smoking, mainly in higher income countries (HIC).¹ Now, around 80% of people who smoke live in low- and middle-income countries (LMIC). Around one billion people could die from smoking by the end of this century.² At least half of all those who do not or cannot stop smoking will die prematurely.

Smoking is the primary risk factor for non-communicable disease (NCD) and contributes significantly to the global NCD burden. The annual death toll from smoking-related disease is more than the combined total from infectious diseases such as malaria (630,000), HIV (720,000) and tuberculosis (1.16 million).^{3,4} It is also more than all known deaths from COVID, currently at an estimated seven million.⁵

Smoking is responsible for around one in six NCD deaths. 6 It causes cardiovascular disease, lung diseases including cancer, and cancers that affect many other parts of the body. Each year, 17 million people die from a NCD before the age of 70 – with 86% of these premature deaths occurring in LMICs. 7

As their impact is more keenly felt worldwide, tackling NCDs and their causes has risen up the global public health agenda. The Sustainable Development Goals (SDGs) are a United Nations initiative, formally adopted by the UN General Assembly on 25

September 2015 in a resolution entitled *Transforming our world: the 2030 Agenda for Sustainable Development*. The resolution includes 17 goals and 169 targets, all of which were set to be achieved by 2030. Their aim was to "end poverty, protect the planet, and ensure prosperity for all as part of a new sustainable development agenda". Reducing tobacco use (predominantly by reducing smoking) would be essential if the goals on reducing NCDs were to be achieved by the 2030 deadline.⁸ In fact, very few of the SDGs will be.⁹

Smoking prevalence has been falling in most countries over the past two decades, and longer in some HIC. Many countries have witnessed dramatic falls in smoking. However, the graphs are now beginning to level off. There are millions of people who have not quit smoking who are still at risk of serious disease and death.

In at least 60 countries, 30% or more of the male population are current tobacco smokers. ¹⁰ In 30 of those countries, that figure is over 40%, and in several it exceeds 50%, with some of those still seeing year-on-year increases.

Data on smoking rates do not include the estimated 300 million people worldwide who use dangerous smokeless products like nasvay, gutka and betel. These products, use of which is concentrated mainly in LMIC in Central, South and Southeast Asia, are implicated in high rates of oral cancer.¹¹

Hidden in plain sight?

In HIC, where general population smoking rates have been falling for longer, smoking now tends to impact most dramatically on our most vulnerable and marginalised communities. Those with mental health, drug and alcohol problems, members of the LGBTQ+ communities and indigenous groups as well as those experiencing poverty and deprivation all smoke at far higher rates than general populations.¹²

The concentration of smoking among people of lower socioeconomic backgrounds and other marginalised groups is affecting the debate about the potential of SNP to reduce smoking-related harm. That is because in HIC, the adult smoker – generally poorer, older – is often hidden in plain sight. Meanwhile, concerns about youth vaping are extremely prominent.

In *The American Journal of Public Health in 2021*, David J.K. Balfour, Neal L. Benowitz and colleagues published 'Balancing Consideration of the Risks and Benefits of E-Cigarettes'. What they noted about American society can equally apply in many HIC:

"To the more privileged members of society, today's smokers may be nearly invisible. Indeed, many affluent, educated US persons may believe the problem of smoking has been largely 'solved'. They do not smoke. Their friends and colleagues do not smoke. There is no smoking in their workplaces nor in the restaurants and bars they frequent. Yet 1 of every 7 US adults remains a smoker today." ¹³

Similar perceptions probably apply to medical and public health officials who occupy the same social strata, some of whom perceive the problems smokers face as a situation of their own making. This may partly explain the opposition to tobacco harm reduction from many in the tobacco control community; their approach can be starkly expressed as 'quit or die'.

However, it is at the human level that the real impact of smoking is felt. Many of us have watched a family member or friend dying of lung cancer, or suffering from COPD





smoking now tends to impact most dramatically on our most vulnerable and marginalised communities

"many affluent, educated US persons may believe the problem of smoking has been largely 'solved'" (Balfour, Benowitz et al)

it is at the human level that the real impact of smoking is felt

or emphysema, living hooked up to an oxygen machine. Many of us know someone who, once active on the sports field, can hardly manage the stairs without stopping to catch their breath. We may know of families struggling to make ends meet, because the main breadwinner has succumbed to a smoking-related disease. Imagine being the doctor having to tell a middle-aged patient they won't see their grandchildren growing up. Imagine being that patient. The tragic stories of smoking's legacy are global and legion.

The business of tobacco

Despite the undeniable, well-documented, and well-publicised reality of smoking harms, millions of people continue smoking, fuelling a highly profitable global tobacco industry. One firm of market analysts has forecast that global revenue from tobacco products, which has risen year on year for over a decade, will hit one trillion US dollars by 2027.¹⁴



In some HIC, such as the US, UK and Japan, cigarette sales are in long-term decline. The top multinationals have reacted by increasing their non-combustible portfolios. In July 2024, Philip Morris International reported that smoke-free products accounted for 38.1% of the company's total net revenues, an increase of 2.7 percentage points on the same quarter the previous year. 15

In December 2023, British American Tobacco (BAT) announced it was writing down the value of its major US combustible brands, Lucky Strike and Newport, by £25bn. 16 It attributed the downrating both to the impact of macroeconomic conditions and the huge popularity of "illicit modern disposables". This indicates that BAT's business is not only suffering because there are fewer smokers. It is also that those same smokers are switching to single-use devices, often obtained through the illegal market – devices that are in competition with BAT's own primary vaping product, Vuse. 17

But in reality, for the multinational tobacco companies, the core business remains combustibles. The return on investment is substantial and the profits consequentially massive because the basic product, the cigarette, has hardly changed in a hundred years. It remains a plug of tobacco leaf wrapped up in paper.

Tobacco and the state

Governments around the world have a complicated relationship with tobacco. Many countries benefit from income generated by tobacco production and the numbers gainfully employed by the tobacco industry – and in some, there are even state-owned or state-involved tobacco companies. The vast majority of countries also benefit from the tax revenue generated by tobacco sales. But every country must also contend with the economic impacts of huge numbers of people who are ill, disabled, cannot work or die prematurely due to smoking-related diseases.

About six million metric tons of tobacco are produced each year in some 120 countries, with 80 per cent of production coming from LMICs and 70 per cent from six countries: Brazil, China, India, Indonesia, the United States and Zimbabwe. 18

According to a report from the International Labour Organization in 2003, around 100 million people are employed worldwide in the tobacco industry. But only about 1.2 million are employed in manufacturing. Some 40 million work in growing and leaf processing, 20 million more in home industries such as hand-rolling bidi or kretek



cigarettes in India and Indonesia, and the rest in tobacco-related processes and industries ranging through distribution and sales. ¹⁹ Employment levels within the industry are falling, but still the global tobacco labour market is substantial. This is particularly the case in countries such as India and Indonesia, where millions of otherwise impoverished people rely on the industry for their primary source of income. ²⁰

Globally, 18 governments have investments of 10% or more in domestic tobacco product manufacture, mainly cigarettes. Eight have a state tobacco monopoly; three more own majority stakes of between 51 – 91% of their domestic industry.²¹ The Chinese National Tobacco Company (CNTC) is one such state-owned monopoly, and is the largest manufacturer of cigarettes in the world.

Even if not directly involved in manufacture and sale of tobacco products, governments benefit from their sale through tax regimes. The WHO calculated that in 2018, the duty, or excise tax, paid on cigarettes raised \$360 billion USD worldwide, of which \$162 billion USD went to governments in LMIC. It's estimated that a further \$31 billion USD would be added to the global total if the illegal market in tobacco could be eliminated.²²

Combining import and domestic taxes on tobacco products, the export revenue from the world's major growing countries, and the income from state-involved or owned tobacco industries, it is clear that tobacco use and production brings huge benefits to the treasuries of most countries in the world. Yet tobacco use also brings major economic costs. The annual health expenditure costs and productivity losses associated with smoking have been calculated at nearly 2% of global gross domestic product: that's a staggering \$2 trillion USD.

Nevertheless, many governments have strong financial, political and social drivers towards maintenance of a vigorous trade in tobacco, which seemingly override societal costs. In addition, through official corruption and weak governance, illegal cigarettes dominate the cigarette economy in many LMIC. The tobacco control community argue that raising taxes is the most effective way of decreasing overall consumption. But generally, imposing a strict tax regime only works in HIC, where the legal market in cigarettes predominates and where robust tax enforcement structures exist. In many LMIC, where the illicit market dominates instead, tax policies are inoperable (see also our section on tax in Chapter Four of this report).

Many governments rely on tobacco not just for income, but in some cases political survival. If the state is more concerned with generating revenue than with the health of its population – a state which may well regard smoking-related disease as self-inflicted – what incentive is there for governments to provide comprehensive smoking cessation programmes? To compound the problem, most smokers live in the poorest countries, already burdened with other health priorities, yet without the health infrastructure to cope.

Failing the adult smoker

The complications of economic interests aside, the vast majority of governments do need to put – or at least, be seen to put – the health of their populations first. After the international public health community decided action had to be taken on smoking, eventually over 180 countries committed to doing so.

For much of the 20th century, smoking-related death and disease was largely an issue for higher income countries. The WHO therefore regarded this as a problem for those countries to deal with domestically – as it focused on tackling the deadly communicable diseases affecting LMIC. But a changing global economic climate, as much as a growing public health imperative, highlighted the need for more concerted action at an international level. The growth of a transnational tobacco industry needed to be countered by a transnational agreement on tobacco control.²³

The WHO Framework Convention on Tobacco Control (FCTC) is the international agreement that was developed in response to the global nature of the public health challenge of tobacco use and smoking. ²⁴ Enacted in 2005, its specific aim is to reduce smoking-related death and disease. The FCTC's guidelines – in the WHO's words – "provide the foundation for countries to implement and manage tobacco control". To oversee the progress of Parties in implementing the FCTC, the WHO introduced a monitoring system in 2007, in partnership with Bloomberg Philanthropies; the MPOWER measures "are intended to assist in the country-level implementation of effective interventions to reduce the demand for tobacco, contained in the WHO FCTC". ²⁵

MPOWER is an acronym, which stands for:

Monitor tobacco use

Protect people from tobacco smoke;

Offer help to quit tobacco use;

Warn about the dangers of tobacco;

Enforce bans on tobacco advertising,
promotion and sponsorship; and

Raise taxes on tobacco.




In its annual 'Reports on the global tobacco epidemic', the WHO provides updates on the number of countries that have implemented MPOWER measures, and what level of implementation they have achieved. In 2023, the WHO reported that, as of 2022, 151 countries had achieved at least one MPOWER measure at the 'highest level of achievement'. According to the WHO, this means 5.6 billion people, or 71% of the world's population, are "covered" by at least one MPOWER measure.²⁶

The problem is that many of the MPOWER goals, such as smoking bans or bans on sales to minors, simply involve putting legislation on the statute book, or engaging in activity like a public health campaign. While laws may be passed, many countries, particularly LMIC, do not have sufficient enforcement capacity to deliver on bans of any kind, so nothing changes on the ground. Meanwhile, public health campaigns tend to celebrate outputs rather than outcomes. It could be argued that the same can be said for much of MPOWER itself.

One obvious way to effect population-wide health changes would be to significantly improve smoking cessation services for people who want to quit. However, the WHO admits that this is the weakest part of the global tobacco control landscape. 'Offering help to quit tobacco' – the 'O' in MPOWER – is also, not coincidentally, one of the most expensive measures for countries to implement. In 2021, the WHO acknowledged that cessation services are "insufficient and unavailable in much of the world", and that they had been "further neglected" as a consequence of the COVID pandemic.²⁷

What does the global landscape for the availability of Nicotine Replacement Therapy (NRT) look like?



The map does not provide the full picture, however, it only shows where NRT products can be legally marketed by the pharmaceutical companies that manufacture them. The fact that legislation allows NRT to be sold does not mean that people who smoke can easily access it.

In some HIC, people can go to their healthcare provider or dedicated smoking cessation service, and obtain NRT for free. People may also be able to purchase NRT over the counter from pharmacies or other retailers.

But in many LMIC, home to four in every five people who smoke, accessing NRT may be a different story. For example, while NRT is officially available in India, its cost may be beyond the reach of people living in poverty. It is reported that health centres have few supplies, and access is set to become even more restricted following a recent decision to make the products available only on prescription.²⁹

What else can be done?

After two decades of the FCTC, at least one billion people smoke, and there are over eight million smoking-related deaths every year. Writing in *The Lancet* in 2022, Robert Beaglehole and Ruth Bonita, both emeritus professors at the University of Auckland and both global experts on the prevention of NCDs, shared this assessment:

"Tobacco control is not working for most of the world. Four out of five of the world's smokers are in LMIC. In these countries where most of the eight million deaths caused by tobacco occur each year, rates of tobacco use are falling only slowly. Globally, the overall number of tobacco users has barely changed [...]
[M]ost countries are not on track to achieve the SDG 3.4 for non-communicable diseases; its achievement will require a much more ambitious tobacco target [...]
The FCTC is no longer fit for purpose, especially for low-income countries." 30

These conclusions are particularly damning given that both formerly worked at the WHO; Beaglehole was Director of the Department of Chronic Diseases and Health Promotion, while Bonita was Director of Surveillance in the NCD Cluster.



the growth of a transnational tobacco industry needed a transnational agreement on tobacco control

the FCTC's specific aim is to reduce smoking-related death and disease

many MPOWER goals simply involve putting legislation on the statute book

in 2021, the WHO acknowledged that cessation services are "insufficient and unavailable in much of the world"

the fact that legislation allows NRT to be sold does not mean that people who smoke can easily access it





"the FCTC is no longer fit for purpose, especially for low-income countries" (Beaglehole and Bonita)

it is imperative to encourage people who do not want to or cannot quit smoking to switch to less dangerous ways of consuming nicotine

harm reduction drills to the heart of the universal right to health

the harm reduction movement was first initiated not by doctors or public health officials but communities affected by HIV and AIDS

the key element is the reduction of, or complete substitution for, risky tobacco use

choice is important as consumers may need to experiment to find which SNP works for them

People continue to smoke primarily because of the reinforcing properties of nicotine. Yet it is not nicotine that causes tobacco-related disease, but the toxins released in smoke when tobacco burns. Therefore, in addition to whatever tobacco control policies are deemed expedient, it is imperative to try and encourage people who do not want to or cannot quit smoking to switch to significantly less dangerous ways of consuming nicotine. This is the principle behind tobacco harm reduction. 31,32

Tobacco harm reduction

Harm reduction is often explained by reference to car seatbelts. Driving is risky. But no government would ban people from driving because it carries a risk of harm. Seatbelts do not eliminate the risks associated with driving, but their use significantly decreases the chance of serious injury in most collisions. Seatbelts save lives.

This is a reasonable analogy as far as it goes. But harm reduction is not just about health and safety. As it applies to drug use and HIV/AIDS prevention - and now tobacco - harm reduction drills to the heart of the universal right to health.

The universal right to health was one of the founding principles of the WHO when it was established in 1948. Although not explicitly stated, it follows that this right must be extended to every citizen, even if they are engaging in activities which may earn the disapproval of wider society.

It was this principle that lay at the heart of the harm reduction movement of the 1980s. The movement was initiated not by doctors or public health officials, but by gay and drug-injecting communities affected by HIV and AIDS. These communities knew that, despite the fear of contracting HIV, people would continue to inject drugs or have risky sex; simply advising abstinence would not work. It was therefore both pragmatic and compassionate to ensure people could access help that would reduce their risk of harm and the onward transmission of the virus to others. This included the provision of condoms, clean needles and opiate-based medicines. enabling people who used heroin to reduce their intake or switch completely, helping stabilise otherwise chaotic lives.

Under a harm reduction approach for tobacco, where nicotine abstinence is unachievable, the substitution of SNP for smoking represents a net benefit both to individuals and to public health.

People who cannot quit smoking or using the more dangerous forms of smokeless tobacco should have access to the full range of SNP - vapes, heated tobacco, snus, nicotine pouches or nicotine replacement therapy. This is not simply about consumer choice, but a pathway to better health. People can make improvements to their health outcomes by completely switching from smoking to SNP or by dual use, with the potential to reduce the number of cigarettes smoked over time until they can quit completely.33,34

Product choice is important as consumers attempting to switch away from smoking may need to experiment with more than one type of SNP until they find one that works for them. Alternatively, people may use more than one type of SNP over the longer term. The key element is the reduction of, or complete substitution for, risky tobacco use.

Tobacco harm reduction is supported by the right to health under Article 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR).35 The ICESCR affirms the obligation of States to support people in making informed choices about

15

their health. It is an approach that uses a language of empowerment and enablement, and recognises people as a key resource. This is fundamental to tobacco harm reduction.

Tobacco harm reduction and the FCTC

Article 1 (d) of the FCTC states:

"'Tobacco control' means a range of supply, demand and harm reduction strategies that aim to improve the health of a population by eliminating or reducing their consumption of tobacco products and exposure to tobacco smoke"³⁶

While named as the third pillar of 'tobacco control', the term 'harm reduction' is not defined in the FCTC. The architects of the Convention say the phrase was included following conversations with the tobacco industry. For years, the industry had been trying to develop products that would allow the consumption of nicotine without combustion. But all efforts ended in failure – failures which are scrutinised in detail in the third biennial GSTHR report, *The Right Side of History*. By the time the FCTC was enacted in 2005, there were still no viable commercial products on the market.



However, despite scepticism among WHO officials that the industry could deliver viable non-combustible products, or were even sincere in their intentions to do so, it was recognised that over time such products might be developed. The Convention preamble therefore obliges Parties to "promote measures of tobacco control based on current and relevant scientific, technical and economic considerations".

It is clear tobacco control now needs to be reassessed in light of the advent of SNP. Beaglehole and Bonita (2022) argue that "neither WHO nor the FCTC are grounded in the latest evidence on the role of innovative nicotine delivery devices in assisting the transition from cigarettes to much less harmful products [...] The missing strategy in WHO and FCTC policies is harm reduction". 38

MPOWER should be broadened to accommodate the huge potential of harm reduction, as shown below. The revised system must monitor the degree to which countries are assisting adult tobacco users to switch away from the most dangerous modes of consumption. Under a new EMPOWERED model, enforcement interventions would be balanced with a broader public health approach that enables adults who use risky tobacco to make informed choices about their health.




tobacco harm reduction is supported by the right to health under Article 12 of the ICESCR

the FCTC obliges Parties to "promote measures of tobacco control based on current and relevant scientific, technical and economic considerations"

"the missing strategy in WHO and FCTC policies is harm reduction" (Beaglehole and Bonita)

the moral basis for tobacco harm reduction is clear



The moral basis for THR is clear, but does it work in practice? There is a growing body of evidence demonstrating the potential for harm reduction to improve the health of adults who smoke. This can be through a range of both older and more recently developed safer nicotine products.

The advent of THR has opened up many opportunities for people who want to make that crucial switch away from using combustible to non-combustible products. An overview of this evidence base forms the focus of the next chapter.

Chapter Two: The evidence for tobacco harm reduction

"People smoke for nicotine, but they die from the tar."39 These words, which many have come to regard as the founding statement of THR, were published in the British Medical Journal in 1976 in an article by Michael Russell.

But this British psychiatrist and tobacco researcher had actually opened the door to THR five years previously. In a 1971 paper in the British Journal of Medical Psychology, he had been the first to identify that "dependence on the pharmacological effects of nicotine" was "the main reason" why people continued smoking.40



At that time, researchers often saw smoking simply as a habit - and consequently, something that should be easy to stop. But Russell knew this was not the case. Curiosity about people and their actions drove his medical practice; in a 2003 interview, reflecting on his decision to specialise in psychiatry, he said: "I found learning to understand people's thoughts, feelings and behaviour much more interesting than [...] the functioning of their hearts, bowels, liver or stomach."41 With colleagues at the Addiction Research Unit of London's Institute of Psychiatry, Michael Russell, fuelled by his understanding of nicotine's role, worked to develop smoking cessation therapies.

Meanwhile, the tobacco industry was, of course, continuing to sell millions of cigarettes. It was also busy trying to quell growing public concern over the detrimental health effects of smoking. Since the 1960s, companies had been manufacturing and promoting 'low tar', 'light' or even 'ultra-light' brands, advertising the use of filters which they claimed reduced or removed harmful elements - the tar - from the smoke.

Consumers were encouraged to believe these products were healthier than conventional cigarettes. 42,43 They were not. Over the course of the twentieth century, tobacco companies would spend many millions of dollars attempting to mitigate the risks of combustion or give the impression of doing so. There were numerous iterations of the filter cigarette, and some companies even experimented with nicotine delivery without combustion. But all these efforts failed. Chapters Two and Three of the GSTHR's 2022 report, The Right Side of History, delve into the history of these (mostly secretive) ventures in some depth.44

Russell's now famous 1976 article in the British Medical Journal is entitled 'Lowtar medium nicotine cigarettes: a new approach to safer smoking'. It addresses a major issue with the 'low-tar' cigarettes then on sale; the products were also low in nicotine, and therefore would not satisfy the consumer:

"To expect people who cannot stop smoking to smoke cigarettes that have hardly any nicotine is illogical. People smoke for nicotine but they die from the tar. Their risk of lung cancer and bronchitis might be more quickly and effectively reduced if attention were focused on how to reduce their tar intake, irrespective of nicotine intake."45



Michael Russell, a British psychiatrist and tobacco researcher, opened the door to THR in 1971

the tobacco industry was busy trying to quell growing public concern over the detrimental health effects of smoking

tobacco companies spent many millions of dollars attempting to mitigate the risks of combustion or give the impression of doing so

Of course, it is now clear that the 'safer smoking' Russell referred to in the title of his BMJ article is an oxymoron. But his analysis – and the spirit of compassionate enquiry he brought to the field – would resonate for many years to come, leading many to view him as the 'father' of THR.

THR: into the twenty-first century

The next significant scientific milestone for a THR approach came a quarter of a century after Michael Russell's key findings. In 2001, the US Institute of Medicine published a report titled 'Clearing the smoke: assessing the science base for tobacco harm reduction'. It provided one of the first definitions of THR from an official and credible source:



"a product is harm reducing if it lowers total tobacco mortality and morbidity even though the use of that product may involve continued exposure to tobacco-related toxicants"

— US Institute of Medicine

"making effective, affordable, socially acceptable, low-hazard nicotine products... could generate significant health gains" - Royal College of Physicians, UK

look beyond vaping and it is possible to find a wealth of evidence that details both the safety record and substitution potential of another SNP: Swedishstyle pasteurised snus "For the purposes of this report, a product is harm reducing if it lowers total tobacco mortality and morbidity even though the use of that product may involve continued exposure to tobacco-related toxicants." 46

'Clearing the smoke' highlighted what it called Potential Reduced Exposure Products (PREPs) that "have been or could be demonstrated to reduce exposure to some of the toxicants in most conventional products". At the time of the report's publication in 2001, the only products to which this description could refer were certain brands of smokeless tobacco. Stonewall, marketed in the USA by Star Scientific Inc., and General Snus, sold by Swedish Match, had both been the subject of provisional studies.

Interest continued to grow in the early 2000s about how to identify tobacco products that may carry fewer health risks than cigarettes - as well as suitable methods to test them. And six years after the US Institute of Medicine report, the UK Royal College of Physicians (RCP) published 'Harm reduction in nicotine addiction' (2007), which argued "for the application of harm-reduction strategies to tobacco dependence". The authors suggested "that making effective, affordable, socially acceptable, low-hazard nicotine products… could generate significant health gains".⁴⁷

As in 2001, however, the only less risky alternatives to cigarettes available were oral smokeless products, and the UK had effectively banned these back in 1992 after concerns that young people were using an American smokeless tobacco, Skoal Bandits. And so THR would remain a concept without widespread real-world application – until vaping devices emerged onto the scene.

Is that really the full picture? The safety and efficacy of vaping as a tool for smoking cessation has dominated scientific research and media commentary in the early years of the twenty-first century. This is a consequence of the global popularity and attention that vaping products have gained over the past two decades.

But look beyond vaping and it is possible to find a wealth of evidence that details both the safety record and substitution potential of another SNP: Swedish-style pasteurised snus.

Meanwhile in Scandinavia: the quiet success story of Swedish snus

Snus has been used in Sweden for over 200 years – and the evidence base for the role snus can play in THR has developed over a much longer period of time. Named after the Swedish word for snuff, snus is made from ground tobacco leaves that are mixed with salt and water. It may also contain food-grade tobacco smoke aroma, or other flavourings, and is placed under the upper lip either in small teabag-like sachets called portion snus, or can be used loose. Snus is most widely used in Scandinavia, particularly in Sweden and Norway.

The Swedish snus on sale today is distinct from other types of oral tobacco products because of the way it is produced. Unlike some other smokeless tobaccos, the tobacco in Swedish snus is not fermented, but pasteurised.

'What is snus?'.52

This heat-treatment process inhibits the growth of bacteria that assist in the formation of a range of toxicants found in tobacco products. Pasteurisation also contributes to its chemical stability, enhancing the shelf-life of the final product.

The production of snus became significantly more safety-focused during the 20th century. Changes introduced by manufacturers resulted in substantial decreases in the levels of unwanted substances in the product; a voluntary quality standard for snus products, the GothiaTek® standard, now sets maximum levels for certain constituents.⁴⁸ There are also strict requirements for how the tobacco used in snus is grown. The tobacco leaves are then either air- or sun-cured, significantly reducing the levels of a toxicant called benzo(a)pyrene.49

Snus has been used in Sweden since the 18th century. It was the dominant mode of tobacco consumption until the 1930s, when it was overtaken by cigarettes. But following two well-publicised UK and US medical reports on the dangers of smoking in the early 1960s, cigarette use in Sweden began to decline, while snus use began to increase; this appears to have happened spontaneously, with no intentional public health messaging that described the relative risks of the two products.

By the 1990s, snus had overtaken smoking among Swedish men. Uptake continued and spread to other population groups, and over the border into Norway; turn to our in-depth country profile for more on the Norwegian experience in Section Six.

High levels of snus use in Sweden and Norway are today associated with very low levels of smoking and smoking-related disease. Almost one in four Swedish men (23%) used snus daily in 2018.50 Sweden has by far the lowest rate of smoking in Europe. It is the only EU state to have achieved 'smoke-free status', classically defined as less than 5% adult smoking prevalence in the adult population aged between 15 and 54. By comparison, the average EU smoking rate for this population is 26%.51 Swedish men also have Europe's lowest level of tobacco-related mortality, with 152 deaths attributable to smoking per 100,000, compared with the European average of 373 deaths per 100,000. For a closer examination of the product, its use and role substituting for combustible cigarettes, see the 2022 GSTHR Briefing Paper,

The long-term and widespread availability and cultural acceptance of snus in Sweden and Norway has led to observable changes in consumer behaviour around nicotine consumption. This is THR in action. So why has snus not brought about an end to smoking worldwide? One major factor is the mode of consumption. Many people who use nicotine by inhaling the smoke of combustible cigarettes do not find oral use of nicotine as appealing. And this is why the advent of nicotine vaping devices sparked a global revolution in tobacco harm reduction.

Vaping – and the role of consumer demand

The first vaping devices, invented by Hon Lik and made by Ruyan, were launched on the Chinese market in 2004. Just a few years later, similar devices were being sold in the US, UK and elsewhere. The battery-operated devices produce an aerosol containing nicotine and a range of flavourings. The battery heats up a coil or atomiser, this turns the flavoured liquid into a vapour to be inhaled. The handto-mouth action and experience of using the product provides a reasonable simulacrum of smoking.



the production of snus became significantly more safety-focused during the 20th century

by the 1990s, snus had overtaken smoking among Swedish men

Sweden is the only EU state to have achieved 'smoke-free status'



in light of the rise in use and availability of vaping devices, scientists and regulators began looking at the products more closely

PHE did not identify any new evidence that forced a change to its overall assessment about the relative safety of vaping compared to smoking

"people in the e-cigarette group were more likely to report complete abstinence from combustible cigarettes" – Hollings Cancer Center



Consumers were interested in the products, then most commonly termed 'e-cigarettes'. They began gaining popularity, as people were successfully using them to switch away from smoking. Users started sharing information on dedicated online message boards, posting their experiences, tips on 'modding' (modifying) devices, or simply where to buy quality devices or e-liquids.

In light of the rise in use and availability of vaping devices, scientists and regulators began looking at the products more closely. In the UK in 2010, vapers were concerned when the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) opened a consultation on "whether and how to bring unlicensed nicotine containing products, such as electronic cigarettes, within the medicines licensing regime".53

Over a thousand individuals submitted responses to the MHRA consultation. Most explained that vaping devices had helped them quit smoking, and asked policymakers to avoid restricting access to vapes fearing that a return to combustible cigarettes would be the inevitable consequence. The proposals for medical licensing in the UK were dropped. For more on the history of vaping products, and the important role consumers played in both their technical and social development, see Chapters Three and Four of the GSTHR's 2022 report, The Right Side of History.

It was in 2015 that Public Health England (PHE), an executive agency of the UK Government's Department of Health and Social Care, published what would become a landmark review exploring the safety and harm reduction potential of nicotine vaping devices. In the review, PHE concluded that, while not completely risk-free, emissions from vapes were unlikely to exceed 5% that of combustible cigarettes.⁵⁴

The foreword to the report saw PHE's Chief Executive Duncan Selbie communicate this information in a way that was intended to be more accessible to the public alongside another crucial finding of the review:

"In a nutshell, best estimates show e-cigarettes are 95% less harmful to your health than normal cigarettes, and when supported by a smoking cessation service, help most smokers to quit tobacco altogether."55

In 2016, the RCP published a near two-hundred-page update to its 2007 report. In 'Nicotine without smoke: tobacco harm reduction', its key findings and recommendations mirrored the conclusions of PHE, and included the following (emphasis in the original):

"E-cigarettes are not currently made to medicines standards and are probably more hazardous than NRT. However, the hazard to health arising from long-term vapour inhalation from the e-cigarettes available today is unlikely to exceed 5% of the harm from smoking tobacco. [...] [In] the interests of public health it is important to promote the use of e-cigarettes, NRT and other non-tobacco nicotine products as widely as possible as a substitute for smoking in the UK."56

PHE continued with regular updates to its review of vapes for a decade until the organisation's dissolution in 2022, when its responsibilities were passed to the new Office for Health Improvement and Disparities. PHE did not identify any new evidence that forced a change to its overall assessment about the relative safety of vaping compared to smoking, and the potential health benefits for smokers who switched.

Another substantive update from the RCP was published in 2024. While the report, 'E-cigarettes and harm reduction: An evidence review', did acknowledge concerns over a rise in the use of vaping products by young people in the UK, the authors did not waver from the RCP's earlier conclusions about the important role of vaping in smoking cessation. This was in spite of the huge number of scientific papers published in the eight years since its previous update. The report concluded that [emphasis added]:

"Since the 2016 RCP report the evidence of the effectiveness of e-cigarettes as an aid to quitting has become much stronger. Use of e-cigarettes by young people and non-smokers has increased substantially in recent years, [and] prompt remedial measures are needed to curb youth vaping without undermining use by adult smokers as an aid to quitting." 57

The 2015 PHE report was the first of its kind. It was in the UK where researchers first identified the link between smoking and lung cancer in the 1950s; the UK also led the way in acknowledging the lower risks of e-cigarettes compared to smoking and their potential role in harm reduction. For more on how THR developed in the UK, turn to the in-depth country profile in the Regional and National insights section.

Medical and public health bodies around the world began to undertake their own assessments of the harm reduction potential of vaping. Many came out in favour:

"The use of e-cigarettes is expected to have a lower risk of disease and death than tobacco smoking. [...] E-cigarettes have the potential to reduce the enormous burden of disease and death caused by tobacco smoking if most smokers switch to e-cigarettes."

International Agency for Research on Cancer (see footnote).58

"The Ministry considers vaping products could disrupt inequities and contribute to a Smokefree 2025. The evidence on vaping products indicates they carry much less risk than smoking cigarettes but are not risk-free. Evidence is growing that vaping can help people to quit smoking. There is no international evidence that vaping products are undermining the long-term decline in cigarette smoking among adults and youth and may in fact be contributing to it."

New Zealand Ministry of Health (2020).59

"Vaping can benefit public health, given substantial evidence supporting the potential of vaping to reduce smoking's [death] toll. [...] Frequent vaping increases adult smoking cessation [and] completely substituting vaping for smoking likely reduces health risks, possibly substantially."

From 'Balancing Consideration of the Risks and Benefits of E-Cigarettes', a statement from fifteen past Presidents of The Society for Research on Nicotine and Tobacco, published in the American Journal of Public Health (2021).⁶⁰

"Nicotine vaping products are a safer alternative to tobacco smoking and offer a harm minimisation tool when first line pharmacotherapies and/or behavioural interventions have been unsuccessful."

The Royal Australian & New Zealand College of Psychiatrists (2023).61

Vaping to quit smoking

The efficacy of vaping as an exit strategy for smoking has also now been explored in numerous large-scale studies. The highly respected Cochrane research network has been active in communicating the results of research in



this area since 2014. Based in the UK but connecting researchers from around the world, Cochrane synthesises, summarises and interprets the findings of medical research to help people, especially policymakers, make evidence-based decisions about health interventions.

At the core of its operation are the Cochrane Reviews, a database of systematic reviews and meta-analyses. Cochrane has now carried out eight systematic reviews under the title 'Electronic cigarettes for smoking cessation', with each review essentially updating the last as new studies are published. The most recent version was published in January 2024. It concluded:

"There is high-certainty evidence that electronic cigarettes with nicotine increase quit rates compared to nicotine replacement therapy and moderate-certainty evidence that they increase quit rates compared to electronic cigarettes without nicotine. Evidence comparing nicotine electronic cigarettes with usual care or no treatment also suggests benefit [...]. Overall incidence of serious adverse events was low across all study arms. We did not detect evidence of serious harm from nicotine electronic cigarettes, but the longest follow-up was two years and the number of studies was small." 62

In August 2023, The Hollings Cancer Center, part of the Medical University of South Carolina, published the results of the largest ever US study of vaping as a route to smoking cessation. Those taking part came from eleven US cities and the research spanned a four-year period. Crucially, the study included people who had not stated any desire to quit smoking. One group of people were supplied with nicotine vapes and were told they could use them as much or as little as they liked. The control group were not given anything.

Matthew Carpenter PhD, the first author on the paper, noted that not giving participants strict instructions on how they should use the vaping devices was a deliberate choice. Unusually for this type of research, the study was designed to be as naturalistic as possible, mimicking real-world conditions. Its findings were significant:

"The study showed that people in the e-cigarette group were more likely to report complete abstinence from combustible cigarettes. They were also more likely to report that they'd reduced the number of cigarettes per day that they smoked and their number of 'quit attempts'. Quit attempts are an important metric because people usually need multiple tries before they can successfully stop smoking." ⁶³

In February 2024, Dr Nancy Rigotti, an international expert in tobacco dependence treatment based at Harvard Medical School, wrote an editorial in *The New England Journal of Medicine* titled 'Electronic Cigarettes For Smoking Cessation – Have We Reached a Tipping Point?'. She concluded:

"It is now time for the medical community to [...] add e-cigarettes to the smoking-cessation toolkit. Clinicians should be prepared to have a risk-benefit discussion about e-cigarettes with their patients who smoke and recommend a trial of the products in appropriate situations.

"U.S. public health agencies and professional medical societies should reconsider their cautious positions on e-cigarettes for smoking cessation. The evidence has brought e-cigarettes to a tipping point. The burden of tobacco-related disease is too big for potential solutions such as e-cigarettes to be ignored".⁶⁴

Newer SNP: heated tobacco products and nicotine pouches

In comparison to both snus and vaping devices, heated tobacco products and nicotine pouches are comparatively new to the market. It is therefore unsurprising that the evidence base for their public health potential is less well developed. Researchers agree that a lot more information – and specifically, more information from non-industry sources – is needed to establish to what extent these products could reduce death and disease from smoking. But what are these products, and what do we know about them so far?

A conventional cigarette burns tobacco at temperatures upwards of 800°C, releasing harmful chemicals into the smoke inhaled by the user; conversely, heated tobacco products are battery-operated electronic devices which heat sticks of tobacco to a temperature of no more than 350°C. Heating tobacco to this level causes nicotine to be released in a vapour inhaled by the user, but the tobacco does not combust.⁶⁵



In 2022, a Cochrane Database Systematic Review titled 'Heated tobacco products for smoking cessation and reducing smoking prevalence' synthesised much of the research available to date. Its conclusions were cautious:

"Heated tobacco probably exposes people to fewer toxins than cigarettes, but possibly more than not using any tobacco. Falls in cigarette sales appeared to speed up following the launch of heated tobacco in Japan, but we are uncertain whether this is caused by people switching from cigarettes to heated tobacco. [...]

"We need more independently-funded research into whether heated tobacco helps people stop smoking, whether it results in unwanted effects, and the impact of rising heated tobacco use on smoking rates." 66

Nicotine pouches, meanwhile, are thumbnail-sized sachets containing vegetable fibres infused with nicotine and a range of flavours. Placed in the mouth between the lip and gum, nicotine is absorbed through the oral mucous membrane. Unlike Swedish snus, with which they are often confused, nicotine pouches do not contain any raw or processed tobacco leaves. The nicotine used in pouches may be synthetic, or extracted from tobacco plants.⁶⁷

In a scoping review for the journal *Nicotine & Tobacco Research* published in June 2024, Nargiz Travis and colleagues examined the evidence for the public health potential of oral nicotine pouches. Their conclusions were also cautious: "[nicotine pouches] appear to be less toxic than cigarettes and deliver comparable nicotine, presenting an alternative for combustible product users." But the researchers noted that 17 of the 62 studies they included in their review were industry-funded:


"Data from independent research is critically needed. Industry marketing of [pouches] may encourage initiation in youth and situational and dual use in adults."68

Regardless of their nicotine delivery method, however, the crucial difference between all SNP and traditional cigarettes remains their lack of combustion. By not burning tobacco, all of these products, to varying degrees, are safer than continued smoking. The chart below illustrates the findings of a 2022 systematic review and meta-analysis by Rachel Murkett and colleagues. It shows the relative risk of different nicotine-containing products, and the stark difference in risk between those that are combustible and non-combustible.⁶⁹



a lot more information – from non-industry sources – is needed to establish to what extent HTP and nicotine pouches could reduce death and disease from smoking

the crucial difference between all SNP and traditional cigarettes remains their lack of combustion



Comparing SNP with nicotine replacement therapy

Resistance to the use of SNP for smoking cessation among some medical professionals may be rooted in their familiarity with nicotine replacement therapy (NRT), and a sense that SNP are an unnecessary and unwarranted complication. NRT has been marketed since the 1980s. It aims to enable people to substitute cigarettes for a range of nicotine-infused products, such as patches, gums and lozenges. Medically approved and licensed, these products are all manufactured by the pharmaceutical companies with which medical professionals are also familiar.

Over the decades, many thousands of people have used NRT products, often with the support of their doctor or health professional, to successfully quit smoking. Research shows that their likelihood of success will have increased if they had access to the kind of talk therapies delivered by dedicated smoking cessation services. There is no doubt that NRT is an important part of the THR product portfolio.

However, using these products does not suit everyone. Many people do not regard themselves as being in need of medical help simply because they smoke. Most people who smoke do not seek professional help to quit. Furthermore, the clinical evidence to date for the efficacy of NRT using currently available products is not particularly encouraging. Overall compliance is poor: an overview of NRT published by the *International Journal of Health Sciences* concluded that "most NRT users discontinue treatment prematurely".⁷⁰

The previously mentioned ongoing Cochrane Review, 'Electronic cigarettes for smoking cessation', funded by both the National Institute for Health Research and Cancer Research UK, has compared the use of vaping for smoking cessation with NRT. The 2022 version concluded:

"If six in 100 people quit by using nicotine replacement therapy, eight to twelve would quit by using electronic cigarettes containing nicotine. This means an additional two to six people in 100 could potentially quit smoking with nicotine containing electronic cigarettes".⁷¹

Another important study – again funded by the National Institute for Health Research and Cancer Research UK – was led by Professor Peter Hajek and colleagues. This randomised controlled trial (RCT) compared the efficacy of e-cigarettes and NRT in combination with behavioural support.

The research studied the experiences of 886 participants who attended National Health Service Stop Smoking Services. The participants were randomly split into two groups. One group was able to choose from an NRT of their choice, including combinations of different products, for up to three months. The other received a vaping starter

pack, consisting of a refillable device with one bottle of e-liquid at a strength of 18mg of nicotine per ml. This group was encouraged to purchase further e-liquids, choosing flavours and strengths that suited them. Both groups also received weekly behavioural support for at least four weeks. The research, published in 2019 in *The New England Journal of Medicine*, delivered an unambiguous conclusion:

"E-cigarettes were more effective for smoking cessation than NRT, when both products were accompanied by behavioural support."⁷²

The findings of this particular study did much to underpin the UK government's decision to launch a pioneering THR intervention in April 2023. Called 'Swap to Stop', the programme is set to offer one million people a free vape starter kit and behavioural support. If the programme's ambition is fulfilled, this will reach almost 1 in 5 of all those who smoke in England.⁷³

Evidence is also now emerging of the changes that can occur both in people's use of vaping devices and their consumption of nicotine after they have switched from smoking. In 2024, the results of a longitudinal study conducted by Jean-François Etter were published in the journal *Addictive Behaviours*. Etter surveyed 375 long-term vapers online between 2012–2016, and then again in 2021, at an average eight-year interval. The author concluded:

"In long-term, continuous users, over a period of 8 years, substantial changes were observed in the models of e-cigarettes used, in the flavours and strength of e-liquids, and in the reasons for vaping. Their level of nicotine dependence tended to decrease over time. These users were satisfied with e-cigarettes and vaped mostly because they felt that vaping was less dangerous than smoking, and for enjoyment."⁷⁴

Etter's conclusion throws up a key, if sometimes controversial, word: 'enjoyment'. Much of the scientific literature fails to acknowledge that many people enjoy vaping, and that this may be key to why vaping is more effective than other smoking cessation interventions. The same is likely to be true of other SNP. While significant




medically approved and licensed, NRT is manufactured by the pharmaceutical companies with which medical professionals are familiar

the clinical evidence to date for the efficacy of NRT using currently available products is not particularly encouraging

'Swap to Stop' is set to offer one million people a free vape starter kit and behavioural support, reaching almost 1 in 5 of all those who smoke in England

the views and experiences of millions of people who used to smoke, and who now benefit from SNP, are frequently overlooked



attention is given to expert views on the use of SNP, the views and experiences of millions of people who used to smoke, and who now benefit from SNP, are frequently overlooked.

Consumers' experiences of switching from smoking to SNP

In the 2020 GSTHR report Burning Issues, Chapter Three, titled 'Not just the nicotine: consumers speak', was dedicated to a series of short interviews with people from around the world whose use of SNP had helped them quit smoking.⁷⁵ A few of those quotes are reproduced below.



"I was in really bad shape, chain smoking 40 a day or more. I did not have proper sleep, I used to have a lot of colds, lot of wheezing, I had to keep going to the doctor again and again. That's when I started researching e-cigarettes. [...] I tried the gum [and] I tried the patch once, but it's not as fast as being absorbed in the lung. [...] Vaping replaced the action of smoking. Smoking is a ritual – the hand to mouth action. Vaping replicates a lot of that muscle memory, even if you are just vaping 0mg. The one thing that vaping does is make you less dependent over time. When I started vaping I was consuming 200ml [of e-liquid] a month, now I'm down to 60ml."

Vaper from India

"I was smoking about 10 a day for at least 30 years. I was [also] using snus from when I was about 18 or 19 years old but back in those days – I am 62 now – people were smoking, drinking and partying so I sort of stuck to both smoking and snus. [...] Ultimately I threw away the cigarettes [in the early 1990s]. I took the pack of cigarettes and tore it apart and stuck to snus instead. I could run much longer, I didn't cough in the morning and there was no stench indoors."

Snus user from Sweden

"I'd been to Tokyo and seen [heated tobacco products] quite a few times there, and [...] in smoking areas in Taiwan. I thought I should give it a try because it looked like people were changing their ways of smoking to this electronic thing. So, why not? I bought it and tried it for a week, while smoking at the same time, then found I couldn't bear the smell of smoking. I didn't really have a reason to quit smoking, I wasn't really trying to quit, I just thought maybe this is a better way. When it cleared up my chest and phlegm, I thought, yes, this is better."

HTP user from Taiwan

"I switched because of breathing problems mainly. I continued to [use] both for about 3 to 4 weeks, but the vape fulfilled what I needed [...]. I do find an improvement in my breathing when I'm out walking a lot. I find a big improvement in that. My cousin uses the vape and my sister as well, they have seen similar improvements in health and they are similar age to myself [73 years old]." Vaper from Ireland

The question of dual use

Those who are sceptical of - or in opposition to - THR often cite dual use of cigarettes and SNP as proof that the products do not help people quit smoking. However, the reality - as outlined in the testimonies above - is that many people find they can reduce their consumption of cigarettes when they start using an SNP; many will eventually manage to quit combustibles all together.

In 2024, the University of East Anglia in the UK published the results of a major RCT. People admitted to Accident and Emergency Units across six hospitals for any reason were screened for their smoking status. These were people who were not necessarily contemplating quitting smoking; the intervention was entirely opportunistic. One group received a vaping starter pack, advice and a referral to smoking cessation services. The other group was only given written information about the local services.

Six months later, almost one in four (23.4%) of the people who were assigned to receive vaping products had quit smoking, compared with 12.9% of those who were given only the written information about local services. Crucially, it was also found that those who received the vape packs but didn't quit altogether were more likely to have reduced the number of cigarettes they smoked than those in the non-vape group. Dr Ian Pope for the University Medical School said:

"Attending the emergency department offers a valuable opportunity for people to be supported to quit smoking, which will improve their chances of recovery from whatever has brought them to hospital, and also prevent future illness... We believe that if this intervention was widely implemented it could result in more than 22,000 extra people quitting smoking each year."76

For dual users who smoke fewer cigarettes, there is strong evidence of a doseresponse relationship between smoking and major disease outcomes. Recent work by the Institute for Health Metrics and Evaluation showed a five-to-seven-fold difference in mortality rates between smokers who consume five or fewer cigarettes a day against those smoking 20-30 cigarettes a day.77

Quitting smoking entirely is the best option to reduce health risks. People who quit smoking entirely before the age of 35 can avoid much of the damage from smoking.⁷⁸ But if quitting entirely is not possible, cutting back does have positive health implications. For people who want to cut down or quit smoking, but who either want or need to continue using nicotine, access to SNP can help them do so at significantly reduced risk.

Nicotine addiction, dependence, or use

It appears that some in the global public health community cannot accept the use of SNP because it means that people are consuming a drug - nicotine - outside of medical supervision. This discomfort is perhaps grounded in vague or nebulous moral objections; to 'not being free' or being a 'slave' to nicotine.⁷⁹



those who are sceptical of – or in opposition to – THR often cite dual use of cigarettes and SNP as proof that the products do not help people quit smoking

many people find they can reduce their consumption of cigarettes when they start using an SNP

for dual users who smoke fewer cigarettes, there is strong evidence of a dose-response relationship between smoking and major disease outcomes

the word 'addiction' has taken on symbolic, cultural and moral connotations far beyond any clinical definitions

isolated from smoking, the use of nicotine offers many people pleasure and even benefit, with relatively low risks attached




Dependence on nicotine – a compulsion to continue using it – is certainly a reality. People who smoke find it hard or impossible to quit even when they are fully aware of the major impact smoking has on their health. As noted at the opening of this chapter, this was understood and acknowledged in the work of Michael Russell as far back as 1971.

Arguably, the words 'addiction' and 'dependence' refer to the same thing. However, the word 'addiction' has, for many people, taken on symbolic, cultural and moral connotations far beyond any clinical definitions. When people talk about an addiction to nicotine, their frame for viewing the state of that addiction is often closely linked to their concept of the physical and mental misery associated with serious drug or alcohol use.

In clinical terms, addiction means that someone is using a substance in such a way that they are putting their health at risk, including the risk of death through intoxication or overdose. It means using in ways that cause the person problems in their relationships and social functioning, the replacement of someone's usual activities with use of the substance, the abandonment of their responsibilities at home or work, or criminal activity to facilitate continued use of the substance.

The impact of the use of nicotine without the attendant risks of smoking simply does not match up to the very serious damage caused by other types of addiction, either at a personal, community, or societal level. Isolated from smoking, the use of nicotine offers many people pleasure and even benefit, with relatively low risks attached.

In fact, the habit-forming nature of nicotine is an essential part of the framework for SNP to effectively challenge the appeal of cigarettes. David Abrams and colleagues developed what they called "a three-dimensional framework for harm minimisation". This envisages a 'sweet spot' for SNP, at the point where the risks to health are low, while the appeal to the user is high due to the product's ability to deliver nicotine in a way that is on a par with smoking.⁸⁰



The three-dimensional framework for harm minimisation. Redrawn from original work of Abrams et al. 2018.

This chapter has reflected on the foundations of tobacco harm reduction, right back to Russell's clear-sighted analysis that "people smoke for nicotine but die from the tar". 81 The consideration of Sweden's large-scale and long-term shift from combustible tobacco to snus has shown that consumers will choose a product that delivers nicotine at a lower risk to their health, if it is available. And not only that, but the data show that those individual consumer choices have already led to significant population-wide decreases in tobacco-related morbidity and mortality.

However, people who smoke will only shift away from combustible tobacco when they have the option of a safer product that is both appropriate for them and appealing. While several regions have a tradition of oral tobacco product use, many do not. As a nicotine delivery system, vaping offers consumers several characteristics of smoking – particularly the hand-to-mouth action and consumption of nicotine via inhalation – but at vastly reduced

risk. The experiences of people who quit smoking by switching to vaping has shown that it offers both a satisfying and enjoyable replacement for cigarettes. This is in large part why vapes – and their widespread uptake among consumers – catalysed THR in the early twenty-first century.

Independent studies provide evidence that vaping is significantly safer than smoking, leading to their acceptance as a cessation tool by many professional public health and medical organisations around the world. And large-scale research has shown time and time again that more people are able to quit smoking by switching to vaping than when they are limited to using NRT. While more independent evidence is needed on how heated tobacco products and nicotine pouches can contribute to THR, their reduced risk profile in comparison to combustible tobacco means that they should be included in the full range of options for people who smoke.

Fulfilling the public health potential of THR using safer nicotine products rests on their large-scale substitution for combustible cigarettes. This means widespread availability and trust in products that appeal to even the most ambivalent of combustible tobacco users – including those not necessarily looking to quit.

So as we approach the end of the first quarter of the twenty-first century, is it yet possible to say that SNP are reducing or replacing smoking? To what extent is large-scale substitution already taking place, and where? Chapter Three will consider the current evidence, from population-wide studies of SNP use in comparison to smoking rates, to the major disruptions affecting global tobacco and nicotine markets. It's time to ask whether SNP are driving cigarettes out for good.



consumers will choose a product that delivers nicotine at a lower risk to their health, if it is available

the data show that those individual consumer choices have already led to significant population-wide decreases in tobacco-related morbidity and mortality

large-scale research has shown time and time again that more people are able to quit smoking by switching to vaping than when they are limited to using NRT

fulfilling the public health potential of THR using safer nicotine products rests on their large-scale substitution for combustible cigarettes

Chapter Three: Global progress towards tobacco harm reduction

Industrial disruption and SNP

The concept of 'creative destruction' was first described in a book, *Capitalism, socialism and democracy*, by influential Austrian economist Joseph Schumpeter. His phrase describes a process of "industrial mutation that incessantly revolutionises the economic structure from within, incessantly destroying the old one, incessantly creating a new one". 82

Since Schumpeter's book was published in 1942, the pace of technological change has increased dramatically. In 2024, it is harder than ever for companies to keep pace. Just as the digital camera, mobile phone and laptop upended their respective sectors, the advent of new, safer ways to consume nicotine has been highly disruptive to the tobacco industry.

In their Annual Report for 2013, investment company Goldman Sachs refreshed Schumpeter's concept for the 21st century:

"The process of creative destruction is primarily driven by product or business model innovation – often abetted by technology – that results in a superior value offering for consumers, be it higher performance, greater convenience or lower cost. This enhanced value proposition is the source from which economic benefits then flow, first to the innovator and over time to its consumers and competitors. The new product or model often proliferates into a new paradigm until subsequent innovation in turn threatens its dominant position."

It is interesting to note that the report authors at Goldman Sachs identified eight 'Disruptive Themes' for its audience of investors and financiers in 2013. Among the eight were cancer immunotherapy, 3-D printing and Big Data. But topping the list were e-cigarettes, which they identified had "the potential to transform the tobacco industry".

As early as 1958, executives in the tobacco industry knew that anything that could genuinely be described as a 'safer product' would challenge their existing commercial model. One remarked that anybody who came up with the 'safe' cigarette would dominate the market.⁸⁴ But no combustible product could ever be truly 'safer' – something



the industry knew early on. Yet companies still proceeded to market this deception in the form of the filter cigarette, while also wasting years and millions of dollars on unsuccessful efforts to make a viable non-combustible product.

When it eventually came, the most dramatic disruption ever to hit the tobacco industry began far beyond its offices, research labs and factories. It was Chinese chemist Hon Lik, working entirely independently, who patented the first commercially viable vaping device in 2003.85 Hon Lik's revolution went beyond the creation of a product that enabled less risky consumption of nicotine. The newly established Beijing Saybolt Ruyan Technologies also offered its consumers a level of choice previously unavailable to the cigarette smoker - of flavours, different nicotine strengths and even styles of device. All were clearly intended to encourage a switch away from smoking. Hon Lik smoked heavily, and his father died of lung cancer.

Single use vaping products went on sale in the USA in 2006.86 In the first year, sales of around \$3 million offered proof of consumer demand. However, the US Food and Drug Administration (FDA) quickly put on the brakes, on the grounds that nicotine vapes were 'drug delivery devices' and thus fell under its jurisdiction. Vaping companies sued the FDA and won, but a legislative war between the government and the emerging vaping industry was sparked which continues to rage almost two decades later (see Chapter Four).

Early nicotine vapes were termed 'cig-a-likes', for their visible resemblance to the combustible cigarettes they were designed to replace. But the consumers who experimented with them found that they suffered from weak battery output and low nicotine strengths, overheated frequently and often leaked. Creative destruction had begun, but there were glitches.

Consumers at the forefront of innovation

What happened next was quite remarkable, possibly unique, in the history of consumer product development. If you are unhappy with the performance of your mobile phone, TV or toaster, you can either switch to a different brand, or wait for an upgrade. Few if any consumers can just go to the garage and build a better one. But that's exactly what the early vaping hobbyists did.

Online chat forums facilitated the exchange of information between people who had taken up vaping. They shared what they had learned about how to improve on current product deficiencies. After a while came a collective realisation: vaping devices did not have to resemble cigarettes. This led to the development of larger, sometimes box or cylindrical-shaped devices known as 'mods' (from 'modification'), enabling a range of innovations such as refillable tanks and more powerful batteries.

Chinese industry meets consumer demand – and tobacco firms wake up

Alongside DIY consumerism was a need for the necessary components. Once Ruyan had shown the way, a new industry rapidly built up in Shenzhen, sometimes known as China's Silicon Valley. Companies began turning out a range of vaping devices and off-the-shelf components, adopting a business strategy of 'copy, improve, innovate'. Today, the global vaping industry is dominated by Chinese companies. While Shenzhen IVPS, Shenzhen KangerTech, Smoor, and RLX may not be instantly recognisable household names in many countries, they are the major players in this vast but still-young industry.



the advent of new, safer ways to consume nicotine has been highly disruptive to the traditional tobacco industry

no combustible product could ever be truly 'safer'

the most dramatic disruption ever to hit the tobacco industry began far beyond its offices, research labs and factories

sales of around \$3 million in the first year offered proof of consumer demand for vapes

what happened next was quite remarkable, possibly unique, in the history of consumer product development But it was in the US, not China, where the early non-tobacco start-ups began to grow the market. For the first six or seven years, the major international tobacco companies showed little interest. This changed suddenly in 2012, when US tobacco company Lorillard bought the US-based vaping company, blu E-cigs.⁸⁷

Lorillard's purchase sounded the gun on a corporate race as tobacco companies vied to keep up. Over the next few years, major tobacco companies either bought into non-tobacco start-ups or began to develop their own non-combustible portfolios.





a new industry rapidly built up in Shenzhen, sometimes known as China's Silicon Valley

in 2012, US tobacco company Lorillard bought the US-based vaping company, blu E-cigs, sounding the gun on a corporate race

today, the vape market remains fastmoving and dynamic - but the window on true product innovation may be closing

analysis of US data supports the idea that nicotine vapes are increasingly being used as a substitute for smoking among adult tobacco users Substantial consumer demand also brought many non-tobacco companies into the market. The result was a dizzying array of devices that generated a new, 21st_century mode of consuming nicotine, with sleek and stylish designs rolling out of the factories. Awareness of vaping was growing too, with companies like JUUL hitting the headlines – and often not for positive reasons.

The vape industry – businesses with links to tobacco companies and those which remained independent – continued innovating. Consumers who like high-tech kit can now buy vapes with touchscreens that can adjust the device's performance, or Bluetooth connectivity that enables users to remotely lock their device, change presets, track the number of puffs or even adjust the vapour output. Today, the vape market remains fast-moving and dynamic with regular product launches promising ever better user experiences. However, as with mobile phones, the window on true product innovation may be closing.

At first, the major tobacco companies focused exclusively on developing their own vape products. But before long, they began to seek ways to expand their non-combustible product ranges. In 2014, Philip Morris International (PMI) launched its first heated tobacco product (HTP), under the brand name IQOS, in Japan and Italy. Expansion into HTP was primarily an option for the big tobacco companies – notably PMI, British American Tobacco (BAT) and Japan Tobacco International (JTI) – because of the significant research and development costs that were required to move these products from design concept to marketplace.

The big question: are SNP replacing combustible cigarettes?

So how has the introduction of SNP affected smoking? We will look at this from three perspectives: the acceptability of SNP compared to cigarettes (among consumers), evidence from market changes in sales of SNP and cigarettes, and changes in the prevalence of smoking and the use of SNPs.

As we explored in Chapter Two, there is strong evidence that many smokers find SNP, such as nicotine vapes, snus, nicotine pouches or HTP, to be acceptable alternatives to traditional cigarettes. In the US, analysis of data in the 2019 Population Assessment of Tobacco and Health (PATH) supports the idea that nicotine vapes are increasingly being used as a substitute for smoking among adult tobacco users.⁸⁹

The thesis that substitution is taking place at a consumer level is supported by the many comparative studies exploring the experiences of people who used either NRT or nicotine vaping in an effort to quit smoking. The major randomised controlled trial (RCT) by Professor Peter Hajek and colleagues referenced in Chapter Two compared the satisfaction and craving reduction between nicotine vapes and nicotine gums or lozenges. It concluded that vapes were more effective at reducing cravings and increasing the participant's overall satisfaction.⁹⁰

The International Tobacco Control (ITC) Policy Evaluation Project is also actively investigating tobacco use and public attitudes towards smoking and vaping in over 30 countries. ⁹¹ Data from this survey indicate that smokeless tobacco products like snus are increasingly popular alternatives to smoking in some European countries.

SNP and nicotine use: an era beyond smoking?

There are many studies of SNP, and in particular nicotine vapes, demonstrating efficacy in helping people quit smoking; evidence that we explored in Chapter Two. These studies primarily highlight the positive impact of SNP on reducing smoking by helping current smokers transition to these alternatives.

However, the broader context of substitution is also important. It is increasingly recognised that, in some markets and among some groups of consumers, SNP are now acting as total replacements for combustible cigarettes. This means that these products are not only being used by people who are switching from smoking, but also by people who are choosing SNPs as their first nicotine product, bypassing combustible cigarettes entirely. Does this mean that there is a broader role that SNPs can play in reducing smoking?

The phenomenon described is particularly evident in countries like Sweden and Norway, where the decline in smoking is associated with two factors: smokers transitioning to snus, and new nicotine users opting for snus instead of cigarettes from the outset (see our in-depth case study exploring the situation in Norway).

These population-level trends challenge the so-called 'gateway hypothesis', often cited by critics of THR. This suggests that the use of nicotine vapes leads non-smokers, particularly young people, to start smoking. However, recent literature indicates that the hypothesis is flawed, as it fails to account for a pre-existing tendency to use nicotine. An association between vaping and smoking initiation can be better explained by a 'common liability' to use both vapes and cigarettes: 92,93,94

"What initially may appear to be a causal association between ENDS [electronic nicotine delivery systems, or vapes] use and cigarette smoking, is likely instead better explained by other factors (e.g. home and social environment, personality characteristics, mental health or emotional challenges) predisposing some people to use products containing nicotine in general, including both ENDS and cigarettes whether or not they used ENDS first."95



Further supporting this, research by Shabab et al. (2021) suggests that adolescents who experiment with vapes are less likely to transition to smoking compared to peers with similar risk profiles.⁹⁶ Population-trend modelling studies reinforce this finding, showing that youth smoking rates are lower now than they would be if vaping did not exist.^{97,98,99,100} What this evidence suggests is that vaping may actually *divert* young people away from smoking cigarettes. The availability of SNP may in fact reduce the initiation of smoking, rather than increasing it.

In summary, the existing research on the substitution effect of SNP suggests that their availability reduces smoking prevalence and overall cigarette consumption through three key mechanisms:

- as a smoking and nicotine cessation aid, enabling people to first quit combustible tobacco, and then quit nicotine use, by reducing their intake over time.
- → as a long-term alternative to cigarettes, for people who are unwilling or unable to give up their consumption of nicotine entirely, and who would otherwise return to smoking.
- as an alternative product for new nicotine users, who would otherwise start smoking.





the broader context of substitution is also important

the products are not only being used by people who are switching from smoking, but also people who are bypassing combustible cigarettes entirely

an association between vaping and smoking initiation can be better explained by a 'common liability' to use both vapes and cigarettes

the availability of SNP may in fact reduce the initiation of smoking, rather than increasing it In the following sections, we'll try to quantify the global progress in THR by assessing the current and projected extent of the substitution effect and where it is occurring, using two main sources: market and prevalence data.

Market data provide insight into overall trends in tobacco and nicotine consumption. But these data primarily reflect economic activity, and when measured in value (currency), they can be distorted by fluctuations in absolute and relative product prices. Additionally, market data may be affected by factors such as population changes or the inability to capture illegal markets. This means that in countries with dynamic demographics or a significant share of illicit markets, changes in market data do not necessarily reflect changes in consumer behaviour and preferences. Despite these limitations, research suggests that market indicators can still serve as useful estimators of changes in prevalence. 101,102

To gain the fullest picture possible, the addition of prevalence data is therefore crucial. Prevalence data directly measure the proportion of the population who are at risk of smoking-related diseases. This enables targeted interventions and the planning of THR strategies. They also provide a clearer picture of behaviour change and its impact on health, making these data a more reliable indicator for assessing and improving public health. Unfortunately, high-quality prevalence data are often scarce, and the data available frequently lack information on consumption levels (for example, smoking or product use intensity) or dual use. This makes it difficult to fully capture the extent to which combustibles are being substituted by SNP.

Replacement of cigarettes by SNP: evidence from the markets

The most effective way to use market data to assess the substitution of cigarettes by SNP is to track volume characteristics (e.g., the number of products used, measured in sticks, kilograms, millilitres, etc.).

This is relatively straightforward for HTP, as both HTP and cigarettes can be measured in sticks. However, comparing volume characteristics is more difficult in the case of cigarettes and nicotine vapes, because they are measured in different units - sticks and millilitres of vape liquid - and the nicotine concentration of vape liquid can also vary significantly, further complicating the comparison.

People also buy their vaping devices separately from the nicotine they consume in it, contained in vape liquid. When people buy cigarettes, the nicotine is contained in that one product. This poses problems for the researcher. Should cigarette sales volume be compared with vape device sales or vape liquid sales? Single use devices present a further complication. How do you compare a single use vaping product that may be used over several days and a cigarette that is smoked in five minutes, with average consumption at around ten per day?

For these reasons, to compare the market trends for combustible tobacco products versus SNP, we are using value instead of volume in the following graphs, with the value standardised to a single currency (USD) and adjusted for inflation. This method has its drawbacks. Firstly, inflation rates can vary significantly between countries. Secondly, cigarette price inflation often surpasses general inflation due to increasing excise tax rates. Additionally, because of continuous technological progress that may reduce SNP production costs, cigarette price inflation likely outpaces SNP price increases.

Bearing these limitations in mind, our calculations nevertheless throw up a number of interesting findings. Market estimates show that, although the nominal value of combustible tobacco sales increased from \$752 billion in 2015 to over \$1 trillion in 2024, when adjusted for inflation (assuming a constant currency value), combustible tobacco sales actually decreased to \$685 billion in 2024. This reflects an 8.9% decline from 2015.


In contrast, inflation-adjusted SNP sales, which include snus, nicotine vaping products, HTP and nicotine pouches, grew nearly sixfold from 2015. In non-adjusted terms, the SNP market reached \$96 billion in 2024.

This growth indicates that SNP have moved beyond their niche status. In 2015, SNP accounted for only 1.4% of the total tobacco and nicotine market. By 2024, this figure had increased to 8.8%, with HTP at 4.2%, nicotine vaping products at 3.2%, nicotine pouches at 1.1%, and snus at 0.3%.

While the global combustible tobacco market is valued at \$1 trillion, China's tobacco market alone accounts for an astonishing \$344 billion of this total. Yet despite being the global centre of production for nicotine vapes, the market for all SNP in China is extremely small, valued currently at \$4 billion. This may sound sizeable in isolation, but it is equivalent to less than 1.2% of the Chinese market for combustibles.


If we remove China's data from our calculations, the scale of the acceleration in the global SNP market becomes clear; it has reached 12.3% of the total market in 2024 - a massive increase from virtually zero in 2004. Our projections, based on Euromonitor 2021 data and linear extrapolation, suggest that SNP sales could reach \$167 billion by 2030. This would increase SNP's market share to 13.6% globally, or 16.8% if China is excluded.

These trends suggest that while combustible tobacco sales remain significantly higher than SNP sales, two key shifts are occurring in the tobacco and nicotine market: the share of SNP in the total tobacco and nicotine market is increasing, and inflationadjusted combustible tobacco sales are declining, while SNP sales are experiencing rapid growth.



are rising across all regions

It should be noted that most of these changes have been in high-income countries (HIC): consumers have more disposable income, access to online sales, fewer restrictions on SNP, and higher public awareness of the risks associated with smoking.




Combustibles
Combined value of all SNP
Snus and nicotine pouches
Nicotine vaping products
Heated tobacco products

Source: Authors' estimates based on Euromonitor International. (2021, December 23)¹⁰³

Our analysis of changes in the market value of SNP across various regions reveals several key trends (see charts below). HTP emerge as the most popular type of SNP in Western Europe and Asia Pacific, with a projected market value of approximately \$22 and \$21 billion, respectively, by 2026. HTP also dominate the markets in Eastern Europe, Latin America, the Middle East, and Africa, indicating a significant consumer shift towards these products. In all these regions, HTP are experiencing accelerating growth, and are among the fastest-growing SNP globally.


In North America, nicotine pouches stand out as the leading SNP market segment, with a projected value slightly above \$20 billion by 2026. The snus market, however, is only expected to reach about \$1 billion. Notably, nicotine pouches, which were absent in 2015, have shown exponential growth, and are expected to surpass vaping market values in North America by 2024.

However, there are regions where certain products remain commercially unknown. Nicotine pouches and snus report zero market value in Australasia, Eastern Europe, Latin America, and the Middle East and Africa. This suggests either a lack of consumer adoption, or the absence of legal market availability in these areas. In Australasia, Latin America, and the Middle East and Africa nicotine pouches and snus have shown little to no change, maintaining a negligible presence throughout the years analysed.




Heated tobacco productsNicotine vaping productsSnus and nicotine pouches

Source: Authors' estimates based on Euromonitor International. (2021, December 23)104



Comparing the charts for SNP (inflation-adjusted value) with those for cigarette sales (number of sticks), cigarette sales have fallen in all regions except Asia Pacific and the Middle East and Africa, while SNP sales are rising across all regions. Although this is a positive indicator for the advance of THR, it is difficult to establish a direct association between the rise in SNP sales and the decline in cigarette sales at a regional level. The lack of association in some regions may be due to regional specifics, individual country characteristics, or differences in sales measurement (inflation-adjusted sales versus cigarette sticks). For instance, in the Middle East and Africa, the growing sales of both cigarettes and SNP may be attributed to factors such as rapidly increasing populations, rising disposable income, the increased presence of the tobacco industry, and less restrictive tobacco control measures compared to the rest of the world. 105,106



SNP market structure and geographical allocation

It is important to note that the global SNP market is undergoing notable changes. According to market estimates, the dominance of nicotine vaping products in the SNP market ended in 2020, when HTP became the market leader by value. This shift was driven by both an increase in the number of HTP users and the fact that HTP are generally more expensive than nicotine vaping products. According to Euromonitor's 2021 data, about 21 million HTP devices were sold in 2020, with this number expected to reach approximately 55 million by 2026. Assuming the number of HTP devices corresponds to the same number of HTP users, this product still significantly lags behind the number of vapers, as we estimate below.



the dominance of nicotine vaping products in the SNP market ended in 2020, when HTP became the market leader by value

projections suggest that the global value of nicotine vapes will reach approximately \$53.3 billion by 2030, while the global value of HTP is expected to reach \$80.4 billion

the US is projected to remain the largest market for nicotine vapes – and with high sales of both nicotine pouches and snus as well, it accounts for more than a quarter of global SNP sales

HTP sales in Italy and Germany are accelerating rapidly, with combined sales expected to match those of Japan by 2026



The growth in the number of HTP consumers has been driven by rapid penetration in Western and Eastern Europe, alongside continued growth in the Asia Pacific region, particularly in Japan. Projections based on Euromonitor's 2021 data suggest that the global value of nicotine vapes will reach approximately \$53.3 billion by 2030, while the global value of HTP is expected to reach \$80.4 billion. This will account for nearly 32% and 48% of the global SNP market respectively.

The US, a focal point for SNP-related developments, is projected to maintain its position as the largest market for nicotine vaping products. Additionally, the US is the largest market for nicotine pouches and the second-largest market for snus, giving it a leading role in the global SNP market through 2026, accounting for more than a quarter of global SNP sales. Meanwhile, Japan continues to lead in HTP sales; however, its share in the global HTP market value is expected to decline gradually from 39% in 2021 to 25% in 2026. This decline is due to accelerating HTP sales in other countries, particularly Italy and Germany, where combined sales are projected to match those of Japan by 2026.


As described earlier, snus use in Sweden has seen dramatic growth, largely due to increased awareness about its relative safety in comparison to smoking.

Recognition among consumers of the relative safety of nicotine once decoupled from the cigarette has similarly generated a market for nicotine pouches, which


allow for discreet consumption in places where use of other safer nicotine products might be prohibited.

The major tobacco companies have now entered the nicotine pouch market, including: Swedish Match, with brands Zyn and Volt, now owned by PMI; BAT, with Lyft and Velo; Imperial Tobacco, with Skruf, Zone X, and Zonnic; JTI with Nordic Spirit; PMI with Shiro; and Altria, with On!. However, smaller companies are increasingly involved in pouch manufacturing. In Iceland, a non-tobacco company, IcePouch, sells the market-leading product, while Sweden has seen the growth of several non-tobacco company pouch start-ups.


Estimated SNP market share by country in 2026




Estimated HTP market share by country in 2026




Estimated snus market share by country in 2026



Estimated nicotine vape market share by country in 2026



Estimated nicotone pouches market share by country in 2026



GSTHR 2024. Data source: Euromonitor 2021

Source: Authors' estimates based on Euromonitor International. (2021, December 23)109

Single-use vapes: disrupting the disruption?

Of course, Hon Lik's original product was actually the first single-use vaping product. But as noted earlier, the early cig-a-likes were unsatisfactory and often expensive. Their flaws led to years of product development and innovation, with refillable or pod systems ultimately coming to dominate the vape market. Or they did, before the arrival of a very different type of disposable vaping product.



the spread of single-use vaping products could be characterised as 'disrupting the disruption'

the fact that the FDA was prioritising enforcement against flavoured prefilled cartridges led many vapers to switch to disposable options

single-use vaping product market share in the US increased from 24.7% to 51.8% between January 2020 and December 2022

the vaping industry quickly went on the front foot If the arrival of nicotine vapes in 2004 was disruptive for the tobacco industry, the more recent explosion in the spread of single-use vaping products has taken things a step further. It could be characterised as 'disrupting the disruption'. This latest shock has not only affected the non-combustible businesses of large tobacco companies, but also some of the established major vaping industry players.

The disposable products that emerged as we entered the 2020s came at a perfect time. As global awareness of vaping was increasing, so was demand. And many new users do not want to be bothered with complicated gadgets. They want to consume nicotine in a way that is significantly safer than smoking, with something that is easy to operate, cheap, and available in a variety of flavours. And that is exactly what the new breed of disposable vapes offered.

There is no doubt that the rise of the disposables has been both dramatic and fast. Single-use vaping product market share in the US increased from 24.7% to 51.8% between January 2020 and December 2022. 110,1111 In the US at least, regulatory changes have played a significant role in this shift. For example, the fact that the FDA was prioritising enforcement against flavoured prefilled cartridges led many vapers to switch to disposable options.

It was inevitable that the popularity of disposables would catch out some of the major transnational tobacco companies. Single-use vaping products have posed an even bigger threat than JUUL did. Even some of the major Chinese vaping companies like SMOOR, who take pride in their track record of innovation, failed to see them coming.

But the vaping industry quickly went on the front foot. Backed by years of product development experience, Chinese manufacturers such as RELX, Vaporesso, Smok, Oxva, Ecigator, Voopoo and others added to their existing product portfolios and began producing what are now the world's leading disposable brands.

The rise of the single-use vape has brought with it increased concerns over youth vaping (discussed further in Chapter Five) and the products' negative environmental impact. Discussions are underway about electrical waste disposal, incentivising the return of used vapes and moves towards recyclable disposables, while some retailers have been offering guidance on recycling.¹¹⁴ These actions alone, however, while welcome, are unlikely to match the scale of the issue.


Evidence from key HTP markets

As highlighted in the previous section, HTP sales have experienced remarkable growth recently. This has been seen not only in Asia Pacific (specifically Japan, see in-depth country profile) but also in Western and Eastern Europe. Analysis of data from places where HTP sales are rapidly increasing is required to understand these trends better.

The following figures present data on retail volume sales of cigarettes and HTP, both measured in sticks. This allows for more straightforward conclusions than sales value (currency) data. However, it is important to note that one HTP stick may not be a perfect substitute for smokers, as it contains a lower dose of nicotine than one cigarette. This suggests that people who switch from smoking may use more HTP sticks per day than the number of cigarettes they previously smoked, based on nicotine volume.

Market data indicate that HTP popularity is accelerating in many countries, coinciding with a decline in cigarette sales. This suggests a substitution effect. These countries can be categorized into several groups:

- Approximately one-to-one substitution of HTP sticks for cigarettes: Hungary, South Korea, Italy, Germany.
- Tigarette sales drop faster than HTP sales increase: Slovakia, Czech Republic, Russia, Japan, Greece.
- Cigarette sales drop slower than HTP sales increase: Kazakhstan, Lithuania, Portugal.





market data indicate that HTP popularity is accelerating in many countries, coinciding with a decline in cigarette sales - suggesting a substitution effect

Lithuania is the only country where HTP sales are projected to surpass cigarette sales by 2026, with Hungary also nearing this milestone

in Sweden there is a strong negative correlation between the sales of cigarettes and snus

snus has been a significant substitute for cigarettes over many years in Sweden Lithuania stands out as the only country where HTP sales are projected to surpass cigarette sales by 2026, with Hungary also nearing this milestone. Remarkably, the rate of HTP adoption and cigarette substitution in these countries is outpacing even Japan.

Despite positive market dynamics, the EU Delegated Directive, which aims to ban all flavours in HTP, could significantly impact sales.¹¹⁷ The Directive is currently being challenged in court; the outcome will be crucial in determining the future of cigarette substitution by HTP in the EU.


Longer term evidence for substitution in Scandinavia

While the market data above focus on recent history and future projections, Sweden offers a long-term perspective on the substitution of combustible tobacco by safer products. The article "Swedish snus and the GothiaTek® standard" by Rutqvist et al. (2011), analyses the consumption of various tobacco products from 1915 to 2011, including cigarettes, cigars, pipe and RYO (roll-your-own) tobacco, snus, and other forms of smokeless tobacco.¹¹⁸

The graph below tracks the consumption of these products in metric tonnes. It shows that cigarette consumption peaked around 1920, then decreased until the mid-1930s before sharply increasing again and reaching its highest point in the 1970s, followed by a steady decline up to 2011. Cigar consumption rose until about 1920, then dropped sharply and remained low but stable, with slight changes over time. The use of pipe and hand-rolled cigarettes slightly increased until the 1940s, then stabilised at a low level with minor fluctuations.

Notably, snus consumption, which was initially low, increased steadily, peaking in the 1980s before gradually falling toward 2011. The consumption of other smokeless tobacco products started to rise significantly in the 1970s, reached a peak around 2000, and then began to decrease, although with some fluctuations.

From these data, we see that there is a strong negative correlation between the sales of cigarettes and snus: as snus sales decreased, cigarette sales increased between 1920 and 1970. Conversely, an increase in snus sales



Cigarettes
Cigars
Pipes and hand rolled cigarettes
Snus
Other smokeless tobacco

Source: Rutqvist et al. (2011)¹¹⁹

corresponds with a decline in cigarette sales after 1970. This pattern suggests that snus has been a significant substitute for cigarettes over many years in Sweden.

The complicating factor of illicit markets in nicotine products

It is important to acknowledge that our market data for SNP relate only to the legal sale of these products. However, in many countries, there are significant illicit markets in nicotine-containing products. We are not referring to these products as 'safer nicotine products' as the lack of certainty over their contents means that their safety cannot be guaranteed.

Many high-demand consumer products have illicit counterparts. Goods can be considered illegal because they are illegally manufactured, because they have been smuggled into a country to avoid taxation, or because the product category is prohibited in the country.

Illegal vapes are especially prevalent in countries such as Australia, Mexico and Brazil which have blanket bans. However, they are also common in countries such as the UK which have a more proportionate control regime. Sales may take place from individuals on the street (perhaps alongside other substances), on market stalls, or via social media platforms.

Illegal products will often be cheaper than regulated versions bought from legitimate shops – but that may not be the only reason why people buy them. These vaping devices may also contain more e-liquid or a higher nicotine strength than is legally permitted in the country, for example. Unfortunately, there are inevitably risks to health when nicotine-containing products have been manufactured in ways that do not conform to agreed product safety standards.

High quality data on these markets and the products they trade in is naturally hard to obtain and therefore is not incorporated into our understanding of substitution effects.

Replacement of cigarettes by SNP: evidence from prevalence data

While market trends show an increase in SNP sales and a decline in cigarette sales, the critical question from a public health perspective is how these shifts affect the prevalence of smoking and SNP use. However, monitoring prevalence data globally is challenging due to limited availability and varying data quality.



A significant challenge is the inconsistent mapping of tobacco and nicotine use, largely because data collection is an extremely difficult and costly task for many countries, especially low- and middle-income countries (LMIC). The COVID-19 pandemic further complicated data collection efforts, while the inflationary pressures that followed have driven up these costs even more. Establishing a reliable trend typically requires data from at least three time points. The more data points collected, the higher the quality of the data and the more robust the conclusions. However, this also increases the cost of data collection.

As of the latest available data, 66 countries have conducted surveys on vaping, and this information has been used to estimate global vaping prevalence. We have extended these estimates to approximately 200 countries where direct survey data might be missing, using statistical methods and country-specific characteristics. However, the precision of these estimates varies, particularly in regions with fewer surveys, such as Africa and South-East Asia. Even within those 66 countries, only a few conduct these surveys consistently and with enough frequency to establish reliable trends.

Table 1 Changes in prevalence of current vaping

Country name	Year range	Nicotine vaping product use (%)	
Estonia	2017 - 2023	1.0 → 9.0	
Latvia	2017 - 2023	1.0 → 8.0	
United Kingdom	2012 - 2022	1.7 → 8.7	
New Zealand	2016 - 2021	2.0 → 8.2	
Lithuania	2017 - 2023	1.0 → 5.0	
Ireland	2017 - 2023	4.0 → 8.0	
Poland	2017 - 2023	1.0 → 4.0	
France	2017 - 2023	4.0 → 7.0	
Slovenia	2017 - 2023	1.0 → 3.0	
Luxembourg	2017 - 2023	2.0 → 4.0	
Bulgaria	2021 - 2023	1.1 → 3.0	
Slovakia	2021 - 2023	1.3 → 3.0	
Italy	2021 - 2023	1.4 → 3.0	
Philippines	2015 - 2021	0.8 → 2.1	
Croatia	2021 - 2023	0.9 → 2.0	
Spain	2017 - 2023	1.0 → 2.0	
Malta	2017 - 2023	2.0 → 3.0	
Denmark	2017 - 2023	2.0 → 3.0	
Cyprus	2017 - 2023	3.0 → 4.0	
Austria	2017 - 2023	3.0 → 4.0	

Source: WHO: Global report on trends in the prevalence of tobacco use 2000-2025, Fourth edition 121 ; Special Eurobarometer 458 122 , 506 123 , 539 124 ; ECigIntelligence 125 .

Note: Countries are listed in order of the magnitude of change in nicotine vaping products use in percentage points.

These countries include Argentina, Australia, Austria, Bangladesh, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Japan, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Netherlands, New Zealand, Norway, Pakistan, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Arab Emirates, United Kingdom, United States, Venezuela.

Another important factor in understanding smoking versus SNP prevalence is the extent of dual use, where individuals use both combustible tobacco products and SNP. Unfortunately, dual-use data are not widely published. Even when surveys include questions on both smoking and SNP use, it is uncommon for this information to be combined in published statistics. Since raw survey data is often not publicly available, it is difficult to produce such statistics later. Furthermore, dual use is a dynamic process, often common at the beginning of the transition to SNP but usually diminishing over time as users settle on one product or the other. Current data are limited, but recent studies indicate that up to 30% of HTP users in Japan also smoke, while 38% of vapers in the UK and over 46% in Mexico are dual users. ^{126,127}

Despite these challenges, available data suggest that the prevalence of the use of various SNP, particularly nicotine vaping products, is on the rise across multiple countries. The data reveal consistent increases in e-cigarette use, with Estonia and Latvia recently experiencing the largest gains, at 8 and 7 percentage points, respectively. The United Kingdom and New Zealand also showed substantial growth, with increases of 7 and 6.2 percentage points. Countries such as Lithuania, Ireland, Poland and France witnessed more moderate rises ranging from 4 to 3 percentage points, while other countries saw smaller increases (see table below).

Moreover, there is strong evidence of an association between the rise in SNP use and a corresponding decrease in smoking prevalence. For instance, in Sweden, daily tobacco smoking rates dropped dramatically from 15.6% in 2003 to 6.3% in 2023, while daily snus use increased to 17.5% during the same period. Similarly, Norway witnessed a significant rise in daily snus users, increasing from 5.0% in 2005 to 16.0% in 2023, which coincided with a sharp decline in daily smoking from 25.0% to 7.0%.

New Zealand also demonstrated a notable pattern, with smoking rates plummeting from 28.9% in 2000 to 10.9% in 2021, while vaping is set to rise from 2.0% in 2016 to a projected 13.0% in 2025. In the UK, smoking prevalence is forecast to decrease significantly from 24.0% in 2005 to 10.8% in 2025, while vaping rates are set to increase to 10.0% over the same period. Similar trends are observed in other countries, including the US, Ireland, Luxembourg and the Philippines (and to a lesser extent, Austria and Lithuania) where smoking rates have declined while vaping rates have risen.




the data reveal consistent increases in e-cigarette use, with Estonia and Latvia recently experiencing the largest gains, at 8 and 7 percentage points, respectively


there is strong evidence of an association between the rise in SNP use and a corresponding decrease in smoking prevalence in Sweden, Norway, New Zealand, the UK, the US, Ireland, Luxembourg and the Philippines


in New Zealand smoking rates plummeted from 28.9% in 2000 to 10.9% in 2021, while vaping is set to rise from 2.0% in 2016 to a projected 13.0% in 2025


both prevalence data and market data provide further convincing evidence of substitution effects in multiple countries across a number of regions




VapersSmokers
























Therefore, we can see that both prevalence data and market data provide further convincing evidence of substitution effects in multiple countries across a number of regions. As we have explored so far in this report, the last two decades have seen significant progress in the growth of SNP markets and product development, particularly in HICs. What we are able to demonstrate here is that this progress is reflected in the extent to which people who smoke have responded by substituting a range of SNP for combustible tobacco.

It is important to acknowledge that this substitution is not limited to current smokers switching to SNP. It also includes new nicotine users who are choosing SNP over cigarettes from the outset. Turn to Sections Four to Seven for some closer analysis into substitution effects in the UK, Norway, Japan and New Zealand - four of the countries that have experienced the most significant changes in nicotine and tobacco consumption since the advent of SNP.

Changes in the number of vapers globally

Obtaining global estimates of vaping product use prevalence is challenging for several reasons, as outlined by the GSTHR team in this article by Jerzyński and Stimson (2023):

- ➡ Information on vaping and other nicotine product use is unavailable for over half of the world's population.
- Txisting surveys often employ different definitions and methodologies, complicating data standardisation across countries.
- patterns.
- ➡ Surveys are conducted infrequently or as one-time events, limiting the ability to track changes over time and adjust estimates accordingly. 129

In our article 'Estimation of the global number of vapers: 82 million worldwide in 2021', we employed a method of assumed similarity for countries with missing data. We averaged the prevalence of vaping across WHO regions, World Bank income classification groups, and the legal status of e-cigarettes in each country. These averages were then applied to the adult population estimates provided by the United Nations for each country.

The prevalence data were adjusted based on the year of the surveys and the market value growth rates of e-cigarette sales from 2015 to 2021. For regions lacking recent survey data, the market growth rate was used to project the prevalence of vaping from the most recent available data. This approach involved correlating market size with prevalence using a coefficient, derived from the relationship observed in two countries (the UK and New Zealand) with available data.


The estimates also included an adjustment for market feedback to account for potential discrepancies between market size and actual consumption. The final global estimate for 2021 was approximately 82 million vapers, with regional variations reflecting the differing market growth rates and survey data availability.

In 2024, the estimates were updated on the basis of new data that emerged after 2021. The forecasting method has also been improved to produce more precise results. According to our new estimates, the global number of vapers increased to 114 million in 2023.





according to the GSTHR's new estimates, the global number of vapers increased to 114 million in 2023



Source: Authors' updated estimates based on Jerzyński, T. and Stimson, G.V. (2023)¹³⁰



will an increase in the use of SNP and a decline in smoking lead to health gains?

all models indicated that the introduction of SNP could have a beneficial effect on population health by reducing smoking-related mortality

one calculation saw up to 6.6 million fewer smoking-attributable deaths in the US between 2016 and 2100 as a consequence of people switching from smoking to vaping

data suggests that in the UK, the majority of the reduction in male smoking between 2012 and 2019 was due to vaping, resulting in 165,660 averted deaths by 2052

Lives saved due to SNP

From a public health perspective, what does this increase in SNP use mean? We now focus on their potential to reduce morbidity and mortality related to smoking. Will an increase in the use of SNP and a decline in smoking lead to health gains?

In 2021, Lee et al. reviewed 13 studies modelling the potential health impacts of SNP on mortality. ¹³¹ Four studies focused exclusively on nicotine vaping products, while others covered a broader range of products, using terms such as modified risk tobacco product (MRTP), new nicotine product, or new tobacco product. Six studies were supported by tobacco companies and seven by public funding. Except for one UK study, all other models focused on the United States.

The models analysed how people transitioned between different tobacco use groups, typically categorized as never smokers, current smokers, and former smokers. Researchers used data on existing transitions between these groups (initiation, cessation, and re-initiation) to estimate how these behaviours changed over time in the population. In addition to tracking these behaviours, the models also accounted for the fact that using SNP carries a lower risk of disease and death compared to traditional smoking.

To calculate the impact of SNP, the models created two scenarios. In the first, SNP were not introduced, representing a 'null scenario'. In the second, SNP were available and used by some people, representing the 'alternative scenario'. The primary goal was to compare how the population would evolve over time in both scenarios, including factors such as how many people started or stopped smoking and how many switched to using SNP.

By examining the differences in population size between the two scenarios, the models estimated how many lives could be saved or lost due to the introduction of SNP. These changes in the simulated population numbers allowed researchers to estimate the reduction in mortality resulting from people switching from smoking to SNP use.

These models have limitations, such as considering only two products, focusing on mortality without considering morbidity impacts, ignoring demographic variables like race or socioeconomic status as risk factors, and not accounting for reductions in passive smoking or other risk factors. Despite these limitations, all models indicated that the introduction of SNP could have a beneficial effect on population health by reducing smoking-related mortality.

David Levy, a professor of oncology at the School of Medicine at Georgetown University, Washington, US, has undertaken significant research in this area. In a 2017 study, Levy and colleagues compared a 'status quo scenario', which projected smoking rates and health outcomes in the US in the absence of vaping, with several 'substitution scenarios' where cigarette use was largely replaced by vaping over a 10-year period. Both scenarios were tested with optimistic and pessimistic assumptions about the relative harms of e-cigarettes compared to cigarettes, as well as their impact on initiation, cessation, and switching. The study projected mortality outcomes by age and sex in the US from 2016 to 2100. In the optimistic scenario, the researchers estimated 6.6 million fewer smoking-related deaths and nearly 87 million fewer life years lost, representing a 25% reduction in deaths and a 35% reduction in life years lost. Even in the pessimistic scenario, there were still 1.6 million fewer deaths (a 6% reduction) and 20.8 million fewer life years lost (an 8% reduction).

In another study, Levy et al. simulated the effects of nicotine vaping products on the 1997 US birth cohort. 133 Instead of assuming a complete replacement of smoking with vaping, the authors created scenarios that track vaping adoption. These scenarios follow individuals as they progress from trying nicotine vaping products to established use, and even consider dual use of both cigarettes and vapes. The model also incorporated cessation behaviours at later stages in life, providing a more realistic view of smoking and vaping dynamics. Furthermore, unlike the 2017 study that focused solely on the health impacts for smokers, this study examines how vaping among individuals who might not otherwise have smoked could influence public health. The study projected significant public health benefits from the use of nicotine vaping products, with a 21% reduction in smokingattributable deaths and a 20% reduction in life years lost, equating to approximately 101,000 fewer deaths and 2 million fewer life years lost for the

1997 cohort.



A similar modelling study conducted by Levy and colleagues in 2021 for all US adults projected that from 2013-2060, the use of nicotine vaping products would result in 1.8 million fewer deaths (10.4% reduction) and nearly 39 million life years saved (19.9% reduction in life years lost). 134

Finally, Levy and colleagues also estimated the impact of nicotine vaping products on smoking prevalence and the resulting smoking-attributable deaths before and after nicotine vaping product access in the US, UK and Canada. 135,136,137 Using indirect simulation models, they projected smoking trends in a counter factual (no-vape) scenario, while controlling for tobacco control policies and comparing these trends with national survey data. The analysis showed that the use of nicotine vaping products contributed to reductions in both smoking prevalence and smoking-attributable deaths in all three countries.

For example, in the UK, 20.2% of the 27.5% relative reduction in male smoking between 2012 and 2019 was attributable to nicotine vaping products, resulting in 165,660 averted deaths by 2052. In the US, half of the reduction in smoking

between 2012 and 2018 was attributable to nicotine vaping products, resulting in 400,000 averted smoking-attributable deaths between 2012 and 2052. In Canada, a 14% reduction in male smoking attributable to nicotine vaping products between 2012 and 2020 yielded 100,000 averted smoking-attributable deaths between 2012 and 2060. A similar methodological approach in Germany, carried out by Levy and colleagues, also showed substantial decreases in deaths (300,000) and life years lost (4.7 million) from 2012 to 2060.



Mendez and Warner (2021) also used simulation analysis to estimate the potential of nicotine vaping products to reduce smoking-related mortality in the US. ¹³⁹ Evaluating 360 possible vaping scenarios, 357 (99%) showed positive life years saved due to vaping, ranging from 143,000 to 65 million by 2100. Most scenarios predicted millions of smokers quitting due to vaping, with these quitters gaining an additional 1.2 to 2.0 years of life compared to those who quit without vaping. Later replication studies in Russia and Georgia showed similar results, with potential reductions in life years lost due to smoking reaching 18.6% and 28.9%, respectively. ^{140,141} However, based on current rates of nicotine vaping product use and SNP regulations in these countries, the most plausible scenarios indicated a 3-8% reduction in smoking-related life years lost.

One recent study looked away from the HIC that dominate much research, instead focusing on the potential for lives saved in Kazakhstan, Pakistan, South Africa and Bangladesh. The authors chose these countries as they are designated as LMIC and have other pressing health priorities, under-staffed health agencies, weak tobacco control enforcement and also high levels of smokeless product users, who also feature in the annual death toll of 350,000 across the four countries. The study found that by combining access to SNP with improved, earlier diagnosis and treatment of lung cancer, about 2.6 million lives could be saved in those four countries combined between 2020 and 2060.142

While most public health benefit models for nicotine vaping products are prospective, Sweden provides a real-world example of the effects of SNP (particularly snus) on public health. In 1981, daily smoking prevalence was 27% in Sweden. By 2022, this had plummeted to 5.3%, while daily snus use rose to 20.2% from 14% in 1982. 143,144,145 This shift significantly reduced smoking-related diseases. The rate of lung cancer cases amongst Swedish men in 2022 was less than half the European average. 146 A 2019 study linked increased snus use to a decline in smoking-related cancers, attributing nearly half of this decrease to snus. 147 Another 2019 study found that substituting smoking with snus in Sweden reduced smoking-related deaths by 50% compared to other EU countries. 148 According to the European Cancer Information System's data, Sweden has the lowest lung cancer incidence and mortality rate among men in the EU and Nordic countries, despite having overall nicotine use around the EU average, underscoring the life-saving benefits of snus. 149



evidence suggests that SNP have a positive impact on reducing smoking-related mortality – the magnitude of that impact depends on the rate of transition to SNP

As we have shown, the evidence available from individual countries enables the formation of national projections about the impact of SNP on smoking-related morbidity and mortality, with a reasonable degree of confidence. However, as yet, global projections for the impact of SNP are currently unavailable. There are major gaps in data availability. A further significant challenge would be accounting for the vast array of cultural, socioeconomic and product availability factors and their interactions. How would these affect the transition from smoking to SNP in different countries?

But although comprehensive global estimates are lacking, we can say that evidence from both HIC and LMIC suggests that SNP have a positive impact on reducing smoking-related mortality. The magnitude of that positive impact depends on how quickly the transition from combustible tobacco to safer alternatives takes place.



Reality check

The evidence is stacking up that SNP can both improve and save lives. But if THR is to have global reach, much will depend on the actions of a few major tobacco companies and those making regulatory decisions on SNP. To what degree are the companies willing to invest in making SNP which are genuinely affordable, acceptable, appropriate and accessible to the global population of over a billion tobacco consumers? Are these companies really committed to transitioning all of their customers to safer products? Or will the regulators decide this for them, banning SNP while millions continue to smoke, allowing the tobacco companies to return to 'business as usual'?

The major companies have an infamous and egregious track record of lies and deceit over cigarette safety. This means that public trust in these companies is, unsurprisingly, virtually non-existent. As the revolution in SNP began a process of creative destruction on the tobacco industry, it was inevitable that the companies would get involved in the manufacture and sale of SNP. But this involvement has brought that lack of public trust with it.

Campaigners against THR have led the public, politicians, and journalists to believe that tobacco companies dominate the sale and distribution of the most widely available and visible SNP, nicotine vapes. This is untrue. PMI, BAT and JTI combined are estimated to command about 26% of the global nicotine vaping product market share by value. The majority share is taken by non-tobacco industry companies, mainly based in China.

But while they may not be the dominant force in the production of nicotine vapes, it is the major tobacco companies that make HTP, and as we have seen, they are also gaining market share in smokeless products, particularly nicotine pouches. And, of course, they all still derive the majority of their profits from selling combustible cigarettes.

Statements committing these businesses to bright futures in which they end smoking and produce SNP instead are frequently issued by the major tobacco companies. They are just as frequently countered by the question 'if the company is that committed to ending smoking, why is it still selling cigarettes today?'



it was inevitable that tobacco companies would get involved in the manufacture and sale of SNP- but this involvement has brought a lack of public trust with it

all tobacco companies still derive the majority of their profits from selling combustible cigarettes

with combustible cigarettes, tobacco companies are selling a highly profitable product that is legal in every country in the world

only four companies were backing public statements with a reasonable level of action in terms of SNP sales and investment

the pace and willingness of this transition largely depend on the level of competition tobacco companies face from SNP producers in specific markets In a speech in September 2023, PMI's CEO Jacek Olczak made the case that companies like his have both the means and the leverage with their consumers to effect a large-scale transition away from combustible cigarettes. He also took aim at what he perceived as some of the major blocks to the company's move to smoke-free products:


"Today's environment and rhetoric make it easier for governments and regulators to do nothing on smoke-free alternatives. It's perceived as safer for political careers to abstain from the debate completely rather than be seen as siding with [PMI]. But, in the end, this is just prolonging the life of cigarettes and risks shortening the lives of those who use them. For smokers today, inaction is not a neutral position. It is a choice with real-world outcomes." ¹⁵¹

Oil companies continue to sell fossil fuels and automotive companies are still selling internal combustion engines, arguing that the profits from their current business will fund their transition to a more environmentally sustainable future. Are there parallels? With combustible cigarettes, tobacco companies are selling a highly profitable product that is legal in every country in the world. As Chapter Four will explore, strict regulatory frameworks or outright prohibitions mean the same cannot be said for SNP. All company CEOs are obligated to act in the best interest of the company - which most often means maximising profits for investors and shareholders. Any other approach sees that CEO fired.

But exactly how committed are the major companies in transitioning their product portfolio away from combustible products to SNP in reality? Research organisation Idwala was engaged to rank the performance of the world's 15 largest tobacco companies against a range of indicators, primarily the level of SNP sales and the degree of investment being made.

They concluded that only four companies were judged to be backing public statements with a reasonable level of action in terms of product sales and investment. Nearly all that output was geared to HIC and very little to LMIC.¹⁵² Since 2008, PMI has invested \$12.5 billion USD in its SNP ventures, with SNP making up 36.4% of its net revenue in 2023. PMI has also indicated its intention that, by 2030, SNP will make up over two thirds of total net revenues.¹⁵³

SNP accounted for 12.3% of BAT's total revenue in 2023, and the company has made a similar declaration to PMI, stating that smokeless products will make up 50% of their total revenue by 2050. This is not reflected throughout the industry, however. SNP made up just 3% of Imperial Brands' net revenue in 2023. The same statement of the industry is not reflected throughout the industry.



Recent research by Levy, et al. (2023) suggests that we are a long way from the narrative of transformation put forward by some tobacco companies becoming a reality. The authors argue that US companies will back alternatives to cigarettes when threatened by competition - in the form of pressure from non-tobacco companies. In the absence of that competition, those companies have less incentive to promote SNP.

Competition itself is largely dependent on government regulation of safer nicotine products. Thus, policies stimulating competition will positively impact innovation, in the shape of better alternatives and better substitutes for cigarettes. The Levy study also emphasises that public health advocates and researchers need to be open to the concept of both tobacco and non-tobacco companies earning profits from selling SNP.

In truth, the picture is mixed. A few companies at least appear to see significant non-combustible portfolios as a percentage of overall turnover and profit in future. But most of the global tobacco companies, whether private, state-owned or with significant state investment, are a very long way from turning all their production capacity over to non-combustibles. The pace and willingness of this transition largely depend on the level of competition they face from SNP producers in specific markets. And as we have said, in some of the major tobacco-producing countries, whole economies are reliant on the more dangerous combustible and risky oral product industry.

Additionally, products that are both available and affordable to HIC consumers are simply out of reach to those living in LMIC. Given the financial, political and cultural obstacles in the way of SNP take-up in many lower income countries, the reluctance of companies with global reach (US or China-based) to invest in developing relevant SNP markets is unsurprising.

Twenty years of the SNP revolution: development at pace

SNP development has come a very long way in a remarkably short space of time since the first, basic e-cigarette was launched twenty years ago. Today, there is a dizzying array of product options. Nicotine vapes range from basic, cheap single use products to high tech devices, and a huge range of flavour choices. Numerous different brands of HTP are available, and Swedish snus and nicotine pouches are gaining in prominence.

But individual nicotine users' choices are often limited by regulatory restrictions, bans or simply by companies deciding not to market a product in their country. This can limit consumers to certain product categories or within product categories, for example in terms of their choice of flavours, limiting the efficacy of THR.

Of course, consumer uptake has also undergone dramatic shifts. Vaping remains dominant, with the GSTHR's 2024 estimate of the global number of vapers increasing to 114 million in 2023, up from our previous estimate

of 82 million in 2021. There seems to be little doubt that the emergence of the single use vape has played a part in accelerating this growth.

But other SNP are on the rise as well. HTP have taken off in several countries around the world since 2015; as a more expensive product, their market value now exceeds that of the vape market in those countries. In some Nordic countries, snus is now the dominant nicotine consumer choice, while very recently, nicotine pouches have made substantial inroads into the North American SNP market. All the available metrics for SNP growth appear to be on the up; SNP are here to stay.



all the available metrics for SNP growth appear to be on the up; SNP are here to stay

there is an association between the increasing numbers of people who are using SNP and a decline in the prevalence of smoking

the data reveal SNP to be life-saving



Overall market trend data suggest that while combustible tobacco sales remain significantly higher than SNP sales, the share of SNP in the total tobacco and nicotine market is increasing – and that adjusting for inflation, combustible tobacco sales are declining, while SNP sales are experiencing rapid growth.

The impact that the growth of SNP is having on smoking is also strongly suggested by prevalence data from a number of countries including Japan, New Zealand, Norway, the Philippines, Sweden, the United Kingdom and the USA. All indicate that there is an association between the increasing numbers of people who are using SNP and a decline in the prevalence of smoking. This is strongly suggestive of substitution effects of SNP for cigarettes at a population level - and that is good news. Because the data reveal SNP to be life-saving: the significant reductions in smoking achieved by switching to SNP have been shown to have real-world impacts in terms of the number of early deaths avoided.

By analysing how far SNP are substituting for combustible cigarettes worldwide, it is clear that the process of creative destruction unleashed on the tobacco industry is well underway – but it is not complete yet. How can major transnational and state-owned tobacco companies be persuaded to turn their backs on the vast profits of the combustible cigarette for good? Much will depend on national and international regulation and control regimes for SNP – the subject of the next chapter.

Chapter Four: Global regulation and control

The global regulatory and control landscape for SNP is very mixed. There are wide variations in how governments have responded to the emergence of these products, with official responses ranging from bans - in some cases using existing tobacco control laws - to a variety of regulatory frameworks, or indifference and inaction.

In this chapter, we look first at how regulation and control of SNP has been discussed at an international level, at meetings of the Framework Convention on Tobacco Control (FCTC). It is important to note that even for Parties to the FCTC - the countries that have signed and ratified the Convention - tobacco control remains a domestic issue. While, technically, the FCTC is 'legally' binding, there are no enforcement consequences for non-compliance. If anything, the FCTC could be seen as "morally" binding. 158

Over recent years, the WHO, and numerous influential organisations and funders associated with it, have explicitly called for countries to either ban or heavily regulate SNP. In reality, a wide range of measures have been introduced by countries keen to influence their domestic SNP markets and consumers in different ways. By no means all of them follow the WHO party line.

Measures brought in to deal with the emergence and uptake of SNP fall into different groups. At the top level, there is the issue of product legality. Are the main SNP product categories legally available in the country? Then, where products are legally available, there are a wide variety of regulations in place covering, for example, procedures for product approval, product characteristics, marketing, advertising, health warnings, taxation, packaging and flavours. We will turn to these later in the chapter, after considering the international context for tobacco control.

An international perspective: the WHO, FCTC Secretariat and the Conference of the Parties

International tobacco control is guided by the Articles contained in the FCTC, which was enacted in 2005. 159 This was before most SNP became widely commercially available.

The Convention preamble declares a determination to "promote measures of tobacco control based on current and relevant scientific, technical and economic considerations" [emphasis added]. Thus, there is a recognition that developments may occur in future which could affect the implementation of the FCTC. It is evident from this text, therefore, that the architects of the Convention never intended it to be set in stone.

Notably, the phrase 'harm reduction' appears in Article 1(d), within the Introduction to the FCTC, but its meaning is not explained further. Article 1(d) offers instead a definition of 'tobacco control' according to the Convention - with harm reduction acting as the third of three strategic pillars:

"and then 'tobacco control' means a range of supply, demand and harm reduction strategies that aim to improve the health of a population by eliminating or reducing their consumption of tobacco products and exposure to tobacco smoke."160



a wide range of measures have been introduced by countries - not all of them follow the WHO party line

the architects of the Convention never intended it to be set in stone

advice on SNP could be accommodated within the Convention Articles, or in new guidelines

there has been no attempt to harness the potential of new technology into tobacco control – quite the opposite

the WHO's current position is that SNP are no safer than smoking, do not help in cessation, and risk the renormalisation of smoking, especially for young people



In light of the evidence demonstrating that SNP are substantially safer than smoking, and that they can assist in smoking cessation, advice on SNP could be accommodated within the Convention Articles, or in new guidelines issued on proportionate control that reflects the science. But to date, no such accommodations have been made.

Every two years, the Parties to the FCTC meet at the Conference of the Parties (COP). Those who observe the COP process believe that the FCTC Secretariat, which strongly influences the agenda, has been doing all in its power to avoid a debate on the subject of SNP and their role in tobacco harm reduction.

Decisions taken at COP meetings can be of huge importance for people who continue to smoke and people who use safer nicotine products – but they are not permitted representation at the summits. Clearly, too, there has been no attempt to harness the potential of new technology into tobacco control – quite the opposite.

Advertising, covered under Article 13 of the FCTC, is one area in which new guidelines could play a significant part in assisting people who smoke to switch to safer products, for example. While not undermining the general ban on cigarette advertising, Parties could be encouraged to allow the promotion (or even be involved in the promotion) of SNP to adults who already smoke. At the very least, companies should be permitted to place inserts in packs of combustible products, informing people of the potential to reduce the risk to their health by switching to a safer product.

But this could not happen without a significant change of policy at the WHO. The WHO's current position is that SNP are no safer than smoking, do not help in cessation, and risk the renormalisation of smoking, especially for young people. This approach has underpinned almost every recommendation on the subject presented to every COP since the FCTC Secretariat raised initial concerns back in 2008.

To explore how the WHO position on SNP has developed, we present here a timeline of COP meetings since 2008, highlighting actions or discussions that took place that hold relevance for SNP as well as their role in THR, with a particular focus on COP10, the most recent meeting, which took place in February 2024.

We discuss a number of reports which were submitted by the FCTC Secretariat to different COP meetings, all of which relate to the following two Articles of the FCTC:

Article 9 - Regulation of the contents of tobacco products

"The Conference of the Parties, in consultation with competent international bodies, shall propose guidelines for testing and measuring the contents and emissions of tobacco products, and for the regulation of

these contents and emissions. Each Party shall, where approved by competent national authorities, adopt and implement effective legislative, executive and administrative or other measures for such testing and measuring, and for such regulation."¹⁶²

Article 10 - Regulation of tobacco product disclosures

"Each Party shall, in accordance with its national law, adopt and implement effective legislative, executive, administrative or other measures requiring manufacturers and importers of tobacco products to disclose to governmental authorities information about the contents and emissions of tobacco products. Each Party shall further adopt and implement effective measures for public disclosure of information about the toxic constituents of the tobacco products and the emissions that they may produce." ¹⁶³

These two Articles, or more precisely, the *interpretation* of the two Articles, are instrumental to determining the extent of the FCTC's influence on the regulation of SNP. Currently, Articles 9 and 10 officially apply only to tobacco products. In recent years, however, some COP observers believe that the FCTC Secretariat has sought to encourage Parties to widen this scope. If this were to occur, Article 9 and 10 could also be applied to products including vapes and HTP, which would have significant implications for their regulation and control.

This concern notwithstanding, Articles 9 and 10 have for some time thrown up immensely complicated and technical issues, and been the subject of considerable discussion, debate and even occasional dissent between the Parties and the FCTC Secretariat.

Before going any further, it is also important to note that the WHO and FCTC terminology for nicotine vaping devices is 'Electronic Nicotine Delivery Systems' or ENDS, with the later addition of ENNDS for 'Electronic Non-Nicotine Delivery Systems' and 'D-ENDS' for 'Disposable Electronic Nicotine Delivery Systems'.

COP3 (2008): Initial considerations of ENDS

ENDS were first mentioned in the context of a COP meeting in a progress report which recommended producing guidelines for Articles 9 and 10 to the Third Session of the COP.

At that point, the WHO did not appear to be taking a strong position on their regulation.¹⁶⁴ Nevertheless, by 2009, Brazil, Uruguay and the Seychelles had implemented a total ban on nicotine vaping devices.^{165,166,167}

COP4 (2010): Parties asked to consider if ENDS should be regulated as tobacco products

At the Fourth Session, the working group tasked with producing guidelines for Articles 9 and 10 submitted a progress report, in which the COP was asked to consider whether ENDS should be considered as tobacco products, despite the fact that they do not contain tobacco. 168

For the same session, the Convention Secretariat produced a report, 'Control and prevention of smokeless tobacco products and electronic cigarettes'. It contained the Convention Secretariat's guidance to the working group: ENDS *should* be regarded as tobacco products.¹⁶⁹



by 2009, Brazil, Uruguay and the Seychelles had implemented a total ban on nicotine vaping devices

the paper on ENDS contained the WHO's first 'warning' to Parties that tobacco companies were now involved in the manufacture and supply of nicotine vapes

the clear acknowledgement of the potential of harm reduction using nicotine-containing products is striking, given WHO's later position

This report set the direction of travel. The section on smokeless tobaccos correctly focused on India and South-East Asia, home to the most dangerous forms of these products. With regards to ENDS, however, the paper asserted that there was no evidence to back claims of relative safety, or their efficacy as products to aid smoking cessation. Still, there was no general call to ban products.

COP5 (2012): Secretariat call for Parties to survey availability of ENDS in their country

The Fifth Session of the COP was presented with an FCTC Secretariat report, 'Electronic nicotine delivery systems including electronic cigarettes'. ¹⁷⁰ It reported the results of a survey conducted by the Secretariat among the Parties, to ascertain the extent and availability of ENDS use in their countries. Out of 176 Parties, only 33 replied. Only 16 could state that vaping products were available in their country. Only two had any prevalence data.

The WHO did not report any scientific or clinical assessments of the products themselves. Strangely, although the established recommendation was that ENDS were to be regarded as tobacco products, the WHO Study Group on Tobacco Product Regulation (TOBReg), the organisation's scientific body on tobacco control, reported that "ENDS designed for the purpose of direct nicotine delivery to the respiratory system fall into a regulatory gap in most countries, escaping regulation as drugs and avoiding the controls applicable to tobacco products".¹⁷¹

The FCTC Secretariat paper on ENDS did contain something very significant, however: the WHO's first 'warning' to Parties that tobacco companies were now involved in the manufacture and supply of nicotine vapes. In paragraph 30 of the paper, the FCTC reported the purchase of independent vape manufacturers by tobacco companies, stating "[they] are taking notice of the emerging products". 172


By 2012, no additional countries had banned vapes. Among the few that had replied to the FCTC survey, there was a mix of regulation and no regulation. Overall, the message to Parties from the WHO was: 'we don't know enough about these products'.

COP6 (2014): WHO acknowledges conflicting views on ENDS

The paper prepared by the FCTC Secretariat for the Sixth Session of the COP in 2014 was titled 'Electronic Nicotine Delivery Systems'. 173 For the first time, the WHO recognised that the emergence of vaping was provoking a range of reactions in the public health community:

"ENDS are the subject of a public health dispute among bona fide tobacco-control advocates that has become more divisive as their use has increased. Whereas some experts welcome ENDS as a pathway to reduction of tobacco smoking, others characterize them as products that could undermine efforts to denormalize tobacco use."

Further into the paper, there are hints at the potential benefits of nicotine vapes. Under a section on 'Health risks to users and non-users', the paper concluded that "therefore it is very likely that average ENDS use produces lower exposures to toxicants than combustible products". On the issue of helping people who smoke to quit, the paper refers to the 2014 US Surgeon General Report. It had concluded that:



"ENDS are much more likely to provide public health benefits only in an environment where the appeal, accessibility, promotion and use of cigarettes and other combusted tobacco products are rapidly reduced." 174

What would be the obvious way of facilitating this process? To ensure every effort was made to persuade people who smoke to switch. Instead, much of the paper is devoted to urging Parties to prohibit the marketing and promotion of ENDS, alongside other alleged risks of allowing the ENDS market to flourish, including referencing the 'gateway theory' and undermining tobacco control efforts.

Under the heading 'General Considerations', the paper stated:

"Public health authorities need to prioritize research and invest adequately to elucidate evidentiary uncertainties as soon as possible. However, the greater responsibility to prove claims about ENDS scientifically should remain with the industry."175

This was disingenuous in two respects. Few countries outside the US would have the capacity to conduct their own research. They would inevitably rely on scientific advice from the WHO. Judging by the references in this paper, this was already heavily weighted against the potential public health benefits of nicotine vaping. Secondly, it is hard to see how industry could make the scientific case as it was (and remains) very difficult for industry science to be published in academic journals.

Finally, this paper noted the results of the 2014 WHO survey on ENDS regulation, where it was found that 13 countries had banned the sale of vapes containing nicotine. Among the conclusions was this assessment:

"However, the majority of these countries report that ENDS are available to the public, probably through illicit trade and crossborder Internet sales."176

COP7 (2016): Tobacco industry involvement seals the fate of ENDS

COP7 saw the publication of a WHO report titled 'Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)'.177

The report directly addressed the 'role of ENDS/ENNDS in tobacco control' under section five. The clear acknowledgement of the potential of harm reduction using nicotine-containing products that pose fewer health risks than combustible tobacco is striking, given the WHO's later position:

"If the great majority of tobacco smokers who are unable or unwilling to quit would switch without delay to using an alternative source of nicotine with lower health risks, and eventually stop using it, this would represent a significant contemporary public health achievement."178

This statement was followed by caveats around uptake of any such product among youth and non-smokers. There was also recognition that debate continued over whether nicotine vapes could perform the function outlined above:

"Whether ENDS/ENNDS can do this job is still a subject of debate between those who want their use to be swiftly encouraged and endorsed on the basis of available evidence, and others who urge caution given the existing scientific uncertainties as well as the performance variability of products and the diversity of user behaviour."179

Unfortunately for those advocating in favour of harm reduction, while this paper appears to have been influential in the development of the WHO's stance on vaping, it was not as a consequence of the points above. What seems to have had the most impact came instead, it would appear, from the section on 'Commercial interests', which contains this observation:

"Initially, the growth of the ENDS/ENNDS market was driven by companies that were independent from traditional transnational tobacco companies (TTCs). However, TTCs are rapidly increasing their share of what is so far a generally unregulated market. [...] The engagement of TTCs in the marketing of ENDS/ENNDS is a major threat to tobacco control."180

The point made in this brief paragraph can now be understood as a key driver for the attitude adopted by WHO and its allies, first toward nicotine vapes, and later, other SNP. To many observers, it seems that from this point on, organisations which opposed THR/SNP, and the funders of those organisations, were focused less on the potential benefits of SNP to reduce death and disease from smoking, and more on re-energising the war against the tobacco industry.

One more important development occurred at COP7, as far as tobacco harm reduction is concerned. It exemplifies the hardening stance on 'ENDS' – along with evidence of discontent emerging among some Parties in response.

The committee stage is where the main business is conducted at COP meetings. There are two committees, formed from Parties to the FCTC; Committee A deals with policy matters and Committee B with administrative ones. In 2016, after discussion, Committee A, submitted its draft report for Parties to consider at the plenary stage. The draft report included this provision:

"INVITES Parties to consider applying regulatory measures such as those referred to in document FCTC/COP/7/11 to prohibit or restrict the manufacture, importation, distribution, presentation, sale and use of ENDS/ENNDS, as appropriate to national laws and public health objectives." [emphasis added]

During the committee discussions, some Parties present wanted the statement to reflect that any regulation of 'ENDS/ENNDS' should be 'science-based'. However, after objections from others, those words did not appear.



"the engagement of traditional transnational tobacco companies in the marketing of ENDS/ENNDS is a major threat to tobacco control" – FCTC Secretariat

from this point on, organisations which opposed THR/SNP were focused [...] on re-energising the war against the tobacco industry

some Parties wanted the statement to reflect that any regulation of ENDS/ ENNDS should be 'science-based' – but those words did not appear

by 2018, 30 countries had banned or severely restricted consumer access to vapes

COP8 (2018): HTP enter the fray, and the spread of ENDS continues

By the time of the Eighth Session in 2018, HTP were now on the market in a number of countries. Produced only by the major tobacco companies and containing tobacco, Parties were informed that they were therefore unequivocally subject to the provisions of the FCTC.

The FCTC Secretariat produced a 'progress report' on the regulatory and market landscape since the first COP report in 2008. Reading this, there certainly had been progress in the spread of nicotine vaping devices (or in the WHO's terminology, ENDS/ENNDS) across the world, although primarily in HIC. However, 30 countries had already banned or severely restricted consumer access to vapes.

COP9 (2021): The pandemic delays further developments

COP9, initially scheduled for 2020, was delayed for a year because of COVID. Ultimately, the meeting was conducted online in 2021. There were no substantive discussions on any topic - although two important papers relevant to THR were held over until COP10.

COP10 (2024): How long can the WHO ignore THR?

In a February 2024 Lancet comment, published immediately prior to COP10, two distinguished former WHO Directors, Professor Robert Beaglehole, a global public health practitioner, and Professor Ruth Bonita, an epidemiologist, explicitly called for a change of direction from their former employers. Titled 'Harnessing tobacco harm reduction', Beaglehole and Bonita said:

"Countries that are reaping the benefit of tobacco harm reduction, such as New Zealand, Sweden, Norway, England, and Japan, should encourage participating countries at COP10 to support proposals that will quickly reduce smoking rates." 183



This was not the first time Beaglehole and Bonita had spoken up. In a presentation in 2021, Robert Beaglehole argued that "progressive countries [should] be working together to reform WHO, to reform COP", directly addressing his WHO colleagues as "the harm reduction deniers". 184 And in 2022, Beaglehole and Bonita, again in The Lancet, stated baldly that "the FCTC is no longer fit for purpose, especially for low-income countries". 185

But in the lead up to COP10, held in Panama City, there was little to indicate that any change of heart was on the FCTC agenda. In a dedicated Briefing Paper, 'The FCTC COP10 Agenda and supporting documents: implications for the future of tobacco harm reduction', the GSTHR noted:

"Neither the Agenda, nor the accompanying published COP10 documents, nor various other reports intended to influence the Parties at the COP consider that SNP offer any opportunities for public health. There is no guidance for countries wishing to incorporate THR and SNP into their tobacco control policies, including how to regulate them in proportion to the level of risk they pose. SNP are presented as a threat to tobacco control, rather than as a potential tool to both support a switch from smoking and reduce high-risk tobacco use."186

While the FCTC Secretariat's position on SNP appeared unchanged in the agenda and supporting documents, however, some of the Parties' opening statements in Panama suggested that not all were planning to fall in line.

Most of what takes place at COP happens behind closed doors, and the meetings receive little or no coverage in mainstream media. A website called Copwatch, established by consumers of SNP who advocate for THR, aims to rectify this lack of scrutiny. The authors provide updates on what emerges into the public sphere about the proceedings of COP meetings. Copwatch highlighted some of the countries whose positions looked to be straying from the official 'party line' on THR:

"The [Philippines] was one of many which challenged the WHO to consider harm reduction as a valid option to reduce the harms of combustible use. [...] They were not the only delegation to do so. Disappointed pro-WHO groups objected that 'a number of countries, led by Guatemala and including the Philippines, China, Russia, Antigua and Barbuda, echoed industry talking points'. Translation: They didn't fall into line with the policies favoured by the WHO."187

Copwatch later added New Zealand, Armenia, El Salvador and St Kitts and Nevis to the list of countries that made positive statements about SNP and THR. 188 In one of the most interesting, a former Prime Minister of the Caribbean state of St Kitts and Nevis, Denzil Douglas, noted:

"Although the convention that guides us itself describes tobacco control as a range of supply, demand and harm reduction strategies [...] the public health community must define these terms on a more detailed manner. It is important to note [...] that the proven concept of harm reduction plays a significant role in other areas of public health, such as sexually transmitted infections, HIV AIDS, drug and alcohol addiction, and in fact, air pollution. [...]



in the lead up to COP10, held in Panama City, there was little to indicate that any change of heart was on the agenda

some of the Parties' opening statements in Panama suggested that not all were planning to fall in line

while Working Groups can be open to all Parties, Expert Groups are firmly within the control of the FCTC Bureau

this stalemate is indicative that a growing number of Parties are resisting the imposition of decisions made for them by the FCTC leadership

the FCTC Secretariat's unilateral view was that all HTP emissions – which do not burn tobacco, but heat it – count as 'smoke' "The tobacco control community should not reject the idea of harm reduction per se but we should learn from the best practices of proven public health-oriented measures while preventing the tobacco industry from hijacking that important term." 189


He then said, "with the above in mind, we would like to present a proposal...", but was immediately interrupted by the President of the COP, Ms. Dhlamini, who told Douglas to "confine [himself] to the agenda". Undeterred, he tried again: "Right. And we are proposing a working group which I intend to spend more time...". Again, Ms. Dhlamini interjected swiftly, saying "it is not the time for a proposal". ¹⁹⁰

The St Kitts and Nevis proposal was specifically for a 'working group'. This is important – and perhaps explains the President's desire to close down the suggestion so quickly. 'Working Groups' or 'Expert Groups' can be established under FCTC procedure to scrutinise specific issues. But while Working Groups can be open to all Parties, Expert Groups are firmly within the control of the FCTC Bureau and are heavily linked to WHO bodies as well as selected NGOs, most funded by Bloomberg, all of which tend to be opposed to THR.¹⁹¹

The 'Working Group' versus 'Expert Group' question was the source of one of the most protracted debates at COP10, in relation to Articles 9 and 10. As noted earlier, these cover the 'regulation of tobacco products and their disclosure' and are crucial to how the FCTC deals with SNP. The Article 9 and 10 Working Group was suspended in 2018. Following two consultations by the FCTC Secretariat in 2020 and 2021, a majority of Parties indicated they wished the Working Group to continue. Yet in the official documents supplied ahead of COP10, Parties were instead invited to replace the Article 9 and 10 Working Group with an Expert Group.

In Panama, the debate over this issue went on for five days. It took up so much time that multiple other agenda items had to be moved to accommodate it. The St Kitts and Nevis proposal came up again – as did the question of the inclusion of nicotine vapes in this workstream. The official report of COP10 notes:

"Some Parties urged the Committee to also consider a draft decision that would call for the creation of an intersessional working group on harm reduction.



Other Parties considered that harm reduction went beyond the scope of the Article 9 and 10 agenda item currently under consideration, which dealt exclusively with the contents and emissions of tobacco products; a technical report on harm reduction by WHO would be more appropriate. A suggestion that the Working Group's mandate should be extended to cover nicotine and non-nicotine delivery systems (ENDS/ENNDS) was opposed on the same grounds."193

After five days of debating this and other related points, no consensus could be reached. This stalemate is indicative that a growing number of Parties are resisting the imposition of decisions made for them by the FCTC leadership and its networks - particularly when it comes to matters relevant to tobacco harm reduction.

The two papers relating to safer nicotine products that had been held over from 2021 formed part of the relevant substantive discussions at COP10. One of the papers was titled 'Challenges posed by and the classification of novel and emerging tobacco products'. 194 The paper sought to consider the definition of 'smoke' in relation to the emissions of 'novel and emerging tobacco products'. This is important, as protecting "present and future generations from the devastating [...] consequences of tobacco consumption and exposure to tobacco smoke" is the stated objective of the FCTC.195

The FCTC Secretariat had urged Parties to conduct their own research into HTP. In reality, the Secretariat would have been aware this research was unlikely to happen, largely due to the cost. The FCTC Secretariat's unilateral view was that all emissions from HTP - which do not burn tobacco but heat it - count as 'smoke'. By that token, HTP should logically be controlled under the FCTC. In a report, the Secretariat included information on the approach to HTP from 17 high-income countries. Ten had already applied existing smoke-free legislation to the products. 196 Neither Sweden nor Germany featured on the list. Perhaps that had something to do with the fact that legal cases in both countries, brought by PMI, had found that the 'heat sticks' used in HTP should in fact be classed as 'smokeless tobacco products'.197,198

While the primary focus of this paper was HTP, it is worth noting that some of the wording leaves open the possibility for the emissions of other products to be similarly reclassified:

"Novel and emerging tobacco products, particularly HTPs, emit pyrolysis products such as volatile aldehydes; therefore, these aerosols are clearly within the scientific definition of 'smoke'." 199

The second paper held over from 2021 was titled 'Comprehensive report on research and evidence on novel and emerging tobacco products, in particular heated tobacco products, in response to paragraphs 2(a)-(d) of decision FCTC/COP8(22)'. Despite claiming to be comprehensive, the document was only ten pages long. It focused almost exclusively on HTP, repeating the contents of previous papers about HTP emissions, health risks, and market size, highlighting areas of 'uncertainty' and stating that HTP were not harmless.200 Of course, not even the staunchest THR advocate would make such a claim.

Beyond COP10

If the organisers were keen to keep harm reduction off the official agenda, outside of the conference centre in Panama City, things were different. THR advocates and consumers of SNP - denied entry to the official proceedings - held parallel sessions. It appears that their presence did not go unnoticed by the WHO. According to multiple reports, the Panamanian authorities raided hotels where THR advocates were staying, apparently in search of 't-shirts and pamphlets advertising harmful products'.201

The reality is that any discussion of harm reduction under the FCTC would inevitably force a recognition that products like vapes, HTP, snus and nicotine pouches, when well-regulated, contribute to tobacco control through harm reduction. The evidence supports the assertion that they would "improve the health of a population by eliminating or reducing their consumption of risky tobacco products and exposure



the Panamanian authorities raided hotels where THR advocates were staying

safer alternatives to combustible cigarettes should not be regarded as. and subject to the same controls as, the risky tobacco products they could replace

to tobacco smoke" (Article 1D, FCTC).²⁰² Logically, safer alternatives to combustible cigarettes should not be regarded as, and subject to the same controls as, the risky tobacco products they could replace.

But a Party consensus in support of this would signal a complete rejection of current WHO policy on 'novel and emerging tobacco and nicotine products', the term the WHO uses to refer to SNP. This is very unlikely. After yet another COP meeting, the issue of THR is still not officially on the table. So, everything has gone into stasis once again, until COP11, scheduled to take place in Geneva in November 2025.

As noted at the outset of this chapter, tobacco control is a matter for individual countries, with the exception of work on cross-border smuggling of illicit tobacco. Yet while the WHO and FCTC Secretariat are always careful to emphasise the sovereign rights of Parties to formulate their own policies, there is still clear pressure from the top for policy harmonisation when it comes to the regulation and control of SNP. In official COP documents and other communiqués, the FCTC Secretariat (and the WHO more broadly) have encouraged countries to adopt tight controls on these products. But how have governments chosen to respond to SNP? What does the global legal landscape look like in 2024?



a notable increase in the number of countries implementing bans on vaping occurred between 2009 and the release of our first GSTHR report in 2018

the regulatory environment for SNP is notably more complex and nuanced than that of combustible tobacco products

The current legal landscape for SNP

The global regulatory environment for SNP is both diverse and constantly evolving. Over the past decade, the trend has generally been toward stricter regulations or outright bans on SNP. Nicotine vaping products have been at the centre of much of the debate and regulatory change. This heightened focus is likely due to vapes being more widely accepted internationally (at least up until 2020, as discussed in Chapter 3), having been on the market longer than HTP and nicotine pouches, and drawing significant concern from regulators, particularly regarding youth vaping (explored in Chapter 5).

A notable increase in the number of countries implementing bans on vaping occurred between 2009 and the release of our first GSTHR report in 2018. 203

For the past six years, the GSTHR project has been closely monitoring these developments, having established the world's largest THR database. This free-to-access online resource supplies data on the use, availability and regulation of SNP, as well as smoking prevalence and mortality, across over 200 countries and regions. With frequent, often daily updates, the GSTHR website closely tracks changes in legislation.²⁰⁴

Since the database was created in 2018, there has been movement in both directions in terms of the regulation of vapes – some countries have imposed new bans, while others have relaxed their laws, making them legally available. For instance, by 2024, countries such as Chile, India, Kazakhstan, Kuwait, Laos, Norway, Taiwan, and Vietnam had instituted bans on vapes. Conversely, nations such as Bahrain, Egypt, Lebanon, New Zealand, Saudi Arabia, and the UAE lifted theirs, making nicotine vaping products legally accessible to their populations by 2024.

The regulatory environment for SNP is notably more complex and nuanced than that of combustible tobacco products. It is overly simplistic to claim that a country has 'banned' vaping, as some media and online sources do. In reality, a ban can range from an outright prohibition on the sale, production or import of vaping products, to a de facto ban where products are only available with a prescription, or where nicotine-containing liquids are banned while nicotine-free liquids are permitted.

Further complexity arises in countries with federal systems like the USA and Canada, where laws can vary significantly from state to state.

Legal availability

To provide a global perspective on SNP regulation and to simplify the classification of product legality, we grouped the legal status of SNP in each country into three categories:

- 1. Legally available (or legally available consumer products, LACP):
 - a. Countries where the sale and use of SNP as a consumer product are permitted under specific laws that regulate their sale and use, without heavy restrictions (in this case, we consider heavy restrictions to be e.g. banning nicotine in the product, only allowing purchase with prescription or from medically licensed professionals).
 - b. Countries where there is no specific legislation regulating SNP, but where they are regulated under general tobacco laws. For example, if combustible or smokeless tobacco products are not banned in a country, SNP would also be considered legally available under these general laws.
- 2. Banned: Countries where the sale and/or use of SNP are explicitly prohibited by law or so heavily restricted (e.g., prescription-only, medically licensed SNP only, bans on nicotine-containing SNP) that it effectively prohibits their sale as consumer goods.

3. No information:

- a. Countries where there is no information available on their regulatory status, meaning we lack data on whether specific or general tobacco laws permit or ban their sale/use.
- b. Countries where SNP fall outside the legal framework entirely, meaning they are neither specifically banned nor regulated.

As of 2024, at least one category of SNP (nicotine vapes, HTP, snus or nicotine pouches) is legally available in 129 countries. This covers four billion people, which represents 71% of the global adult population.

Not all countries allow all categories of SNP, however. Moreover, regulators typically favour only one type of SNP, while banning others. In 45 countries, only one type of SNP is legally available, covering 502 million people (9%). A further 31 countries allow for two SNP, covering nearly 2 billion people (34%), 26 countries permit three SNP, covering 381 million people (7%). Four types of SNP are legally available in only 27 countries, covering 1.2 billion people (21%).

In 72 countries, no SNP are legally available, affecting 1.7 billion people, or 29% of the global population. 'Not legally available' does not *necessarily* mean that SNP are banned – while this category includes countries that do have bans on all products (of which there are five:

India, Qatar, Thailand, Turkmenistan and Vietnam),

it also includes those where there is no specific

legislation on any product, or where information is unavailable (53 countries) and where these categories are mixed.


At least one kind of SNP is legally available in 129 countries




Table 2 Legal availability of SNP (nicotine vaping devices, heated tobacco products, snus and nicotine pouches)

Number of legally available safer nicotine products	Number of countries	Population covered (millions)	Percentage of global population covered
At least one SNP is legally available	129	4,066	71.14%
One SNP is legally available	45	502	8.79%
Two SNP are legally available	31	1,961	34.31%
Three SNP are legally available	26	381	6.66%
Four SNP are legally available	27	1,222	21.38%
No safer nicotine products are legally available	72	1,650	28.86%

Analysing the global landscape for SNP by product type reveals significant regulatory diversity. The graph below illustrates the legal status of SNP across the global adult population.







About 54% of the global adult population, equivalent to 3.1 billion people, live in countries where nicotine vapes are legally available. In contrast, 36% (2 billion people) reside in countries where vaping is banned, while 10% (610 million people) are in countries with no specific legislation or available information.

HTP have a slightly different distribution. They are legally available to 36% of the global adult population (2 billion people), while half of the population (50%, or 2.9 billion people) lives in areas where these products are banned. The remaining 14% (790 million people) are in regions with no clear regulatory stance.

Snus is legally available to 58% of the global adult population (3.3 billion people), making it more widely accessible than both vaping products and heated tobacco. However, 32% of people (1.8 billion) live in countries where snus is banned, and 10% (570 million) are in areas with unclear regulations.

Finally, nicotine pouches are legally available to 35% of the adult population (2 billion people), while half of the population (50%, or 2.9 billion people) resides in areas where they are banned. The remaining 15% (840 million people) are in regions with no specific regulation or available information.


It is worth noting, in any discussion over the prohibition of safer nicotine products, the fact that no countries currently ban combustible tobacco. This means the deadliest type of nicotine delivery system – the combustible cigarette – is currently legally available to 100% of the world's population.

The maps below illustrate the legal availability of the various safer nicotine product categories worldwide. Although no clear geographical pattern emerges from these regulations, there is a notable trend: it is uncommon for a product to have either legal availability or banned status in just one or two countries within a region. Generally, if a product is a legally available consumer product, or conversely, is banned in one country, the same status is likely to apply across the majority of neighbouring countries within that region. This suggests that regional influences often shape national policies, leading to similar regulatory environments across entire regions.





nicotine vapes are legally available to 54% of the global adult population, HTP to 36%, snus to 58% and nicotine pouches to 35% - but combustible cigarettes to 100%

the deadliest nicotine delivery system of all – the combustible cigarette – is legal everywhere on earth










Regulation of flavours


Even if a product is legally available, the availability of flavours is another important factor incentivising the substitution of smoking by SNP or helping avoid a relapse to smoking.²⁰⁵ Our focus is on the regulation of flavours for nicotine vaping products and HTP, primarily due to the availability of data.

The regulation of flavours varies significantly across different countries. There are no restrictions on flavours for nicotine vapes in 41 countries, which allow a wide range of choices. However, 10 countries have implemented restrictions, permitting only tobacco, mint, and menthol flavours, or in some cases, only tobacco or no flavours at all. When it comes to HTP, 30 countries allow all flavours, whereas 25 countries have put restrictions in place.

The maps below illustrate the diverse regulatory approaches to flavours used in safer nicotine products around the world.







Other regulatory aspects

Beyond product and flavour availability, several other regulatory domains significantly impact consumers, including retail restrictions, advertising and promotion, health warnings and labelling, product content, and taxation.

These policies, like those governing product and flavour availability, vary considerably across different countries. To illustrate the range of regulatory approaches, this analysis focuses on the top countries by SNP market size, excluding the United States and Canada due to the significant variation in regulations across states within these countries (see table below).

 Table 3, 4 SNP regulatory provisions in top SNP markets

		Legal av	<i>r</i> ailability	1	Flavours				Sale restrictions				Sales Age
Country	NVP	HTP	SNUS	NP	NVP	HTP	SNUS	NP	NVP	HTP	SNUS	NP	AII SNP
Japan	В	LACP	LACP	В	РСВ	MF	MF	РСВ	PCB	SR	SR	РСВ	20
Italy	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	SR	SR	PCB	SR	18
UK	LACP	LACP	В	LACP	MF	MF	РСВ	MF	GR	GR	PCB	GR	18
Germany	LACP	LACP	В	В	MF	TF or NF	РСВ	РСВ	GR	GR	РСВ	РСВ	18
Indonesia	LACP	LACP	LACP	LACP	MF	MF	MF	MF	GR	GR	GR	GR	18
China	LACP	В	LACP	В	TF or NF	PCB	MF	РСВ	GR	РСВ	GR	РСВ	18
Russia	LACP	LACP	В	В	РСВ	PCB	РСВ	PCB	GR	GR	PCB	РСВ	18
Poland	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	GR	PCB	GR	18
South Korea	LACP	LACP	LACP	LACP	MF	MF	MF	MF	SR	SR	SR	SR	19
Sweden	LACP	LACP	LACP	LACP	MF	TF or NF	MF	MF	GR	GR	GR	GR	18
South Africa	LACP	LACP	LACP	LACP	MF	MF	MF	MF	GR	GR	GR	GR	18
Switzerland	LACP	LACP	LACP	LACP	MF	MF	MF	MF	GR	GR	GR	GR	18
Ukraine	LACP	LACP	В	LACP	TF or NF	MF	РСВ	MF	GR	GR	РСВ	GR	18
France	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	SR	PCB	GR	18
Czech Republic	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	GR	PCB	GR	18
Hungary	LACP	LACP	В	LACP	TF or NF	TF or NF	РСВ	No info	SR	SR	РСВ	SR	18
Greece	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	GR	РСВ	GR	18
Uruguay	В	LACP	LACP	LACP	РСВ	MF	MF	MF	PCB	GR	GR	GR	18
Kazakhstan	В	LACP	В	В	РСВ	MF	РСВ	РСВ	РСВ	GR	РСВ	РСВ	21
Norway	В	В	LACP	В	РСВ	РСВ	MF	РСВ	PCB	РСВ	SR	РСВ	18
Romania	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	GR	РСВ	GR	18
Portugal	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	GR	РСВ	GR	18
Lithuania	LACP	LACP	В	В	TF or NF	TF or NF	РСВ	РСВ	GR	GR	РСВ	РСВ	18
Spain	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	SR	РСВ	GR	18
Austria	LACP	LACP	В	LACP	MF	TF or NF	РСВ	MF	GR	SR	РСВ	GR	18
Denmark	LACP	LACP	В	LACP	TMMF	TF or NF	РСВ	MF	GR	GR	РСВ	GR	18

Source: GSTHR4

	Sale via the internet			rnet	Poi		ale prod play	uct	Health warnings on product packaging				Excise tax compared to excise duty on cigarettes			
Country	NVP	НТР	SNUS	NP	NVP	НТР	SNUS	NP	NVP	НТР	SNUS	NP	NVP	НТР	SNUS	NP
Japan	РСВ	Α	Α	РСВ	РСВ	Α	Α	РСВ	РСВ	THW	THW	РСВ	РСВ	<10%	<50%	РСВ
Italy	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	PCB	THW	<10%	<50%	PCB	<10%
UK	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	No excise	<50%	PCB	No excise
Germany	Α	Α	РСВ	РСВ	Α	Α	РСВ	РСВ	THW	THW	РСВ	РСВ	<10%	>=50%	PCB	РСВ
Indonesia	Α	Α	Α	Α	Α	Α	Α	Α	THW	THW	GHW/PP	THW	<50%	>=50%	<50%	>=50%
China	Р	РСВ	Р	РСВ	Α	РСВ	Α	РСВ	THW	PCB	THW	РСВ	>=50%	>=50%	No excise	PCB
Russia	Р	Р	РСВ	РСВ	Р	Р	РСВ	РСВ	THW	THW	РСВ	РСВ	<50%	>=50%	PCB	РСВ
Poland	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	<10%	<50%	PCB	No excise
South Korea	Р	Р	Р	Р	Α	Α	Α	Α	GHW/PF	GHW/PI	PGHW/PP	GHW/PF	>=50%	>=50%	>=50%	>=50%
Sweden	Α	Α	Α	Α	Α	Α	Α	Α	THW	THW	THW	THW	<50%	<50%	<50%	<10%
South Africa	Α	Α	Р	Α	Α	Α	Α	Α	THW	GHW/PI	PGHW/PP	THW	<50%	>=50%	>=50%	No excise
Switzerland	Α	Α	Р	Α	Α	Α	Α	Α	THW	THW	THW	THW	No excise	<50%	<50%	<50%
Ukraine	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	<50%	<50%	PCB	No excise
France	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	No excise	>=50%	PCB	No excise
Czech Republic	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	No excise	<50%	PCB	No excise
Hungary	Α	Α	РСВ	Α	Α	Α	РСВ	Α	No info	THW	РСВ	THW	<10%	>=50%	РСВ	No excise
Greece	Α	Α	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	<10%	<50%	PCB	No excise
Uruguay	РСВ	Р	Р	No info	PCB	Р	Р	Α	РСВ	GHW/PI	PGHW/PP	THW	РСВ	No excise	No excise	eNo excise
Kazakhstan	РСВ	Р	РСВ	РСВ	РСВ	Р	РСВ	РСВ	РСВ	GHW/PI	PCB	РСВ	РСВ	>=50%	PCB	РСВ
Norway	РСВ	PCB	A	РСВ	РСВ	РСВ	Р	РСВ	РСВ	PCB	THW	РСВ	РСВ	PCB	<50%	РСВ
Romania	Α	Α	РСВ	Α	A	Α	РСВ	Α	THW	THW	РСВ	THW	<10%	<50%	РСВ	No excise
Portugal	Р	Р	РСВ	Α	A	Р	РСВ	Α	THW	THW	РСВ	THW	<50%	<50%	PCB	No excise
Lithuania	Р	Р	РСВ	РСВ	Р	Р	PCB	РСВ	THW	THW	РСВ	РСВ	<10%	<50%	PCB	РСВ
Spain	Α	Р	РСВ	Α	Α	Α	РСВ	Α	THW	THW	РСВ	THW	No excise	<50%	PCB	No excise
Austria	Α	Α	РСВ	Α	Α	Α	PCB	Α	THW	THW	РСВ	THW	No excise	<50%	PCB	No excise
Denmark	Α	Α	РСВ	Α	Α	Α	РСВ	Р	GHW/PF	GHW/PI	PCB	THW	<10%	<50%	РСВ	<50%

Source: GSTHR4

The following abbreviations were used in the construction of the table for clarity and consistency:

A – allowed

B - banned

P - prohibited

NVP - nicotine vaping products

HTP - heated tobacco products

NP - nicotine pouches

LACP - legally available consumer product

PCB - this product category is banned

MF - most flavours are available

TMMF - only tobacco, mint, and menthol flavours are allowed

TF or NF - only tobacco or no flavours are allowed

THW - text health warning

GHW or PP - graphic health warning or plain packaging

GR - general retail (regardless of licensing schemes)

SR - specialised retail only



South Korea, Sweden, South Africa, and Switzerland stand out with some of the most liberal regulatory frameworks for SNP

Kazakhstan and Norway represent some of the most restrictive regulatory environments, where only one type of SNP is legally available

the availability of SNP through general retail versus specialist retail channels further distinguishes liberal from restrictive markets From this sample of countries, South Korea, Sweden, South Africa, and Switzerland stand out with some of the most liberal regulatory frameworks for SNP. In these countries, all four categories of SNP – nicotine vapes, HTP, snus, and nicotine pouches – are legally available. Additionally, these nations impose minimal restrictions on flavours (with the exception of Sweden for HTP) and allow wide availability through general retail channels (except in South Korea, where only specialist stores can sell SNP).

Conversely, Kazakhstan and Norway represent some of the most restrictive regulatory environments, where only one type of SNP is legally available - HTP in Kazakhstan and snus in Norway. Furthermore, Kazakhstan imposes the same restrictions on HTP as it does on combustible cigarettes.

In a range of other countries, such as Japan, Germany, China, Russia, and Lithuania, only two types of SNP are legally available. Others take a more selective regulatory approach, typically banning one type of SNP, often snus. This is especially the case in EU countries, where snus is generally prohibited. Uruguay is unique in this list as it bans only nicotine vapes, while other SNP categories are legally available.

Regarding flavours, existing restrictions primarily affect HTP, for which only tobacco or no flavour at all is typically allowed. The same restrictions apply to nicotine vaping products in China, Ukraine, Hungary, and Lithuania. Notably, no flavour restrictions are in place for snus and nicotine pouches in any countries where these products are legally available.

Sales restrictions and age limits are other tools used by governments to control the accessibility of SNP. The table reveals that most countries set the legal sales age for SNP at 18 years, aligning with global tobacco control standards. However, in Kazakhstan, Japan, and South Korea the restrictions are slightly more stringent, with age limits (for both cigarettes and SNP) at 21, 20, and 19 years, respectively.

The availability of SNP through general retail versus specialist retail channels further distinguishes liberal from restrictive markets. In countries like the UK, Indonesia, Sweden, and South Africa, SNP are widely available through general retail channels, making them accessible to consumers. In contrast, countries like South Korea, Italy, and Hungary restrict sales to specialist retail stores, which may require special licenses or for specific conditions to be met. This approach limits the accessibility of SNP, potentially reducing their appeal and use compared to combustible cigarettes.



Internet sales and point-of-sale (POS) display regulations add another layer of complexity to SNP regulation. In China, Russia, South Korea, Uruguay, Kazakhstan, and Lithuania, the sale of SNP through online retail channels is banned, which restricts consumer access, particularly in regions where physical retail options are limited. However, many European countries, including Italy, the UK, Sweden, Poland, and France, allow internet sales, recognising the growing trend of online shopping and providing consumers with convenient access to SNP.

Meanwhile, POS display regulations also vary widely, with some countries like Russia, Uruguay, Kazakhstan, Norway and Lithuania prohibiting the display of SNP at points of sale to reduce their visibility. Others allow it, making these products more visible and potentially more appealing to consumers who might otherwise choose combustibles.

Health warnings on SNP packaging range from simple text warnings to graphic health warnings (GHW) or plain packaging (PP). The majority of the countries in the selected sample use only text health warnings. These mostly differ from those on combustible cigarettes, focusing instead on nicotine addiction and potential health hazards associated with use of the product, rather than standard 'smoking kills' messages. However, South Korea, Indonesia, Uruguay, Kazakhstan, and Denmark have adopted more stringent measures, requiring either GHW or PP for specific categories of SNP.

Lastly, excise taxes on SNP and their rates vary widely. This influences the affordability and, consequently, the demand for these products. The picture around taxation is even more diverse than for the previously discussed regulatory domains.

Uruguay is the only country in the sample that does not levy excise taxes on the SNP categories legally available in the country.

Many countries, including Japan, Italy, Germany, Indonesia, South Korea, Sweden, and Denmark, tax all SNP categories that are legally available. Among these, South Korea and Indonesia impose relatively high taxes on SNP. Generally, HTP are the product category taxed most heavily compared to others. In contrast, nicotine pouches are mostly free of excise taxes.

Due to its importance and complexity, the taxation and pricing of SNP is further discussed in the following section.





tobacco control analysts often point to taxation as the most effective way of controlling product demand and influencing consumer choices

by 2023, among countries permitting the sale of nicotine vapes, at least 52 had implemented taxes on them

Taxation and pricing of SNP

We have indicated the primary modes of tobacco control as imposed on SNP. Tobacco control analysts often point to taxation as the most effective way of controlling product demand and influencing consumer choices. This section explores the taxation and pricing of SNP, primarily focusing on nicotine vapes and HTP. We examine the tax regimes and rates applied to these products and assess how much the taxes are reflected in retail prices. Additionally, and importantly, we compare the affordability of SNP to that of combustible cigarettes.

Taxation of SNP around the world


With the emergence of vapes, HTP and other new nicotine and tobacco products, policymakers have used varied taxation strategies. By 2023, among countries permitting the sale of nicotine vapes, at least 52 had implemented taxes on them. Of these, 37 tax all e-liquids, while 17 only tax those containing nicotine. Most countries impose a specific excise tax on e-liquids, with 30 applying a uniform tax rate and nine using a tiered system. An ad valorem system is used in 11 countries while four use a mixed system. A further 12 countries specifically tax vaping devices, typically imposing a lower tax burden on closed systems compared to e-liquids sold separately.

Table 5 Types of excise applied to nicotine vaping products, as of May 2023

Type of excise tax	Taxing only nicotine-containing e-liquids	Taxing all e-liquids
Specific uniform	Albania, Kazakhstan*, Kyrgyzstan, Portugal, Romania, Russia	Armenia, Azerbaijan, Belarus, Bulgaria, Croatia, Cyprus, Estonia, Finland, Georgia, Germany, Greece, Hungary, Latvia, Lithuania, Malaysia, Montenegro, North Macedonia, Pakistan, Poland, Serbia, South Africa, South Korea, Ukraine, Uzbekistan
Specific tiered	Denmark, Indonesia, Philippines, Sweden	Canada, Italy, Morocco, Slovenia
Ad valorem uniform	Bahrain, Ecuador, Jordan, Saudi Arabia	Costa Rica, Maldives, Paraguay, Togo, United Arab Emirates
Ad valorem tiered	China	
Mixed		Egypt, Ghana, Israel, Kenya

Source: Global taxation of ENDS and ENNDS: a cross-country evaluation and Recommendations for Taxation²⁰⁷ Note: While this table reflects the tax situation as of May 2023, Kazakhstan banned the sale of all types of nicotine vaping product in April 2024, with the ban taking effect in June 2024. As a result, excise taxes on nicotine vaping products are no longer applicable in that country (see Section Three: Eastern Europe and Central Asia for details).

Out of the 52 countries which tax nicotine vapes, Belarus had the highest excise tax burden at 88%. This was followed by Portugal at 85%, Norway at 78%, and Kazakhstan at 77%. Ukraine, Georgia, and Malaysia had excise tax burdens of 62%, 65%, and 60%, respectively. Nineteen countries had an excise tax burden exceeding 50%, while another 19% had burdens below 30%. The lowest excise tax burdens were noted in Costa Rica and Paraguay (both at 4%), Kenya (3%), and Croatia (0%).



Source: Global taxation of ENDS and ENNDS: a cross-country evaluation and Recommendations for Taxation²⁰⁸

Countries typically impose lower taxes on nicotine vaping products than on cigarettes. Among the 52 countries that levy taxes on e-liquids, data on excise tax rates or retail prices are missing for two countries. However, of the remaining 50 countries with available data, 15 impose a higher excise tax burden on nicotine vapes compared to cigarettes, which runs counter to the principles of risk-proportionate excise taxation.²⁰⁹

As of 2023, 66 countries levy taxes on HTP.²¹⁰ Most countries use a specific excise tax rate based on the weight of tobacco, which can be challenging for tax collection due to verification difficulties. Consequently, an increasing number of countries are opting to tax HTP per stick, irrespective of tobacco content.

Table 6 Types of excise applied on HTP, as of 2022

Type of Excise Tax	Base unit	Country					
Specific	Kg of tobacco	Albania, Austria, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czechia, Denmark, Estonia, Greece, Iceland, Indonesia, Ireland, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Montenegro, Morocco, Netherlands, New Zealand, North Macedonia, Pakistan, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Sweden, United Kingdom					
	Sticks	Armenia, Azerbaijan, Hungary, Italy, Japan, Jordan, Peru, Philippines, Republic of Korea, Republic of Moldova, South Africa, Ukraine, United States of America					
Ad valorem	Retail price	Costa Rica, Ecuador, Paraguay, Spain, Switzerland					
	Retail price excluding VAT	Saudi Arabia, United Arab Emirates					
Mixed	Kg of tobacco / Retail price	Finland, France, Germany, Poland, Portugal					
	Sticks / Retail price	Colombia, Georgia					
	Sticks / Wholesale price	Israel, Palestine					

Source: Perucic AM, Sandoval RC, Malik S, Morales-Zamora G. Taxation of novel and emerging nicotine and tobacco products (HTP, ENDS, and ENNDS) globally and in Latin America. Rev Panam Salud Publica. 2022;46:e175.211

In 2023, data from 66 countries showed no instances of HTP being taxed higher than cigarettes, while only a few countries have equal tax rates for HTP and cigarettes. This trend extends to the excise tax burden as well, where the majority of these countries have a lower excise tax burden on HTP. Therefore, taxation seems to be a lesser obstacle for the uptake of HTP, at least in comparison to cigarettes.

Taxation of SNP and rates of excise tax are rapidly changing worldwide, along with regulatory frameworks. An increasing number of countries are introducing excise taxes on these products or raising existing excise tax rates. However, as of 2024, where SNP are legally available, they generally enjoy more favourable taxation compared to cigarettes – although not always proportionate to their relative harms. The maps below illustrate the diverse taxation approaches to various SNP globally.




among 50 countries with available data, 15 impose a higher excise tax burden on nicotine vaping products compared to cigarettes


data from 66 countries showed no instances of HTP being taxed higher than cigarettes, while only a few countries have equal tax rates for HTP and cigarettes











SNP prices compared to cigarettes

Despite favourable taxation, SNP prices are not always lower than cigarette prices. A 2017 study compared the price of combustible cigarettes, disposable e-cigarettes, e-liquids, and e-liquids with rechargeable devices in 45 countries.²¹³ Despite favourable taxation, combustible cigarettes were still more affordable than nicotine vaping products. Specifically, disposables were 3.2 times more expensive than cigarettes in LMIC and 1.3 times more expensive in HIC. E-liquids alone were more expensive than cigarettes in LMIC by 27%, while they were priced at only 44% of cigarette prices in HIC.

A 2019 study of 34 countries found that HTP, despite being taxed at lower rates than cigarettes, were more expensive in half of the surveyed national markets.²¹⁴ By 2023, data indicated that HTP were generally cheaper than cigarettes, except in Poland, South Korea, and Uzbekistan.²¹⁵ In 17 of the countries surveyed, the price difference between HTP and cigarettes was a mere 10%, whereas in the UK and New Zealand, HTP were notably cheaper, costing 2.5 times less than cigarettes.

The initial cost of the devices needed to consume e-liquids or heated tobacco adds another significant cost barrier to switching from smoking to vaping. According to the same 2017 study, accounting for the combined cost of e-liquids and vaping devices, they were less affordable than cigarettes in almost all countries, except the UK.²¹⁶



a survey of 34 countries found that HTP, despite being taxed at lower rates than cigarettes, were more expensive in half of the surveyed national markets

instead of lowering prices to encourage consumers to switch from cigarettes to safer products, companies leverage these tax benefits to increase their profit margins

A 2022 study comparing the cost of nicotine across different products in Switzerland, Germany, the USA, Sweden, France, and the UK found that when adjusted for device price, HTP cost more than regular tobacco products (except in the USA) and other nicotine-containing products.²¹⁷ Considering that cigarette taxes and prices in those countries are generally high and significantly higher than in LMIC, it is likely that this finding holds true in other HIC, while the difference will be much greater in LMIC.

The primary reason why lower taxes on SNP are not fully reflected in lower prices compared to cigarettes lies in the industry's strategy and pricing. Research raises concerns that tax advantages may primarily benefit producers by allowing them to maintain higher profit margins on SNP. Instead of lowering prices to encourage consumers to switch from cigarettes to safer products, companies leverage these tax benefits to increase their profit margins.²¹⁸

Indeed, data from 2023 shows that the difference in excise taxes between cigarettes and HTP was, in most cases, greater than the retail price differences, supporting this argument.²¹⁹ Industry reports also suggest that HTP producers employ this pricing strategy, positioning HTP sticks as value-oriented compared to premium brand cigarettes, and enjoy significantly higher profits from selling HTP compared to cigarettes.



demand for nicotine vapes is more sensitive to price changes than demand for cigarettes

higher vape prices significantly increase the likelihood of smokers opting for conventional cigarettes without influencing their decision to quit


although many countries tax SNP at lower levels than cigarettes, the discrepancy in tax rates between SNP and cigarettes often fails to mirror the actual difference in health risks

government subsidies for SNP, to encourage uptake by adults who smoke, present an unconventional perspective which diverges from traditional tobacco control approaches

the UK stands out as a country that already provides subsidies and preferential tax treatments for smoking cessation products

subsidising NRT in Sweden is costsaving and removes financial barriers, particularly for socioeconomically disadvantaged smokers





Source: Campaign for Tobacco-Free Kids: Heated Tobacco Products and Cigarettes Taxes and Prices Around The World²²⁰ Note: The excise tax gap is defined as the difference between the excise tax rate on cigarettes and the excise tax rate on HTP. Similarly, the price gap refers to the difference between the price of cigarettes and the price of HTP.

Additional reasons for the higher cost of HTP compared to cigarettes may include the significant initial investment that companies had to make in product development. This made their sales unprofitable during the first years the products were on the market. Ongoing research and development efforts to improve existing technologies and create new products also contribute to higher costs.

Optimal SNP taxation

The literature recommends implementing excise taxes on traditional tobacco products through simple tax structures, employing metrics like the number of cigarettes, packs, or weight as a basis.^{221,222} However, designing an optimal taxation strategy for SNP is more complex for several reasons. Firstly, their consumption behaviour differs from that of cigarettes. Secondly, SNP present significantly lower health risks, thereby offering public health benefits, not costs. Lastly, the diversity and constant evolution of these products add to the complexity of establishing an effective taxation framework.

The WHO advises imposing taxes on SNP, recommending that HTP be taxed at the same rate as cigarettes to discourage use by youth and non-users. They also suggest taxing e-liquids uniformly, regardless of nicotine content, and considering taxes on the devices themselves. Similarly, the World Bank advocates for increasing excise taxes on nicotine vapes, combined with even higher taxes on cigarettes, to prevent non-smokers from starting nicotine vape use, reduce dual usage, and encourage those who smoke to switch to vapes. 224

However, current scientific evidence suggests that these recommendations might lead to negative public health outcomes.

Research shows that the demand for nicotine vaping products is highly responsive to price changes, with estimated own-price elasticity ranging from -0.8 to -2.2. 225,226,227,228,229 This means that for every 1% increase in the price of vaping products, the demand falls by 0.8% to 2.2%, suggesting the demand for nicotine vapes is more sensitive to price changes than it is for cigarettes.

Additionally, studies have established that nicotine vaping products and conventional cigarettes are economic substitutes; a price increase in conventional cigarettes tends to boost nicotine vape sales, and vice versa.^{230,231,232,233} Experimental studies

highlight that higher vape prices significantly increase the likelihood of smokers opting for conventional cigarettes without influencing their decision to quit. This indicates that taxing nicotine vaping products could shift vapers back to smoking.²³⁴ Conversely, higher combustible cigarette prices not only decrease the likelihood of choosing cigarettes but also increase the likelihood of choosing nicotine vaping products or quitting altogether.

Therefore, these findings suggest that raising taxes on conventional cigarettes could motivate people who smoke to switch to significantly less risky nicotine vaping products. It could also motivate people to quit using tobacco and nicotine products entirely. However, imposing or increasing excise taxes on nicotine vaping products may encourage the uptake, continuation or re-initiation of smoking among both youth and adults.²³⁵ These conclusions might be generalised to other SNP as well.

Although many countries tax SNP at lower levels than cigarettes, the discrepancy in tax rates between SNP and cigarettes often fails to mirror the actual difference in health risks. Following the evidence suggesting that nicotine vaping products and snus are 95% and 98% safer than smoking, relative tax rates should be in line with their reduced risk. Assuming these tax differences are reflected in retail prices (and not in increased producers' profit margins), it would both acknowledge their lower harm and promote their use as substitutes for combustible tobacco products.

However, the diverse nature of SNP poses a challenge in establishing an optimal taxation framework for them. The complexity of determining appropriate tax bases, along with the challenges of monitoring and collecting taxes from SNP, could lead to policies that exacerbate rather than address market failures associated with smoking.²³⁶ Additionally, the administrative costs of taxing SNP proportionately to their relative risks might outweigh the tax collection itself, potentially having a negative fiscal impact. These considerations suggest that applying zero excise tax rates on SNP might be the most effective taxation strategy, representing a feasible approach for governments to adopt.

Exploring government subsidies for SNP, to encourage uptake by adults who smoke, presents an unconventional perspective which diverges from traditional tobacco control approaches.²³⁷ The primary rationale behind subsidising SNP is to improve public health outcomes, through the provision of direct government support to reduce the cost of safer alternatives compared to combustible tobacco products for individual consumers. This financial assistance aims to lower barriers, encouraging smokers to switch to SNP and thereby potentially mitigating the health risks of smoking. This approach aligns with harm reduction strategies that prioritise minimising the adverse health consequences of nicotine use or dependency through safer nicotine delivery mechanisms.



The UK stands out as a country that already provides subsidies and preferential tax treatments for smoking cessation products, particularly those classified as medicinal. The UK applies a reduced VAT rate of 5% to NRT products, compared to the standard 20% VAT for consumer goods. While nicotine vaping products licensed as medicinal products would also qualify for this tax reduction, it is important to note that currently no vape on the market holds such a license.

Furthermore, the UK's National Health Service (NHS) offers a programme to make NRT products, such as patches, gums, inhalers, sprays, and lozenges, as well as prescription drugs aimed at helping people quit smoking, more accessible and affordable. These products can be prescribed by doctors, and the cost can be reduced or completely covered depending on an individual's income. ²³⁹ A 2020 study analysing the impact of this NHS programme in England found that it contributed to 15.3% of the overall 10.8% reduction in smoking prevalence between 2001 and 2016, highlighting its effectiveness. ²⁴⁰ The 'Swap to Stop' programme – currently being rolled out at the time of writing – is a world-first, that will see nicotine vape starter kits given free of charge to around a million adults who smoke. ²⁴¹

A 2023 study analysing the cost-effectiveness of subsidising NRT in Sweden found that this cessation policy is cost-saving and removes financial barriers, particularly for socioeconomically disadvantaged smokers. This may play a role in reducing health inequalities.²⁴² Considering the evidence demonstrating the greater effectiveness of vapes compared to NRT in encouraging smoking cessation, subsidising SNP will likely lead to even greater public health and economic gains.



the WHO has tried to fill the vacuum of uncertainty around new ways of consuming nicotine

interventions from a handful of countries at COP10 indicated that the conversation about harm reduction cannot be put off forever

all of these policy levers should be directed towards encouraging more people who smoke to switch to safer products

increasing access to safer products
that can act as actual and economic
substitutes for combustible cigarettes
should only be seen as good news for
public health

Conclusion

New ways of consuming nicotine have developed so quickly over the past twenty years that governments have been unsure as to the most appropriate regulatory regime to adopt. The WHO has tried to fill this vacuum of uncertainty. Using its influence at meetings of the FCTC COP, the WHO has encouraged countries to adopt a progressively more prohibitionist approach to regulating new products, while denying that any public health benefit can be gained from enabling people who smoke to switch to SNP. This directly contradicts the weight of scientific evidence in relation to nicotine vaping and smoking cessation, as well as the experiences of millions of people who have successfully quit smoking by switching.

While the phrase 'harm reduction' appears in the FCTC, it still remains undefined. But there were interventions from a handful of countries at COP10 indicating that the conversation cannot be put off forever, and COP11 in 2025 will be one to watch.

Despite the WHO's encouragement toward prohibition, however, tobacco control remains solely a matter for domestic regulation. In that respect, the regulatory landscape for SNP is both very diverse and constantly evolving. In big picture terms, in 2009, four countries had banned the sale of nicotine vaping products. By 2024, there were 40. Even since 2018, the regulatory landscape has been anything but stable. Some countries have imposed new bans on nicotine vapes, while others have relaxed their laws, making vape products legally available.

But what does it mean when it is claimed that to country has 'banned' vaping, or any SNP category? A ban can range from an outright prohibition on the sale, production and import of SNP, to a de facto ban. And even legality comes with its complexities. In this chapter we have distinguished between countries where SNP are on sale as consumer products under tailored regulation, where they are on sale in the absence of specific legislation, but covered under tobacco laws. And, of course, there are countries where there is no information available on the regulatory status of various product categories, or where they are outside the legal framework neither banned nor

regulated. In many of these countries, the upshot is that consumers are left in the dark – and more likely to remain using the nicotine delivery system they are most familiar with, the combustible cigarette.

As well as product legality, there are other regulatory domains that significantly impact consumers and their likelihood to adopt SNP. These include the availability of flavours, retail restrictions (both internet and domestic sales points), advertising and promotion, health warnings and labelling, product content, and taxation. These policies vary considerably across different countries. All of these policy levers should be directed towards encouraging more people who smoke to switch to safer products. And a tobacco industry that grandstands about a non-combustible future must ensure that lower. risk-proportionate tax rates for SNP are reflected in price points that make switching more cost-effective to adults who smoke.



But despite the many regulatory obstacles to product access as of 2024, our research shows that at least one kind of SNP (nicotine vaping products, HTP, snus or nicotine pouches) is legally available in 129 countries. That covers four billion people, representing 71% of the global adult population. Given that combustible cigarettes, the most lethal method of nicotine delivery, are legally on sale in every country worldwide, increasing access to safer products that can act as actual and economic substitutes should only be seen as good news for public health.

Unfortunately, the legislative response to SNP in many countries, particularly LMIC, has too often been caught up in a web of financial, political, professional and ideological interests laced together by mis- and disinformation from public health agencies, medical organisations and charities that are otherwise credible. The result has been nothing short of an 'infodemic', the subject of the next chapter.

Chapter Five: The challenges to tobacco harm reduction



many fears have developed as a result of poor quality science on SNP, or have formed through persistent exposure to mis- and disinformation about SNP and THR

the arrival of vaping was the creative disruption in the delivery of nicotine that opened up new possibilities in THR

there is no doubt that concern over the tobacco industry's involvement has negatively impacted attitudes to vaping and other SNP

the arrival of SNP onto domestic markets dominated by state-owned tobacco companies might not be welcomed by governments with economic interests in tobacco manufacturing To reach its potential and hasten an end to smoking, tobacco harm reduction must overcome a multitude of challenges, many of which have been discussed in previous chapters. But here, we will propose that some of the most significant challenges to THR are both more fundamental and more intangible. This is because they are rooted in people's attitudes and emotions, in their ideals and moral outlook.

The arrival of most major disruptive technologies bring with them understandable concerns about unintended or unforeseen consequences when they first arrive. This chapter considers fears about safer nicotine products (SNP), which often centre on the role of the tobacco industry, the perceived health risks of nicotine, their use among young people, and more recently, their environmental impacts. Many fears have developed as a result of poor quality science on SNP, or formed through persistent exposure to mis- and disinformation about SNP and THR. There are active campaigns that seek to undermine and discredit THR and those who advocate for it.

There is frustration among those who advocate for THR that a lack of trust in the approach is drawing focus from the much bigger crisis: the eight million people who die every year as a direct result of smoking. Ultimately, however, until the trust issue is overcome among all stakeholders – including people who smoke, people working in tobacco control, health professionals, policymakers, and the media – harm reduction for tobacco will not reach its full potential.

Distrust of the tobacco industry and its motives

As highlighted earlier in this report, views about SNP and their role in smoking cessation are polarised among experts who work in tobacco and nicotine research. In this regard, THR has similarities with other contested areas of science and health research

The arrival of vaping was the creative disruption in the delivery of nicotine that opened up new possibilities in THR. When the first vaping products emerged in the early 2000s, they did so with little fanfare, remaining fairly niche for several years. These products were either manufactured and sold directly by Chinese companies, or by independent companies working with suppliers in Shenzhen. It is fair to say that many professionals, even those with an interest in smoking cessation and tobacco control, were broadly unsighted on their arrival. And while the industry was in the hands of small and medium size non-tobacco companies, it generally remained under the radar of political and media scrutiny.

Once vaping increased in popularity among consumers, this began to change. Health researchers started to pay more attention to vaping products, to consider their potential risks as well as their potential benefits to public health. Our first biennial report in 2018, No Fire, No Smoke, quantified this surge of interest. From 2007-12, there were a total of 53 publications recorded which had the terms 'e-cigarette', 'electronic cigarette', or 'e-cig' in either the abstract or the title. Between 2013 and 2017, that figure jumped to over 1500.²⁴³

But it was not only among researchers that interest had been piqued. With proof of consumer demand, from 2012 onwards, tobacco companies began to take a stake in vaping. This development marked a major shift in attitudes in

the health and tobacco control community. As noted in Chapter Four, in documentation prepared for COP7 in 2016, the WHO stated unequivocally: "the engagement of traditional tobacco transnational companies in the marketing of ENDS/ENNDS is a major threat to tobacco control." ²⁴⁴ It is both unsurprising and understandable that concerns would be raised, given the tobacco industry's egregious history of deception about the dangers of smoking (see Chapters Two and Three).

There is no doubt that concerns about the tobacco industry's involvement have negatively impacted attitudes to vaping and other SNP. But these suspicions are coupled with a limited understanding of who is actually producing many of the products. As shown in Chapter Three, the reality is that the majority of vaping products are *still* made by non-tobacco industry players. PMI, JTI and BAT combined command around 26% of the global nicotine vaping product market share by value.²⁴⁵

This does little to allay concerns, however – especially as those same companies still manufacture and make most of their profits from cigarettes, are the sole manufacturers of HTP and are increasingly moving into oral nicotine products. From the moment that traditional tobacco company involvement in SNP production began, there was a marked increase in hostility, not only towards individual products, but also towards the very concept of THR.

The subsequent adoption of the phrase 'tobacco harm reduction' by some tobacco companies, as part of their communications about transitioning away from combustibles, has unfortunately done nothing to improve trust in the approach.²⁴⁶ The tobacco industry's legacy is colouring what should be an objective, science-based and evidence-led assessment of THR, which has the potential to be one of the most impactful public health advances of our time. While discomfort at the involvement of the tobacco industry is understandable, the reality is, as always, complex.

As noted in Chapter Three, unless those tobacco companies who have stated their ambitions to transition to manufacturing SNP are permitted to do so, there is a risk they will return to a combustibles-led, business-as-usual model. There are few major Research and Development costs associated with the combustible cigarette – in contrast to the costs of developing new SNP. Over a billion people still smoke, so profits will continue coming in. The tobacco industry is not simply going to disappear because it has been wished away. It sells a highly profitable consumer product that, as well as being lethal, is legally sold in every country in the world.

Although they garner a significant amount of attention – and criticism – the companies that have identified a desire to transition toward SNP are actually very few. The majority of global tobacco production is not in their hands, but in those of major state-owned or state-involved companies. The Chinese National Tobacco Corporation is the world's largest manufacturer of cigarettes.²⁴⁷ In most of these organisations, transition to SNP is not even on the agenda. The arrival of SNP onto domestic markets dominated by state-owned tobacco companies might not be welcomed by governments with economic interests in tobacco manufacturing.

Intertwined with concern about who manufactures SNP, however, is another barrier to the acceptance of THR: fear of nicotine's perceived risks to health.

Perceived risks of nicotine



Concern about the health risks of nicotine appear to cluster into three main groups:

- 1) Conflation of the risks between smoking and nicotine use;
- 2) The absolute risks of using nicotine, in isolation from smoke;
- 3) Nicotine dependence.



empowering smokers to make sensible choices will require supporting them to develop the necessary understanding through public health messaging of the relative harms of combustion in relation to other sources of harm from smoking tobacco

although nicotine dependence
is undoubtedly real, without the
accompanying risks of smoking,
long-term use of nicotine has been
determined to be safe

Most people know that smoking is very dangerous for their health; if asked what is in cigarette smoke, the majority are unable to identify benzene, cadmium, formaldehyde or any of the other harmful chemicals released when a cigarette burns. They are, however, much more likely to be able to identify nicotine and tar. The association appears clear in many people's minds: nicotine must be harmful in itself.

Evidence of this confusion is supported by data from the International Tobacco Control Four Country Smoking and Vaping Survey. Researchers analysed the responses of people who smoke to understand their perceptions of the relative contributions to smoking-related morbidity from combustion products, nicotine, other substances present in unburnt tobacco and additives, and the impact this may have on their intention to use vaping products to quit. The study found that "most smokers lack conceptual coherence about smoking harms, with many either not knowing the relative harm that combustion, nicotine, additives, and unburnt tobacco cause or reporting inconsistent responses". The researchers concluded that:

"Health educators should be aware that many smokers have inadequate knowledge to make informed decisions, and do not automatically make logical integrating links between information. Empowering smokers to make sensible choices will require supporting them to develop the necessary understanding through public health messaging of the relative harms of combustion in relation to other sources of harm from smoking tobacco. This may also help them recognize and reject the misleading messages to which they are often subjected." ²⁴⁸

Healthcare professionals have also been shown to misunderstand the type and nature of the risks of nicotine. This has been demonstrated in multiple studies and in multiple countries over time. A study of US nurses in 2007, published in *Nicotine and Tobacco Research*, found that 60% believed that nicotine causes cancer and 72% believed that nicotine patches could cause heart attacks.²⁴⁹ A study of US physicians in 2020, published in the *Journal of General Internal Medicine*, found that "the majority of physicians 'strongly agreed' that nicotine directly contributes to the development of cardiovascular disease (83%), COPD (80%), and cancer (81%)."²⁵⁰ And a survey of 15,335 physicians in 11 countries, conducted by Sermo and funded by Global Action to End Smoking in 2022, found that 97% of doctors in Indonesia, 91% of doctors in China, and 88% of doctors in India believed that nicotine caused lung cancer.²⁵¹

These misperceptions persist despite the fact that nicotine has been used in NRT products for many years, and joined the WHO's Model List of Essential Medicines in March 2009.²⁵²

Fears about 'addiction to nicotine' are also frequent and significant. Although nicotine dependence is undoubtedly real, without the accompanying risks of smoking, long term use of nicotine has been determined to be safe.²⁵³ Isolated from smoking, many people enjoy and find that they benefit from their use of the substance, and in the form of SNP, they can do this with relatively low risks attached.²⁵⁴ Yet the words 'addiction' and 'dependence' are heavy with cultural connotations, judgements and stigma. A study published in the *International Journal of Drug Policy* asked people who smoke about their attitudes to what they termed 'clean nicotine' products. It found that:

"Many smokers are interested in using clean nicotine, but do not want to replace their addiction to smoking with addiction to an alternative product. Negative attitudes towards nicotine addiction may be a deterrent to harm reduction approaches that entail the continued use of nicotine." ²⁵⁵

There are challenges ahead in navigating a social and cultural reassessment of nicotine without smoke, and this is in no small part due to concerns about how the use of SNP affects young people. However, in order to maximise the smoking cessation potential of SNP, directly working to overcome fears related to nicotine among people who smoke, among healthcare professionals and among policymakers will be essential in order to expand delivery of and trust in THR.


Vaping and young people

It is unsurprising that some young people have been attracted to experiment with vaping. It is also unsurprising that this would raise concerns – among health researchers, parents, educators and politicians. Driven by significant media interest, concerns about young people vaping have been exacerbated by the recent and rapid rise of cheap single use vapes in a wide range of flavours. This has been characterised by some as part of an attempt by 'Big Tobacco' to draw in young nicotine users as cigarette sales fall.

Effective regulation and enforcement is necessary to restrict access to those who are underage and curb any inappropriate sales or marketing. But much of the anxiety about young people's use of SNP builds on people's existing fears of nicotine, its perceived risks to health and the threat of addiction – some of which may be inaccurate or exaggerated.


Official pronouncements, public or NGO-led campaigning, and some science reporting, have raised concerns among the general public about 'epidemic' levels of vaping among young people.^{256,257} In many countries, these concerns have had political ramifications, in the form of overly restrictive legislative controls or prohibitions which prevent adults who smoke from accessing safer products.

How valid are such claims of an 'epidemic'? The data are largely limited to those HIC which represent the most significant vaping markets. The chart below detailing trends in youth vaping in a number of HIC is compiled using national data from each country listed.²⁵⁸ It shows that from a peak in 2018-21, the trends in youth vaping are beginning to decline in a number of countries. The exceptions to this are the UK (labelled GB), which remains on an upward curve, and Australia, which – despite imposing very restrictive regulation – is experiencing a significant rise.




The chart above shows that the most dramatic fall in youth vaping has taken place in the US. This has had little impact on US-based campaign groups who continue to focus on the teen vaping narrative.²⁶⁰

When exploring the results of various surveys and studies it is important to recognise that most youth who experiment with vaping are not frequent users. For example, in Australia in 2022–2023, while around 15% of youth reported 'current' vaping, only 3% vaped 'daily'. In the US, only 3% of youth vaped 'daily', with 4% involved in 'frequent' vaping. Similar patterns are observed in other countries, indicating that much of youth vaping is temporary experimentation rather than habitual use. This pattern of temporary experimentation is aligned with the findings that most youth engage in vaping out of curiosity, boredom, or social reasons, rather than as a habitual practice. All practice.



In Canada, youth vaping rose temporarily after 2018 when vapes were legalised, but then returned to very low levels, as shown in the chart below. A small upturn in use, prior to a return to the status quo, mirrors other situations when banned products or substances have become legal (for example, cannabis).^{263,264}





concerns about young people vaping have been exacerbated by the recent and rapid rise of cheap single-use vapes in a wide range of flavours

exploring the results of various surveys and studies it is important to recognise that most youth who experiment with vaping are not frequent users Even in countries without evidence of widespread youth vaping, vape bans have been introduced under the banner of 'protecting young people'. The prohibitive stance taken by the Indian authorities offers one such example. In 2019, the government announced a ban on e-cigarettes "to prevent a youth 'epidemic'". Yet in 2022, the authors of a study of adolescent vaping in India admitted, "there is [a] dearth of qualitative data on adolescent use of e-cigarettes in the country". He study was limited to 24 teenagers who self-reported vaping. Data from the Global Adult Tobacco Survey, a study of 14 countries covering the earlier years of 2015-2018, identified fewer than 186,000 people in the whole of India who were current users of vapes. This in a country with a population of 1.5 billion, over 80 million consumers of combustible tobacco products and 199 million consumers of smokeless tobacco products. 267,268

Kazakhstan presents another case. In June 2024, the country banned the production, import, and sale of e-cigarettes. While this was ostensibly to protect younger generations, official data hardly supported claims of an 'epidemic'. In May 2023, Deputy Nurgal Tau proposed the ban to the country's Prime Minister Alikhan Smailov, stating:

"Electronic cigarettes destroy human lungs... According to the results of a study conducted by the WHO in Kazakhstan, the number of adolescents aged 11 to 15 using electronic cigarettes has tripled in four years. The current epidemic of addiction to electronic cigarettes is growing at a progressive rate." ²⁶⁹

The most recent data from the Health Behaviour in School-Aged Children Survey (HBSC) conducted in Kazakhstan in 2022 found that 5.8% of children reported e-cigarette use in the past 30 days (current vaping) with 9.8% having used e-cigarettes once or twice in their lifetime. Whether this can be defined as an epidemic is perhaps a moot point, as the products are banned.

Vaping and environmental concerns

As noted earlier, the rise of the single-use vape has been both dramatic and fast. Concern about young people's use of vapes is now accompanied by consternation about the negative environmental impact of single-use vapes. This has become a very visible problem in many places, with single-use vapes and vape packaging now a regular addition to the tonnes of litter thoughtlessly discarded every day on streets, in parks and on beaches.²⁷¹

Single-use vapes – and to a certain extent, other vaping devices and some other safer nicotine products – pose specific challenges in terms of the environment and sustainability. The need to limit single-use plastics is relevant both to disposable devices and e-liquid bottles. There are issues over the sourcing and use of lithium, a limited natural resource, particularly for single-use products. And there is also the question of how to dispose of these batteries safely, avoiding potential contamination and fire risks.²⁷² Some parts of the vaping industry are responding to these problems, including by incentivising the return of used vapes for recycling, and improvements to device design and electrical waste disposal.²⁷³



even in countries without evidence of widespread youth vaping, vape bans have been introduced under the banner of 'protecting young people'

concern about young people's use of vapes is accompanied by consternation about the negative environmental impact of single-use vapes

the context of SNP waste should be viewed in the far more significant issue of cigarette waste

The context of SNP waste should be viewed in the far more significant issue of cigarette waste. In 2023, an article in the *Journal of Hazardous Materials* found that cigarette butts are one of the world's most frequently littered items. The authors noted that "the low biodegradability of cellulose acetate filters and toxic chemical leaching from cigarette butts are the most important aspects of [their] environmental toxicity".²⁷⁴

With environmental concerns high on political, media and societal agendas, awareness of these problems has now been hitched to the wagon of anti-THR campaigning, seized on as another useful tool by the people and organisations who oppose and seek to discredit the concept.



Bad science – which can inform bad policy

Research that investigates the safety profile of all nicotine-containing products, their efficacy as smoking cessation tools and the applicability of harm reduction strategies is essential to the future of THR. Most researchers produce independent and well-constructed studies that do just that.

Unfortunately, however, there have also been numerous instances of research published in peer-reviewed journals that have used flawed methodologies and come to unwarranted conclusions. Several high-profile retractions have occurred after complaints.²⁷⁵ In one now infamous example, a study, conducted by UCSF's Stanton Glantz and published in the *Journal of the American Heart Association*, claimed that vaping doubled the risk of heart attacks. It was retracted after it was confirmed that the majority of the heart attacks experienced by study participants occurred before people began vaping.²⁷⁶

In an article for *Tobacco Reporter* in 2023, policy consultant Clive Bates listed a number of flaws he has frequently observed in studies about SNP.²⁷⁷ Some of his points are paraphrased and summarised here:

Poor toxicology. If a product, for example vape liquid, contains a dangerous chemical, this may not make it toxic – there must be sufficient exposure to cause harm.

Lack of meaningful comparisons. Many studies fail to show data on the effects of smoke-free products with context, for example in comparison to cigarette smoke.

Observations versus risks. Although it is a stimulant with many effects on the body, epidemiological studies generally do not show nicotine exposure to be harmful to health.

Unrealistic operating conditions. Some research employs machines to measure emissions from vapes or HTP, but using conditions that do not replicate how people would actually use the product - e.g. if it was overheated, it would taste terrible.

Over-interpreting animal and cell studies. Human cells in Petri dishes ('in vitro') or tests on animals ('in vivo') do not necessarily respond the same way that the human body would.

Correlation * causation. Observations may show, for example, that research participants who vape also experience a harmful effect. However, while this may be a correlation (or association), too many studies suggest that vaping causes the harmful effect.

Confounding by smoking history. Studies must make the smoking history of participants clear. Most of those who are old enough to vape and experience conditions such as heart disease used to smoke, and it is likely that the smoking caused the ill health.²⁷⁸

As well as poor quality science, there is also misleading communication of science.

The results of the vast majority of scientific studies are never communicated to the general public. But if considered newsworthy, studies will be selected by university press offices, written up into a press release, and then issued to journalists – most of whom will not be subject specialists – for them to write up in print or online articles, or report in broadcast media. What qualifies as newsworthy is often issues that are emotive, contentious or draw a lot of political focus. SNP, and in particular vaping, definitely qualify. And journalists receive hundreds of press releases every day. Good news is not as interesting as bad – and headlines have to grab attention.

The misinterpretation of scientific findings is by no means limited to the science on SNP. However, misunderstandings or misrepresentations are particularly frequent with regards to SNP research, especially about vaping. In one example, an article in *The Sun*, one of the UK's most-read tabloid newspapers, was headlined 'HOLY SMOKES: Vaping teens at risk of toxic metal exposure 'linked to brain damage' – worst-offending flavours revealed' (29 April 2024).²⁷⁹ The first line of the article reads: "VAPING could damage teenagers' developing brains because liquids contain toxic metals, according to research."

The Sun's report was referring to a study published in Tobacco Control, 'Biomarkers of metal exposure in adolescent e-cigarette users: correlations with vaping frequency and flavouring.' Experts responded to the study via the UK's Science Media Centre, which aims to support high-quality reporting on science, "particularly on controversial and headline news stories when most confusion and misinformation occurs". One came from a statistician, Professor Kevin McConway:

"It's interesting that the researchers point out generally that lead, uranium and their compounds are known to cause human health problems, without referring to the levels of lead and uranium actually found in the research participants. This research didn't directly measure any health problems in the participants, only biomarker levels in their urine. More important to me as a statistician, is that this research can't establish that the higher levels of lead and uranium in the urine of participants who said they vaped more often were actually caused by their vaping. It's possible that that was the cause, or at least part of it – but there are several alternative explanations." 282

On this occasion, *The Sun* article was updated to incorporate Professor McConway's comment, but it appeared late in the article. This more reassuring assessment is unlikely to be the impression that most readers would take away from the report, especially if they simply glanced at the headline, opening lines and brightly coloured infographic showing which flavours were the "worst offenders". And there are many instances when no such counterpoint is even included, leaving readers worried about teenage sons, daughters or grandchildren.



the results of the vast majority of scientific studies are never communicated to the general public

the misinterpretation of scientific findings is by no means limited to the science on SNP

The role of the WHO and Article 5.3

As the leading global public health agency, the WHO has a central role in reducing death and disease from smoking, and so it is in their interest to promote all possible options in fulfilment of the mission of the FCTC. Likewise, the WHO should be at the forefront of dispelling the many myths about SNP. The organisation has an excellent track record when it comes to addressing what is often dangerous misinformation about HIV/AIDS, vaccines and COVID (with the exception of suggesting that people who vape are more likely to contract the virus). 283,284,285

The universal right to health, enshrined in the WHO's founding charter, states that "the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being". This includes people who smoke. To ensure its commitment of 'leaving no one behind', the WHO and all public health agencies have a moral duty to present balanced health information, to give people agency over their own health, and the right to make informed choices.

Everyone working in tobacco control and in tobacco harm reduction wants the same outcome: an end to smoking-related death and disease. The differences arise in how best to achieve this. The fear and lack of trust that characterise many people's responses to THR are likely to be particularly acute among those who have spent their whole professional lives viewing the tobacco industry as 'the enemy'. With colleagues and peers, they have been united against a common cause for decades. And for most of the time that the FCTC has been in existence, the more 'ideological' opposition to the industry has been knitted into its implementation through the guidelines to one particular article of the Convention.

As originally formulated, Article 5.3 of the Convention encourages Parties to avoid being influenced by the industry in crafting tobacco control polices, and to be open and transparent





the WHO should be at the forefront of dispelling the many myths about SNP

the WHO and all public health agencies have a moral duty to present balanced health information

everyone working in tobacco control and in tobacco harm reduction wants the same outcome: an end to smokingrelated death and disease

the Q&A section of the WHO website about e-cigarettes, published in 2020. claims – falsely – that nicotine is harmful to health, vapes are a danger to bystanders, pose a significant risk of lung injury and threaten the brain development of teenagers

the effect of this type of misinformation – from the world's leading global public health organisation – is to undermine efforts to help people quit smoking



about dealings with the industry.²⁸⁷ In 2008, five years after the FCTC came into force, 'Guidelines for the implementation of Article 5.3' were published.²⁸⁸ In the document, the WHO set out guiding principles, the first of which is asserted as a statement of fact:

"There is a fundamental and irreconcilable conflict between the tobacco industry's interests and public health policy interests."

Operating in line with this principle, nothing that is beneficial to the tobacco industry can ever be beneficial for public health. Not even switching from the production of lethal combustible tobacco products to products that are demonstrably safer.

And so the WHO has been active in its opposition to SNP and THR. This has included the dissemination of mis- and disinformation. Among many examples, one stands out in particular, a Q&A section of the WHO website about e-cigarettes, published in 2020. It claims - falsely - that nicotine is harmful to health, vapes are a danger to bystanders, pose a significant risk of lung injury and threaten the brain development of teenagers. It also states: "E-cigarettes as consumer products have not been proven to be effective for cessation at the population level."289 This is simply untrue: the statement ignores the gold standard Cochrane Review (to name just one) that says the opposite.²⁹⁰

The WHO E-cigarette Q&A drew strong criticism when it was published. Professor Peter Hajek, Director of the Tobacco Dependence Research Unit at Queen Mary University of London, was especially scathing:

"The WHO has a history of anti-vaping activism that is damaging their reputation. This document is particularly malign. Practically all the factual statements in it are wrong. [...] Vaping does not lead young people to smoking - smoking among young people is at [an] all-time low. There is no evidence that vaping increases risk of heart disease or that [it] could have any effect at all on bystanders' health. [...] There is clear evidence that e-cigarettes help smokers quit. The authors of this document should take responsibility for using blatant misinformation that is likely to prevent smokers from switching to a much less risky alternative."291

As Professor Hajek notes, the effect of this type of misinformation - from the world's leading global public health organisation - is to undermine efforts to help people quit smoking. Persistent misinformation around SNP has prompted uncertainty among legislators about the most appropriate control regime for these products. Despite the overwhelming body of evidence demonstrating their safety relative to smoking, and their huge potential as cessation aids, our research shows that legal purchase of any SNP category is not possible for 1.7 billion people worldwide (see Chapter Four). Whereas combustible cigarettes remain legal to purchase for the entire global adult population.

The implementation of the FCTC could be adapted to incorporate harm reduction; the wording is there in Article 1d), as we have noted in Chapter Four. If the MPOWER monitoring mechanism was broadened to our proposed EMPOWERED model, incorporating 'Engage with affected communities', 'Encourage smokers to switch to SNP' and 'Deliver accurate information about safer alternatives', enforcement interventions would be balanced with a broader public health approach. This would enable adults who use risky tobacco to make informed choices about their health.292

The campaign against THR

Another important factor in the WHO's approach to SNP can be found in its funding. As we have explored in previous reports, the WHO's work on tobacco control is largely funded by Bloomberg Philanthropies and, to a lesser extent, the Gates Foundation.²⁹³ Through his philanthropic work, Michael Bloomberg has committed nearly \$1 billion to combatting tobacco use worldwide. In recent years, Bloomberg has directed hundreds of millions of dollars to public-facing anti-vaping campaigns. As Kenneth Warner, distinguished former president of the Society for Research on Nicotine and Tobacco said in an interview with Marc Gunther in 2021: "Michael Bloomberg has done great things for public health. But he is way off base on this."294

A global network of NGOs, also funded by Bloomberg, is closely allied with the WHO. These organisations are permitted to attend and observe meetings of the FCTC COP. Allied to this network are several medical associations and academic institutions, some of whom also benefit from the same funding sources, who promulgate mis- and disinformation about SNP and THR, through academic journals that appear to have 'taken sides' in the debate.²⁹⁵

In the 'Guidelines to the implementation of Article 5.3', Principle 2 states that Parties should be accountable and transparent "when dealing with the tobacco industry" whilst Principle 3 states that Parties should "require the tobacco industry and those working to further its interests to operate and act in a manner that is accountable and transparent".²⁹⁶ Transparency and accountability are vital in relation to potential corporate influence on policymaking - but it should also extend to the potential influence of philanthropic actors.

The over-interpretation of these principles has ultimately led to the suppression of free speech in the tobacco and nicotine field and about THR. A situation has been created whereby even to advocate for THR is taken as de facto support for the tobacco industry and its products. Ad hominem attacks are commonplace, on academics, health professionals and consumer advocates, who either have had, or are assumed to have had any interaction with the tobacco industry, for whatever reason, however tangentially and however long ago.

Individuals and representatives from organisations that are publicly pro-THR have been banned from speaking at certain tobacco control conferences, or had invitations abruptly withdrawn after information about their views or activities is quietly shared with conference organisers. Many THR experts are never invited to speak at tobacco control conferences, and those who advocate for THR are banned from attending certain events. Whisper campaigns have led to the abandonment of planned THR events; in February 2023, the 'THR Summit Spain 2023 Congress', saw its host organisation pull out and its cancellation just days before opening, after a media storm of accusations about its content, deemed 'favourable to electronic cigarettes'.297

Researchers working in public health and tobacco control have been warned off attending some events by their institutions. People are told that attendance at conferences which host certain THR experts, or industry scientists or representatives, could put their future careers and funding in jeopardy. This stifles the potential for learning and innovation in tobacco control and broader efforts to reduce smokingrelated disease and death - and it has a chilling effect on the very research into SNP that the WHO and others insist is needed.

The Tobacco Tactics website is run by the University of Bath's Tobacco Control Research Group with funding from Bloomberg Philanthropies among others.²⁹⁸ Described as a "knowledge exchange platform", the site's stated purpose is to detail "key issues in tobacco control, as well as focussing on the global tobacco industry and



in recent years, Bloomberg has directed hundreds of millions of dollars to public-facing anti-vaping campaigns

a global network of NGOs, also funded by Bloomberg, is closely allied with the WHO

a situation has been created whereby even to advocate for THR is taken as de facto support for the tobacco industry and its products

many THR experts are never invited to speak at tobacco control conferences, and those who advocate for THR are banned from attending certain events

early career researchers are either being warned off or are scared off working in THR by the threat that simply being associated with the field could pose to their future prospects

those connected to or interacting with it".²⁹⁹ It offers a searchable database of names and organisations deemed to be connected to or interacting with the tobacco industry – many people associated with the making of this report are 'named and shamed'. The website's 'About us' page ensures that it covers all bases:

"Being mentioned on Tobacco Tactics does not necessarily mean that the organisation or individual receives funding, monetary or in-kind, from the tobacco industry; instead we attempt to detail the nature of any link to the industry. Conversely, where there is no information on Tobacco Tactics about an organisation or individual, further research or due diligence should still be undertaken before assuming that there is no link to industry or potential conflict of interest."³⁰⁰

Bloomberg also funds the work of investigative journalists, such as those at The Bureau of Investigative Journalism (funding through Vital Strategies) and The Examination (funding from Bloomberg Philanthropies). Their journalists supply mainstream media outlets with articles that seek to discredit individuals or organisations whose support for THR is determined to be solely as a consequence of alleged or actual interactions with the tobacco industry.

While scrutiny of the tobacco and SNP industry and their actions is both necessary and important, the policing and denial of science, the *ad hominem* attacks, no-platforming and personal smears are not. Early career researchers are either being warned off or are scared off working in THR by the threat that simply being associated with the field could pose to their future prospects. This is not healthy.

Prohibition, illegal markets, fear and lack of trust

As shown earlier in the chapter, policymakers can be influenced in their decision to prohibit SNP or institute heavy restrictions on their use by a range of factors. These may include the encouragement of the WHO FCTC Secretariat and public communications from the WHO more generally. They may also include a focus on domestic matters, perhaps due to fears around youth vaping and the significant negative media and public attention this attracts. But prohibition and heavy restrictions on SNP, as well as the existence of widespread illicit markets and links to crime, all have the effect of raising fears about and lack of trust in SNP and THR even further – and can also lead to other unintended consequences.


As we noted briefly in Chapter Three, there are a variety of ways in which nicotine-containing products can be classed as illegal:

- ⇒ In some countries, all SNP are illegal, regardless of who has made them or how they have been manufactured.
- In many countries, certain categories of SNP are legal, but products made by reputable manufacturers are smuggled in to avoid paying tax and import duties. These products may be sold more cheaply than those



imported legally, potentially through more informal retail channels, such as on market stalls or by street sellers.

Counterfeit nicotine-containing products that mimic well-known products, or simply products of unknown branding can be present on any illegal market. This type of product can be unsafe in various ways. They may be poorly manufactured, have low quality or dangerous batteries, contain additives that would not pass safety standards, or contain excessively high nicotine strengths and cannot be referred to as 'safer nicotine



In the USA, where the FDA has only authorised a handful of SNP, the vape market has been flooded with illegal imported products, not necessarily unsafe, but simply cashing in on demand.³⁰⁵ Meanwhile, observers in Australia have linked the expanding presence of an illegal market in vapes with the government's prohibitionist policies. The country's restrictions on vapes are so strict they almost amount to prohibition, yet Australia has one of the highest youth vaping rates in the world. Criminal gangs control the vape market, with fire-bombings of shops, homicide, extortion and other criminal activity linked to the supply of both illicit tobacco and illegal vapes. 306

In countries where prohibition is not total, highly restrictive regulations can also have unintended consequences. As shown in Chapter Four, the tendency towards e-liquid flavour bans, which began in the USA, has now reached into other regions such as the European Union. This is a regulatory response driven by the belief that adolescent vaping is substantially driven by a wide range of flavours and the use of eye-catching names. The 2023 UK ASH Briefing, 'Addressing common myths about vaping', makes clear that a wide choice of flavours is not the main reason why young people vape.307

Flavour bans often have the effect of a proxy ban on vaping more broadly. Flavours are an essential part of the process that enables people to transition out of smoking, by ridding themselves of the taste of tobacco and finding a flavour of vape liquid that appeals to them. 308,309,310 Nevertheless, in the USA, 375 locations and seven states have banned all flavours, with most also including menthol in the ban. Only tobacco flavour is permitted.

Researchers from the Yale University School of Health analysed data from all the locations that had banned flavours to assess the impact. The headline finding was that flavour restrictions caused a fall in vape sales and a rise in cigarette sales, which the authors noted aligned "with 16 out of 18 other studies" assessing cigarette use following adoptions of a range of policies making SNP harder to access, more expensive or less appealing.311

In 2023, new restrictions were introduced in New Zealand on flavour descriptions. Labels can only describe the actual flavour of the liquid, using one or two names from a list that has nearly 60 words on it. Both flavour names and descriptors are allowed, meaning that, for example, tropical watermelon or sweet custard would be permitted.³¹²



prohibition and heavy restrictions on SNP, as well as the existence of widespread illicit markets and links to crime, all have the effect of raising fears about and lack of trust in SNP and THR

counterfeit nicotine-containing products are a problem even in countries such as the UK which have a relatively proportionate control regime

flavours are an essential part of the process that enables people to transition out of smoking, by ridding themselves of the taste of tobacco and finding a flavour of vape liquid that appeals to them

while fear and lack of trust feeds into policymakers' decisions to effect bans, bans and illegality further drive fear and lack of trust in SNP and THR among consumers

THR consumers are entitled to choice when it comes to flavours, but there may be a case for expediency as in the example of New Zealand.

So while fear and lack of trust feeds into policymakers' decisions to effect bans, bans and illegality further drive fear and lack of trust in SNP and THR among consumers. Regular consumers will know their trusted retail sources and products. But the public health imperative is to encourage current adult smokers to switch. If somebody who smokes is looking to switch, how are they to assess what products to buy and from where, when the headlines on SNP and THR are almost always bad?

Fears about and lack of trust in SNP among people who smoke

As we have argued throughout this chapter, the people who are most likely to experience negative consequences from the fear and lack of trust around SNP are those who smoke. And as we have also shown, it is not at all surprising that there is confusion about the relative safety of SNP compared to combustible cigarettes.

Studies have confirmed that repeated exposure to negative news coverage about vaping increased beliefs about harms and reduced beliefs about benefits. 313,314 A randomised controlled experiment among US adults found that viewing negative headlines about vapes "led to stronger beliefs about harms and weaker beliefs about benefits, compared with positive headlines", while "viewing conflicting headlines appeared to have a similar effect as negative headlines in lowering never users' beliefs about e-cigarette benefits, compared with positive headlines". 315



the people who are most likely to experience negative consequences from the fear and lack of trust around SNP are those who smoke

evidence from both HIC and LMIC suggests that access to SNP can reduce smoking-related mortality Perhaps unusually, the UK population not only sees negative stories in the media about vaping, but also receives advice from the National Health Service about using vaping devices to quit smoking, and news of the rollout of the government's major 'Swap to Stop' programme, through which a million free vaping starter kits will be given to people to help them quit smoking. 316,317,318 But recent research from University College London has found that harm perceptions about vaping had worsened significantly over the last decade among adults in England:

"In 2014, the most common perception was that e-cigarettes were less harmful than cigarettes. However, by June 2023, the proportion who thought e-cigarettes were less harmful had decreased by 40% and the proportion who thought they were more harmful had more than doubled. [...]. As a result, only a minority (26.7%) of adults who smoke now think e-cigarettes are less harmful than cigarettes, including only 19.0% of smokers who do not vape, who would most benefit from switching to a reduced harm product." 319

Thus fear and uncertainty about SNP are dominating the attitude of people who smoke even in the UK, where, as we showed in Chapter Three and demonstrate in our UK country profile later in this report, vaping for smoking cessation is a success story.

Evidence from both HIC and LMIC suggests that access to SNP can reduce smoking-related mortality. The scale of this reduction will depend on how quickly the transition from combustible tobacco to safer alternatives takes place. The divide has to be bridged between tobacco harm reduction, public health and 'traditional' tobacco control. Animosities must be set aside and fear redirected – as the biggest concern should be what happens if THR is not facilitated.

Listening to affected communities – people who use nicotine

Our latest estimations show that the global number of vapers increased to 114 million in 2023 (see Chapter Three). Previous estimates have put the number of heated tobacco product users at 20 million and users of snus and other smokeless products at 10 million – although given market changes, it is likely that these numbers have also increased.

Most consumers use SNP because their chosen product or products have helped them reduce their cigarette use or quit and maintain smoking cessation. In countries where legal SNP access is denied, they often have to purchase illegal and potentially dangerous counterfeit products. In response to the challenges they face, groups of consumers have come together to advocate for and counter the opposition to THR in many countries. Like those who drove the early uptake and development of vaping, today's consumer advocates are also unusual; it is rare to find groups advocating for access to a consumer product on health grounds. Many people are motivated to join a consumer advocacy campaign because they fear that losing access to their chosen product or products may lead them smoke again.

As we note in our GSTHR Briefing Paper on consumer advocacy organisations:

"Their approach and activities depend on the situation in their country and region, but they are all working to raise awareness of tobacco harm reduction. If regulatory proposals threaten to restrict access to products, it is often consumer advocates who step in to voice opposition, and to campaign for appropriate regulation."320

GSTHR research found that the majority of these groups have little or no funding and are run by volunteers.³²¹ Yet they communicate with politicians and policymakers, respond to official consultations, establish websites and social media accounts and set up communication channels with colleagues around the world. National organisations will often group with others to form more resilient regional associations.

The voice of the consumer is absent, however, from most policymaking on tobacco and nicotine at a national level, and especially at the international level. This is despite the fact that consumers are directly impacted by the regulation, control and prohibition of SNP. Consumer advocates are denied access to FCTC COP meetings, are subject to many other discriminations, and are frequently accused of being industry 'shills' simply for campaigning for product access.



most consumers use SNP because their chosen product or products have helped them reduce their cigarette use or quit and maintain smoking cessation

the voice of the consumer is absent. however, from most policymaking on tobacco and nicotine at a national level, and especially at the international level

there is no mechanism for people who use nicotine to share their experiences with international tobacco control policymakers

Barred from entry to the FCTC COP, there is no mechanism for people who use nicotine to share their experiences with international tobacco control policymakers. No consumer group has ever been invited to speak at an FCTC COP meeting. This is very different to the COP meetings for the Framework Convention on Climate Change, where a broad spectrum of civil society groups is invited to observe and participate. 322 It is also very different to how the UN system treats other affected populations.

This failure to take account of the experience of people who used to smoke, or indeed still do, is replicated in many other settings. Yet the principle of 'nothing about us without us' is well established in many countries, throughout many sectors of health and social policy. It is understood that individuals and populations affected by particular issues have their own expertise, which when taken into consideration during the policymaking process, can help deliver positive outcomes for all.

The WHO itself has recognised the value of this approach, and in April 2021, it produced a report, Nothing for us, without us, highlighting the opportunities and potential value of engaging with people to tackle non-communicable diseases (NCDs).323 The report overview states: "People living with NCDs are experts in their own right and if meaningfully engaged can be key partners and drivers in the co-creation, implementation and evaluation of NCD policies, programs, and services."324

It is a matter of huge regret that this admirable ambition is yet to influence the WHO's approach to dealing with one of the greatest contributors to non-communicable disease, premature death and morbidity.

Chapter Six: Conclusions

More than one billion people are still smoking, leading to over eight million deaths a year. A billion people could die from smoking-related causes by the end of this century. Smoking-related diseases top the list of preventable global deaths arising from non-communicable diseases. And around two-thirds of the impact of smoking occurs in low- and middle-income countries. In addition to the human cost, the economic costs of smoking-related disease are also staggering, estimated at \$2 trillion per annum.

The efforts of tobacco control, focussed on taxation and restrictions, have helped achieve reductions in smoking prevalence in some countries, particularly higher income nations. But even here, vulnerable populations are being left behind. Additional strategies are needed to drive down smoking prevalence, save lives and reduce ill health, as rapidly as possible.



smoking-related diseases top the list of preventable global deaths arising from non-communicable diseases

additional strategies are needed to drive down smoking prevalence, save lives and reduce ill health, as rapidly as possible

the development of a new range of combustion-free SNP – vapes, heated tobacco products and nicotine pouches – now offer people the opportunity to consume nicotine in a fundamentally safer way

the first review of e-cigarettes published by Public Health England in 2015 concluded that compared to smoking, e-cigarettes were relatively safe

A change of approach

Tobacco harm reduction using safer nicotine products has the potential to bring about the most dramatic global public health revolution in decades. If fully realised, it could achieve swift and significant reductions in the stark figures of death and disease caused by smoking.

One essential scientific truth is central to the approach: that the primary source of the many health problems associated with the combustible cigarette lie in the act of inhaling the smoke released when it burns. Remove that risk and we are left with the possibility of nicotine consumption being relatively safe. The development of a new range of combustion-free SNP – vapes, heated tobacco products and nicotine pouches – now offer people the opportunity to consume nicotine in a fundamentally safer way. These newer smoke-free products sit alongside longer-established products like snus, American smokeless and nicotine replacement therapy, significantly expanding the range of options.

Two decades on: 2004 to 2024

Although the first commercially viable e-cigarette was introduced in China in 2004, it took a decade before there was significant consumer uptake. Over the past two decades, other new and more established forms of SNP have proved increasingly popular with people who use nicotine. This has created challenges for various sectors, including public health, particularly tobacco control, for policymakers and regulators, and for the tobacco industry. The issue of how to identify and track the uptake of SNP – and so the progress of harm reduction – has become apparent.

An obvious starting point is the scientific evidence. The first review of e-cigarettes published by Public Health England in 2015 concluded that compared to smoking, e-cigarettes were relatively safe. This key message has remained unchanged in close to a decade. Subsequent UK updates and reviews from other medical and public health bodies around the world have supported that conclusion. There is also now a robust and growing body of evidence that the use of nicotine vapes provide an effective exit ramp from smoking, and in so doing, provide an opportunity for improved health.

Similarly favourable scientific assessments have been expressed in respect of oral products such as snus - which brings with it a wealth of epidemiological evidence about its role in reduced smoking-related morbidity and mortality from Scandinavia. And while there have been more cautious assessments in relation to heated tobacco products, these have also been shown to fall significantly lower on the spectrum of risk compared to cigarettes and other combustible tobacco products.

Product development and market growth

The relationship between product development and consumers has been an important factor in the growth of SNP use. The new nicotine industries developed a range of products consumers were willing to use, with elements of the established tobacco sector subsequently playing catch up. There has been continued growth in the range of products, with various types of nicotine pouches, snus, and a wide range of vapes and heated tobacco products now available in some markets.

Many people who were smoking have been motivated to switch to these products, on the understanding that they can continue consuming nicotine but at much lower risk to their health. Trying to determine the actual numbers of people who use SNP instead of smoking is challenging, due to the limited number of public health surveys looking at this issue, and the lack of publicly available market data. However, our research suggests that the global number of vapers has increased from 58 million in 2018 to reach an estimated 114 million in 2023. While regulatory responses to SNP may limit consumer choice in many countries, the evidence is clear: millions are substituting SNP for the cigarette.

The market data that are publicly available provide another valuable indicator particularly in countries where a rise in SNP sales has been matched by a downturn in the cigarette market. Japan, where the introduction of HTP has seen cigarette sales fall over 50% in five years, provides a striking example. No legislative or public health intervention has ever delivered such a dramatic drop in cigarette sales over such a brief period.



many people who were smoking have been motivated to switch to SNP, on the understanding that they can continue consuming nicotine but at much lower risk to their health

Several countries, including New Zealand, Norway and the UK, have witnessed a sharp drop in smoking prevalence at the same time as widespread uptake of one or more categories of SNP. Data now support the theory that, when consumers are given accurate information about the relative safety of SNP and access to affordable and suitable products, significant reductions in smoking rates will occur.

The challenges of regulation

Before the advent of SNP, the role of tobacco regulators and their legislators was relatively straightforward. Cigarettes come in a simple form. They are easy to classify and therefore regulate. The same is largely true for other combustible tobaccos. Things became more complicated when new products emerged that did not burn tobacco, but still contained nicotine.

The mistaken belief that nicotine is among the most dangerous elements in combustible tobacco persists in many sectors. It continues to affect decisions made by regulators about SNP. They also face the challenges posed by understanding any new product category. Many are simply unsure what to do.

Some major organisations, notably the WHO, have adopted a highly sceptical and prohibitionist approach. Despite the increasing weight of evidence to support THR, the WHO continues to deny any potential health benefits of



despite the increasing weight of
evidence to support THR, the WHO
continues to deny any potential health
benefits of switching from cigarettes
to SNP

the country profiles presented all provide evidence of the significant progress that can be made when people who smoke are given the opportunity to substitute cigarettes with safer products

most countries have chosen to assimilate regulations about these products into existing tobacco laws, which over time have become aligned with the recommendations of the FCTC switching from cigarettes to SNP. The organisation and its allies have sought to encourage countries to introduce regulatory frameworks at least as restrictive as those for cigarettes, and in some cases more so.

In several countries, the result is that safer products have been banned while cigarettes remain universally available. At the 2024 Conference of the Parties to the Framework Convention on Tobacco Control in Panama, however, some Parties signalled that they are uncomfortable with the current position on tobacco harm reduction.

Tobacco policy is set domestically in most countries, except in the European Union, in which countries must adopt a minimum regulatory framework. Every country has its own economic, political, social and cultural factors that help determine its individual tobacco control policies. The diversity of the challenges faced and approaches taken are revealed by the national and regional profiles within this report.

Contrasts and contradictions

In Eastern Europe and Central Asia, while smoking rates are high, there is also widespread use of an estimated fifty different varieties of the oral product nasvay. Often of unknown provenance and with unquantified health risks, nasvay use makes up a significant proportion of overall tobacco consumption in the region. In Latin America, meanwhile, there are some striking contrasts. Despite having the highest absolute number of smoking-related deaths and associated costs in the region, the government of Brazil does not appear ready to relax restrictions on vapes, having banned them way back in 2009. By contrast, Chile, which has the highest smoking prevalence and largest proportion of smoking-related deaths in Latin America, has recently introduced a comprehensive package of measures that have been specifically designed to encourage people who smoke to switch to SNP.

The four country profiles presented all provide evidence of the significant progress that can be made when people who smoke are given the opportunity to substitute cigarettes with safer products. This represents a major public health win, but notably one that has required minimal financial investment from the state.



Each of the country profiles shows a different pathway to achieving success in reducing smoking prevalence. The rise in the use of HTP in Japan had little to do with the government, apart from the fact that vapes were effectively banned under existing legislation. A non-interventionist tobacco policy allowed for the advertising of HTP as safer than smoking, and consumers responded. Snus has been available for over two hundred years in Norway, but had been overtaken by smoking in terms of popularity. A shift back towards snus use followed improvements in manufacturing techniques and evidence of its relative low risk compared to cigarettes.

Meanwhile the UK's generally supportive, public health-oriented SNP policies developed after a long history of harm reduction in drugs and the prevention of HIV/AIDS. The New Zealand government adopted a similar approach, explicitly supporting a switch from cigarettes to vapes, which has contributed to a significant reduction in smoking prevalence.

Inevitably, SNP have thrown up numerous challenges for regulators. A number of countries initially banned them but have since lifted some restrictions. Others have introduced new controls. Most, however, have chosen to assimilate regulations about these products into existing tobacco laws, which over time have become aligned with the recommendations of the Framework Convention on Tobacco Control.

Progress hindered by fear, lack of trust and misinformation

Concern about young people's use of SNP, particularly vaping, has prompted regulatory action in some countries - whether this has been supported by evidence or not. Adolescent use of vapes has also been linked in many instances to the availability of flavours, prompting some regulators to introduce flavour bans of varying specificities. The narrative on young people and flavours ignores the evidence around the important role flavours play for people quitting smoking.

The rise of cheap single-use vapes has also amplified concerns about use by young people and the environmental impact of these products, with a number of bans already in place and other countries set to follow suit. There is no doubt that these products are both affordable and easy to use. What is often overlooked, however, is that these features make them particularly well-suited to the most hard-to-reach cigarette users seeking an exit from smoking.

Various financial and economic obstacles to the uptake of SNP were to be expected. The arrival of innovative nicotine-containing products onto the market has constituted the most significant disruption to the global tobacco industry since the invention of the cigarette rolling machine. The agricultural value and export value of tobacco, as well as the domestic tobacco industry, are sizeable in some countries - competition from SNP may not be welcome. And most multinational tobacco companies have been reluctant to invest substantially in SNP, both because of the uncertain trajectories of regulatory control, and an obligation to maximise profits for investors. Combustible cigarettes remain hugely profitable for their manufacturers.

Perhaps less predictable has been the resistance of many organisations to accept the potential offered by SNP. Where research and critical analysis were needed, an infodemic of myths, misinformation and disinformation has emerged. This has been disseminated by often well-intentioned international and national NGOs, as well as some medical, academic and public health organisations. They are frequently funded by generous but misguided philanthropy from sources hostile to THR using SNP.

Some in the media have been happy to amplify more lurid stories and concerns about safer products, which often relate to the lack of trust in the legacy tobacco industry



the arrival of innovative nicotinecontaining products onto the market has constituted the most significant disruption to the global tobacco industry since the invention of the cigarette rolling machine

where research and critical analysis were needed, an infodemic of myths. misinformation and disinformation has emerged

unlike in many other areas of public health, the views and experiences of people who used to smoke and are now using SNP are rarely sought or heard

people are continuing to smoke because they have been led to believe that SNP are as dangerous as or even worse than cigarettes

over two-thirds of the world's population – in nearly 130 countries - can legally access at least one form of SNP

and its motives. Much of the professional discourse and debate around THR has now become toxic. Unlike in many other areas of public health, the views and experiences of people who used to smoke and are now using SNP are rarely sought or heard. Sometimes they are suppressed. The end result is fear and uncertainty about THR, among frontline health professionals, policymakers and – worst of all – among people who smoke. People are continuing to smoke because they have been led to believe that SNP are as dangerous as or even worse than cigarettes.

Tobacco harm reduction: into the future

Despite all the challenges, however, there are many reasons for optimism as we approach the end of this century's first quarter. The use of SNP is increasing. We have clear evidence that, where circumstances allow, people are keen to switch from smoking to safer forms of nicotine use. Our research shows that over two-thirds of the world's population – in nearly 130 countries – can legally access at least one form of SNP. The consumer base is growing, alongside evidence of the public health benefits of the substitution of SNP for smoking. These products are here to stay. And the voice of consumer advocates whose lives they have improved is getting louder.

So much more can be achieved as we look to the next twenty-five years and beyond, if the potential of harm reduction is seized. Many are already benefiting from having switched from smoking to SNP – often despite opposition or indifference from their governments and mixed messaging from health bodies. Statistical modelling demonstrates that in the coming decades, millions of people could live healthier, longer lives if SNP are substituted for smoking. If fully realised, tobacco harm reduction has the potential to rapidly reduce the global number of smokers. This would deliver one of the greatest public health gains of the 21st century.

References

- Jha, P. (2009). Avoidable global cancer deaths and total deaths from smoking. Nature Reviews Cancer, 9(9), 655-664. https://doi.org/10.1038/ nrc2703.
- Jha, P., & Peto, R. (2014). Global Effects of Smoking, of Quitting, and of Taxing Tobacco. New England Journal of Medicine, 370(1), 60-68. https://doi. org/10.1056/NEJMra1308383.
- WHO, Global Malaria Programme. Malaria deaths by world region processed by Our World in Data. (2021). Our World in Data. https:// ourworldindata.org/grapher/global-malaria-deaths-by-world-region.
- IHME, Global Burden of Disease: Number of deaths from HIV/AIDS. Global Health Data Explorer. (2024). Our World in Data. https://ourworldindata.org/ explorers/global-health?tab=chart&facet=none&Health+Area=Infectious+diseases&Indicator=HIV%2FAIDS&Metric=Number+of+deaths&Source=I HME&country=OWID WRL~CHN~ZAF~BRA~USA~GBR~IND~RWA.
- World Health Organization. Cumulative confirmed COVID-19 deaths by world region processed by Our World in Data. (2024). Our World in Data. https://ourworldindata.org/grapher/cumulative-covid-deaths-region.
- Tobacco Use. (2015, July 30). NCD Alliance. https://ncdalliance.org/why-ncds/risk-factors-prevention/tobacco-use.
- WHO. (2021a). Noncommunicable diseases. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/noncommunicablediseases.
- Shapiro, H. (2020). Burning Issues: Global State of Tobacco Harm Reduction 2020. Knowledge-Action-Change. https://gsthr.org/resources/item/ burning-issues-global-state-tobacco-harm-reduction-2020.
- Get the Sustainable Development Goals back on track. (2020). Nature, 577(7788), 7-8. https://doi.org/10.1038/d41586-019-03907-4.
- This is a 2024 projected figure extrapolated from 2018 and 2020 figures. GSTHR estimation based on WHO crude adjusted prevalence point estimate. WHO. (2019a). WHO global report on trends in prevalence of tobacco use 2000–2025, third edition. World Health Organization. https:// www.who.int/publications/i/item/who-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025-third-edition., WHO. (2021b). *WHO* global report on trends in prevalence of tobacco use 2000-2025, fourth edition (4th ed). World Health Organization. https://apps.who.int/iris/ handle/10665/348537. 2024: GSTHR projection from two sources above. For countries where only 2020 data were available values were estimated on basis of trends of tobacco use from WHO, 2021b.
- Hatsukami, D., Zeller, M., Gupta, P., Parascandola, M., & Asma, S. (2014). Smokeless tobacco and public health: A global perspective. https://stacks. cdc.gov/view/cdc/43373.
- The latest data on drug treatment in England revealed that smoking rates among those entering treatment for any form of drug use were in the range of 50%-65%. Adult substance misuse treatment statistics 2022 to 2023: Report . (2023, December 21). GOV.UK. https://www.gov.uk/ government/statistics/substance-misuse-treatment-for-adults-statistics-2022-to-2023/adult-substance-misuse-treatment-statistics-2022-to-2023-report.
- Balfour, D. J. K., Benowitz, N. L., Colby, S. M., Hatsukami, D. K., Lando, H. A., Leischow, S. J., Lerman, C., Mermelstein, R. J., Niaura, R., Perkins, K. A., Pomerleau, O. F., Rigotti, N. A., Swan, G. E., Warner, K. E., & West, R. (2021). Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health, 111(9), 1661-1672. https://doi.org/10.2105/AJPH.2021.306416.
- Trenda, E. (2024, June 27). Global: Tobacco products revenue by country 2023. Statista. https://www.statista.com/forecasts/758622/revenue-ofthe-tobacco-products-market-worldwide-by-country.
- Philip Morris International Reports 2024 Second-Quarter and First-Half Results and Raises Full Year Guidance. (2024). PMI. https:// philipmorrisinternational.gcs-web.com/static-files/8efa194a-14c1-452b-9e88-2c925d0b116f.
- Rumney, E. (2023, December 6). BAT writes down \$31.5 billion from value of U.S. cigarette brands. Reuters. https://www.reuters.com/business/ retail-consumer/bat-takes-315-bln-charge-us-cigarette-brands-2023-12-06/.
- British American Tobacco-2024 First Half Pre-Close Trading Update. (2024). BAT. https://www.bat.com/media/press-releases/_2024/june/jun-04-2024-first-half-pre-close-trading-update.
- Shahbandeh, M. (2024, February 12). Tobacco industry-Statistics & facts. Statista. https://www.statista.com/topics/1593/tobacco/.
- ¹⁹ Up in smoke: What future for tobacco jobs? (2003). International Labour Organization.
- This recent article from an Indian tobacco producers conference, where speakers complained about what they see as restrictive legislation, nevertheless shows the importance of the industry to the Indian economy: Rakesh Kumar Koul (2024). India's Tobacco Sector Calls for Pragmatic Policies. [online] Tobacco Asia. Available at: https://www.tobaccoasia.com/
- features/india%E2%80%99s-tobacco-sector-calls-for-pragmatic-policies/. Malan, D., & Hamilton, B. (2020). Contradictions and Conflicts: State ownership of tobacco companies and the WHO Framework Convention on Tobacco Control. Just Managing Consulting. https://www.smokefreeworld.org/wp-content/uploads/2020/09/Contradictions-and-Conflicts.pdf.
- ²² Tobacco Taxation. (2021, April 12). World Health Organization. https://www.who.int/teams/health-promotion/tobacco-control/economics/ taxation
- 23 Shapiro, H. (2021). Fighting the Last War. The WHO and International Tobacco Control (GSTHR Thematic Reports). Knowledge Action Change. https://gsthr.org/resources/thr-reports/fighting-the-last-war/.
- GSTHR. (2023, April). The Framework Convention on Tobacco Control (FCTC) and the Conference of the Parties (COP): An explainer (updated April 2023). Global State of Tobacco Harm Reduction. https://gsthr.org/briefing-papers/the-framework-convention-on-tobacco-control-fctc-and-theconference-of-the-parties-cop-an-explainer-updated-april-2023/
- ²⁵ MPOWER. (2022). World Health Organization. https://www.who.int/initiatives/mpower.
- 26 WHO report on the global tobacco epidemic, 2023: Protect people from tobacco smoke, (2023), World Health Organization, https://www.who.int/ publications/i/item/9789240077164.
- WHO, 2021b.
- 28 WHO. (2019b). WHO report on the global tobacco epidemic 2019. Offering help to quit tobacco use. World Health Organization. https://www.who. int/publications/i/item/WHO-NMH-PND-2019.5.
- Health experts for keeping NRT available over-the-counter to combat alarming rise in smoking rates-ET HealthWorld. (2024, January 25). ETHealthworld.Com. https://health.economictimes.indiatimes.com/news/industry/health-experts-for-keeping-nrt-available-over-the-counterto-combat-alarming-rise-in-smoking-rates/107133657.
- ³⁰ Beaglehole, R., & Bonita, R. (2022). Tobacco control: Getting to the finish line. The Lancet, 399(10338), 1865. https://doi.org/10.1016/S0140-
- GSTHR. (2022b). The right to health and the right to tobacco harm reduction (GSTHR Briefing Papers). Global State of Tobacco Harm Reduction. https://gsthr.org/briefing-papers/the-right-to-health-and-the-right-to-tobacco-harm-reduction/.
- ³² GSTHR. (2022a). What is Tobacco Harm Reduction? (GSTHR Briefing Papers). Global State of Tobacco Harm Reduction. https://gsthr.org/briefingpapers/what-is-tobacco-harm-reduction/.
- Jackson, S. E., Farrow, E., Brown, J., & Shahab, L. (2020). Is dual use of nicotine products and cigarettes associated with smoking reduction and cessation behaviours? A prospective study in England. BMJ Open, 10(3), e036055. https://doi.org/10.1136/bmjopen-2019-036055.
- Martínez, Ú., Martínez-Loredo, V., Simmons, V. N., Meltzer, L. R., Drobes, D. J., Brandon, K. O., Palmer, A. M., Eissenberg, T., Bullen, C. R., Harrell, P. T., & Brandon, T. H. (2020). How Does Smoking and Nicotine Dependence Change After Onset of Vaping? A Retrospective Analysis of Dual Users. Nicotine & Tobacco Research, 22(5), 764-770. https://doi.org/10.1093/ntr/ntz043.
- GSTHR, 2022b.
- World Health Organization. (2003). WHO Framework Convention on Tobacco Control, updated reprint 2004, 2005. World Health Organisation. https:// fctc.who.int/who-fctc/overview.

- ³⁷ Shapiro, H. (2022). The Right Side of History: The Global State of Tobacco Harm Reduction 2022 (No. 3; The Global State of Tobacco Harm Reduction). Knowledge-Action-Change. https://gsthr.org/resources/item/the-right-side-of-history:-the-global-state-of-tobacco-harm-reduction-2022.
- Beaglehole & Bonita, 2022.
 Russell, M. A. (1976). Low-tar medium-nicotine cigarettes: A new approach to safer smoking. *British Medical Journal*, 1(6023), 1430–1433. https://doi.org/10.1136/bmi.1.6023.1430.
- ³⁹ Russell, M. a. H. (1971). Cigarette smoking: Natural history of a dependence disorder. *British Journal of Medical Psychology*, 44(1), 1–16. https://doi.org/10.1111/j.2044-8341.1971.tb02141.x.
- ⁴⁰ Harding, A. (2009). Michael A H Russell. The Lancet, 374(9697), 1236. https://doi.org/10.1016/S0140-6736(09)61776-1.
- ⁴² Bates, C., & Jarvis, M. (1999). Why low tar cigarettes don't work and how the tobacco industry has fooled the smoking public. https://www.academia.edu/85888406/Why_low_tar_cigarettes_don_t_work_and_how_the_tobacco_industry_has_fooled_the_smoking_public.
- ⁴³ M. A. Russell, 1976.
- ⁴⁴ Shapiro, H. (2022). The Right Side of History: The Global State of Tobacco Harm Reduction 2022. Knowledge-Action-Change. https://gsthr.org/resources/thr-reports/the-right-side-of-history/.
- ⁴⁵ M. A. Russell, 1976.
- ⁴⁶ Institute of Medicine (US) Committee to Assess the Science Base for Tobacco Harm Reduction. (2001). Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction (K. Stratton, P. Shetty, R. Wallace, & S. Bondurant, Eds.). National Academies Press (US). http://www.ncbi.nlm.nih.gov/books/NBK222375/.
- ⁴⁷ Tobacco Advisory Group of the Royal College of Physicians. (2007). Harm reduction in nicotine addiction: Helping people who can't quit. Royal College of Physicians. https://shop.rcplondon.ac.uk/products/harm-reduction-in-nicotine-addiction-helping-people-who-cant-quit.
- ⁴⁸ Rutqvist, L. E., Curvall, M., Hassler, T., Ringberger, T., & Wahlberg, I. (2011). Swedish snus and the GothiaTek® standard. *Harm Reduction Journal*, 8(1), 11. https://doi.org/10.1186/1477-7517-8-11.
- ⁴⁹ Gothiatek standard: B(a)P. (2016, March 7). Swedish Match. https://www.swedishmatch.com/Snus-and-health/GOTHIATEK/GOTHIATEK-standard/BaP/.
- ⁵⁰ Living Conditions Surveys, tobacco habits by indicator, age, sex, observations and period. (2018). [Statistikdatabasen]. Statistics Sweden. http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__LE__LE0101__LE0101H/LE0101H25/.
- ⁵¹ European Commission. (2021). Special Eurobarometer 506: Attitudes of Europeans towards tobacco and electronic cigarettes (\$2240_506_ENG) [Data set]. European Commission. http://data.europa.eu/88u/dataset/\$2240_506_ENG.
- 52 GSTHR. (2022). What is snus and how is it used? (GSTHR Briefing Papers). Global State of Tobacco Harm Reduction. https://gsthr.org/briefing-papers/what-is-snus/.
- ⁵³ Electronic Cigarettes. Volume 508: Debated on Wednesday 7 April 2010. (2010, April 7). [Hansard]. UK Parliament. https://hansard.parliament.uk/commons/2010-04-07/debates/10040762000014/ElectronicCigarettes.
- ⁵⁴ McNeill A, Brose LS, Calder R, Hitchman SC, & McNeill A, Brose LS, Calder R, Hitchman SC. (2015). *E-cigarettes: An evidence update*. Public Health England. https://www.gov.uk/government/publications/e-cigarettes-an-evidence-update.
- ⁵⁵ McNeill A, Brose LS, Calder R, Hitchman SC, & McNeill A, Brose LS, Calder R, Hitchman SC, 2015.
- ⁵⁶ Royal College of Physicians. (2019). *Nicotine without smoke: Tobacco harm reduction* (RCP Policy: Public Health and Health Inequality). Royal College of Physicians. https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction.
- ⁵⁷ E-cigarettes and harm reduction: An evidence review. (2024). The Royal College of Physicians (RCP). https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review/.
- The statement cited forms part of a Question and Answer page on the IARC's European Code against Cancer website. The IARC is a body of the WHO, and its assessment of vaping's harm reduction potential diverges significantly from current WHO policy on THR and SNP. While the cited statement, which dates from 2014, is still accessible on the 'European Code Against Cancer' site, the page now also includes a link to a WHO information page about vaping, added in 2020. It is perhaps noteworthy that although the update states that the IARC endorses the WHO information the link is accompanied by this sentence: "The European Code against Cancer Working Group on Tobacco developed this Question and Answer but had no involvement in the development of the WHO statement."
- European Code Against Cancer-Are e-cigarettes less harmful than conventional cigarettes? (2014, updated 2020). International Agency for Research on Cancer (IARC). https://cancer-code-europe.iarc.fr/index.php/en/ecac-12-ways/tobacco/247-are-e-cigarettes-less-harmful-than-conventional-cigarettes.
- ⁵⁹ New Zealand government. (2020, September 3). *Position statement on vaping*. Ministry of Health NZ. https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/vaping-smokefree-environments-and-regulated-products/position-statement-vaping.
- ⁶⁰ Balfour, D. J. K., Benowitz, N. L., Colby, S. M., Hatsukami, D. K., Lando, H. A., Leischow, S. J., Lerman, C., Mermelstein, R. J., Niaura, R., Perkins, K. A., Pomerleau, O. F., Rigotti, N. A., Swan, G. E., Warner, K. E., & West, R. (2021). Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health, 111(9), 1661–1672. https://doi.org/10.2105/AJPH.2021.306416.
- ⁶¹ E-cigarettes and vaporisers. (2023). The Royal Australian and New Zealand College of Psychiatrists (RANZCP). https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/e-cigarettes-and-vaporisers.
- ⁶² Lindson, N., Butler, A. R., McRobbie, H., Bullen, C., Hajek, P., Begh, R., Theodoulou, A., Notley, C., Rigotti, N. A., Turner, T., Livingstone-Banks, J., Morris, T., & Hartmann-Boyce, J. (2024). Electronic cigarettes for smoking cessation. *The Cochrane Database of Systematic Reviews*, 1(1), CD010216. https://doi.org/10.1002/14651858.CD010216.pub8.
- Eslie Cantu. (2023, August 18). Largest US study of e-cigarettes shows their value as smoking cessation aid. https://hollingscancercenter.musc.edu/news/archive/2023/08/18/largest-us-study-of-ecigarettes-shows-their-value-as-smoking-cessation-aid.
- ⁶⁴ Rigotti, N. A. (2024). Electronic Cigarettes for Smoking Cessation-Have We Reached a Tipping Point? New England Journal of Medicine, 390(7), 664-665. https://doi.org/10.1056/NEJMe2314977.
- ⁶⁵ Cigarette sales halved: Heated tobacco products and the Japanese experience (Briefing Papers). (2024). Global State of Tobacco Harm Reduction (GSTHR). https://gsthr.org/resources/briefing-papers/cigarette-sales-halved-heated-tobacco-products-and-the-japanese-experience/cigarette-sales-halved-heated-tobacco-products-and-the-japanese-experience/.
- ⁶⁶ Tattan-Birch, H., Hartmann-Boyce, J., Kock, L., Simonavicius, E., Brose, L., Jackson, S., Shahab, L., & Brown, J. (2022). Heated tobacco products for smoking cessation and reducing smoking prevalence. *Cochrane Database of Systematic Reviews*, 1. https://doi.org/10.1002/14651858.CD013790. pub2.
- ⁶⁷ GSTHR. (2023). What are nicotine pouches, and how are they made? (GSTHR Briefing Papers). Global State of Tobacco Harm Reduction. https://gsthr.org/briefing-papers/what-are-nicotine-pouches/.
- ⁶⁸ Travis, N., Warner, K. E., Goniewicz, M. L., Oh, H., Ranganathan, R., Meza, R., Hartmann-Boyce, J., & Levy, D. T. (2024). The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review. *Nicotine & Tobacco Research*, ntae131. https://doi.org/10.1093/ntr/ntae131.
- ⁶⁹ Murkett, R., Rugh, M., & Ding, B. (2022). *Nicotine products relative risk assessment: An updated systematic review and meta-analysis* (9:1225). F1000Research. https://doi.org/10.12688/f1000research.26762.2.
- Wadgave, U., & Nagesh, L. (2016). Nicotine Replacement Therapy: An Overview. International Journal of Health Sciences, 10(3), 425-435.
- Hartmann-Boyce, J., McRobbie, H., Butler, A. R., Lindson, N., Bullen, C., Begh, R., Theodoulou, A., Notley, C., Rigotti, N. A., Turner, T., Fanshawe, T. R., & Hajek, P. (2022). Electronic cigarettes for smoking cessation. *Cochrane Database of Systematic Reviews*, 11. https://doi.org/10.1002/14651858. CD010216.pub7.
- ⁷² Hajek, P., Phillips-Waller, A., Przulj, D., Pesola, F., Myers Smith, K., Bisal, N., Li, J., Parrott, S., Sasieni, P., Dawkins, L., Ross, L., Goniewicz, M., Wu, Q., & McRobbie, H. J. (2019). A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. New England Journal of Medicine, 380(7), 629–637. https://doi.org/10.1056/NEJMoa1808779.
- Department of Health and Social Care & Neil O'Brien MP. (2023, April 11). Smokers urged to swap cigarettes for vapes in world first scheme [Press release]. GOV.UK. https://www.gov.uk/government/news/smokers-urged-to-swap-cigarettes-for-vapes-in-world-first-scheme.

A GLOBAL PERSPECTIVE

- 14 Etter, J.-F. (2024). An 8-year longitudinal study of long-term, continuous users of electronic cigarettes. Addictive Behaviors, 149, 107891. https:// doi.org/10.1016/j.addbeh.2023.107891.
- Shapiro, 2020.
- Handing out vapes in A&E helps smokers quit. (2024, March 27). University of East Anglia. https://www.uea.ac.uk/about/news/article/handing-outvapes-in-ae-helps-smokers-quit.
- Smoking. Risk Factor Estimation. (2020). [Global Burden of Disease (GBD)]. Institute for Health Metrics and Evaluation Health Data (IHME). https:// $www.healthdata.org/sites/default/files/files/policy_report/2022/GBD\%202020\%20methods_smoking.pdf.$
- 78 Thomson, B., Emberson, J., Lacey, B., Lewington, S., Peto, R., Jemal, A., & Islami, F. (2022). Association Between Smoking, Smoking Cessation, and Mortality by Race, Ethnicity, and Sex Among US Adults. JAMA Network Open, 5(10), e2231480. https://doi.org/10.1001/jamanetworkopen.2022.31480.
- 79 The word 'addiction' has a very confused and conflicting etymology going back to the Roman period. For a detailed discussion of the concept and how it has evolved see: Rosenthal, R. J., & Faris, S. B. (2019). The etymology and early history of 'addiction'. Addiction Research & Theory, 27(5), 437-449. https://doi.org/10.1080/16066359.2018.1543412.
- 80 Abrams, D. B., Glasser, A. M., Pearson, J. L., Villanti, A. C., Collins, L. K., & Niaura, R. S. (2018). Harm Minimization and Tobacco Control: Reframing Societal Views of Nicotine Use to Rapidly Save Lives. Annual Review of Public Health, 39(1), 193-213. https://doi.org/10.1146/annurevpublhealth-040617-013849.
- M A Russell 1976
- 82 Schumpeter, J. A. (1976). Capitalism, Socialism and Democracy (3rd, 2008th ed.). Routledge. https://doi.org/10.4324/9780203202050.
- 83 Boroujerdi, R. D. (2014). The search for creative destruction. An Excerpt from the August 7, 2013 report (Equity Research). Goldman Sachs Global Investment Research. https://www.goldmansachs.com/s/2013annualreport/assets/downloads/GMS015_07_CreativeDestruction.pdf.
- 84 Parker-Pope, T. (2001, October 2). 'Safer' Cigarettes: A History. NOVA Science Trust. https://www.pbs.org/wgbh/nova/article/safer-cigaretteshistory/.
- 85 For an overview of the 20th century search for safer ways of consuming nicotine, see our report Shapiro, H. (2022). The Right Side of History: The Global State of Tobacco Harm Reduction 2022 (No. 3; GSTHR Major Reports). Knowledge-Action-Change. https://gsthr.org/resources/thr-reports/ the-right-side-of-history/.
- 86 Dunworth, J., & Kryworuka, S. (2013). An Electronic Cigarette Timeline: A History of the Electronic Cigarette Year by Year. ECigaretteDirect. https:// www.ecigarettedirect.co.uk/ashtray-blog/2013/03/electronic-cigarette-timeline.html.
- Solomon, B. (2014, July 15). Reynolds, Lorillard Dump Blu E-Cigarettes In \$27 Billion Merger. Forbes. https://www.forbes.com/sites/ briansolomon/2014/07/15/reynolds-lorillard-dump-blu-e-cigarettes-in-27-billion-merger/.
- 88 PMI Japan. (n.d.). Retrieved 18 September 2024, from https://www.pmi.com/markets/japan/en/overview.
- 89 Cornelius, M. E. (2020). Tobacco Product Use Among Adults-United States, 2019. MMWR. Morbidity and Mortality Weekly Report, 69. https://doi. org/10.15585/mmwr.mm6946a4.
- 90 Hajek, P., Phillips-Waller, A., Przulj, D., Pesola, F., Myers Smith, K., Bisal, N., Li, J., Parrott, S., Sasieni, P., Dawkins, L., Ross, L., Goniewicz, M., Wu, Q., & McRobbie, H. J. (2019). A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. New England Journal of Medicine, 380(7), 629-637. https://doi.org/10.1056/NEJMoa1808779.
- Department of Psychology, University of Waterloo. (2024). Surveys-ITC Project. International Tobacco Control (ITC) Policy Evaluation Project. https://itcproject.org/surveys/.
- 92 Kim, S., & Selya, A. S. (2020). The Relationship Between Electronic Cigarette Use and Conventional Cigarette Smoking Is Largely Attributable to Shared Risk Factors. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, 22(7), 1123–1130. https:// doi.org/10.1093/ntr/ntz157.
- ga Martinelli, T., Candel, M. J. J. M., de Vries, H., Talhout, R., Knapen, V., van Schayck, C. P., & Nagelhout, G. E. (2023). Exploring the gateway hypothesis of e-cigarettes and tobacco: A prospective replication study among adolescents in the Netherlands and Flanders. Tobacco Control, 32(2), 170-178. https://doi.org/10.1136/tobaccocontrol-2021-056528.
- Sokol, N. A., & Feldman, J. M. (2021). High School Seniors Who Used E-Cigarettes May Have Otherwise Been Cigarette Smokers: Evidence From Monitoring the Future (United States, 2009-2018). Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, 23(11), 1958-1961. https://doi.org/10.1093/ntr/ntab102.
- Selya, A. (2024). The "Gateway" hypothesis: Evaluation of evidence and alternative explanations. Harm Reduction Journal, 21(1), 113. https://doi. org/10.1186/s12954-024-01034-6.
- 96 Shahab, L., Beard, E., & Brown, J. (2021). Association of initial e-cigarette and other tobacco product use with subsequent cigarette smoking in adolescents: A cross-sectional, matched control study. Tobacco Control, 30(2), 212-220. https://doi.org/10.1136/tobaccocontrol-2019-055283.
- Foxon, F., & Selya, A. S. (2020). Electronic cigarettes, nicotine use trends and use initiation ages among US adolescents from 1999 to 2018. Addiction, 115(12), 2369-2378. https://doi.org/10.1111/add.15099.
- 98 Meza, R., Jimenez-Mendoza, E., & Levy, D. T. (2020). Trends in Tobacco Use Among Adolescents by Grade, Sex, and Race, 1991-2019. JAMA Network Open, 3(12), e2027465. https://doi.org/10.1001/jamanetworkopen.2020.27465, pp. 1991-2019.
- Wagner, L. M., & Clifton, S. M. (2021). Modeling the public health impact of e-cigarettes on adolescents and adults. Chaos (Woodbury, N.Y.), 31(11), 113137. https://doi.org/10.1063/5.0063593.
- 100 Selya, A. S., & Foxon, F. (2021). Trends in electronic cigarette use and conventional smoking: Quantifying a possible 'diversion' effect among US adolescents. Addiction, 116(7), 1848-1858. https://doi.org/10.1111/add.15385.
- 101 Correlation between time series of market values from Euromonitor International. (2021, December 23). Passport. Euromonitor International. https://www.euromonitor.com/our-expertise/passport. and prevalence data from McNeill, A., Simonavičius, E., Brose, L., Taylor, E., East, K., Zuikova, E., Calder, R., & Robson, D. (2022). Nicotine vaping in England: An evidence update including health risks and perceptions, 2022. A report commissioned by the Office for Health Improvement and Disparities. https://www.gov.uk/government/publications/nicotine-vaping-in-england-
- 102 Correlation between time series of market values from Euromonitor International, 2021. and prevalence data from New Zealand Health Survey. (n.d.). Ministry of Health NZ. Retrieved 23 May 2023, from https://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/ surveys/new-zealand-health-survey.
- ¹⁰³ Euromonitor International, 2021.
- 104 Euromonitor International, 2021,
- 105 Egbe, C. O., Magati, P., Wanyonyi, E., Sessou, L., Owusu-Dabo, E., & Ayo-Yusuf, O. A. (2022). Landscape of tobacco control in sub-Saharan Africa. Tobacco Control, 31(2), 153-159. https://doi.org/10.1136/tobaccocontrol-2021-056540.
- 106 Crosbie, E., Defrank, V., Egbe, C. O., Ayo-Yusuf, O., & Bialous, S. (2021). Tobacco supply and demand strategies used in African countries. Bulletin of the World Health Organization, 99(7), 539-540. https://doi.org/10.2471/BLT.20.266932.
- ¹⁰⁷ Euromonitor International, 2021.
- 108 Euromonitor International, 2021.
- 109 Euromonitor International, 2021.
- ${}^{110}\textit{Monthly E-Cigarette Sales Data Brief, Issue 33.} \ (2023). \ \texttt{CDC Foundation. https://www.cdcfoundation.org/Issue33-MonthlyECigaretteSalesDataBrief} \ (2023). \ {}^{110}\textit{Monthly E-Cigarette Sales Data Brief, Issue 33.} \ (2023). \ {}^{110}\textit{Monthly E-Cigarette SalesDataBrief} \ (2023). \ {}^$ ef_9.10.2023.pdf.
- U.S. E-cigarette Sales Climbed during 2020-2022. (2023, June 22). [CDC Newsroom]. CDC. https://www.cdc.gov/media/releases/2023/p0622ecigarettes-sales.html, pp. 2020-2022.
- ¹¹² Monthly E-Cigarette Sales Data Brief, Issue 33, 2023.
- ¹¹³ U.S. E-cigarette Sales Climbed during 2020-2022, 2023.
- 114 Guide to Recycling your Vape. (n.d.). Vape Superstore. Retrieved 18 September 2024, from https://www.vapesuperstore.co.uk/pages/guide-torecycling-your-vape.

- ¹¹⁵ Upadhyay, S., Rahman, M., Johanson, G., Palmberg, L., & Ganguly, K. (2023). Heated Tobacco Products: Insights into Composition and Toxicity. *Toxics*, 17(8), 667. https://doi.org/10.3390/toxics11080667.
- 116 Euromonitor International, 2021.
- ¹¹⁷ EU seeks to ban flavours in heated tobacco products. (2022, July 1). European Tobacco Harm Reduction Advocates. https://ethra.co/news/112-eu-seeks-to-ban-flavours-in-heated-tobacco-products.
- ¹¹⁸ Rutqvist, L. E., Curvall, M., Hassler, T., Ringberger, T., & Wahlberg, I. (2011). Swedish snus and the GothiaTek® standard. *Harm Reduction Journal*, 8(1), 11. https://doi.org/10.1186/1477-7517-8-11.
- ¹¹⁹ Rutqvist, Curvall, Hassler, Ringberger, & Wahlberg, 2011.
- ¹²⁰ Jerzyński, T., & Stimson, G. V. (2023). Estimation of the global number of vapers: 82 million worldwide in 2021. *Drugs, Habits and Social Policy, ahead-of-print* (ahead-of-print). https://doi.org/10.1108/DHS-07-2022-0028.
- 121 WHO. (2021). WHO global report on trends in prevalence of tobacco use 2000–2025, fourth edition (4th ed). World Health Organization. https://apps.who.int/iris/handle/10665/348537.
- 122 European Commission. (2017). Special Eurobarometer 458: Attitudes of Europeans towards tobacco and electronic cigarettes [Data set]. https://data.europa.eu/euodp/en/data/dataset/S2146_87_1_458_ENG.
- 123 European Commission. (2021). Special Eurobarometer 506: Attitudes of Europeans towards tobacco and electronic cigarettes (\$2240_506_ENG) [Data set]. European Commission. http://data.europa.eu/88u/dataset/\$2240_506_ENG.
- ¹²⁴ European Commission. (2024). Special Eurobarometer 539: Attitudes of Europeans towards tobacco and related products [Data set]. European Commission. https://europa.eu/eurobarometer/surveys/detail/2995.
- ¹²⁵ Market and legal information in the e-cigarette and vaping sector. (2023). Tamarind Media Limited (T/A ECigIntelligence). https://ecigintelligence.com/.
- 126 Odani, S., & Tabuchi, T. (2022). Prevalence and denial of current tobacco product use: Combustible and heated tobacco products, Japan, 2022. Preventive Medicine Reports, 30, 102031. https://doi.org/10.1016/j.pmedr.2022.102031.
- 127 Barrera-Núñez, D. A., López-Olmedo, N., Zavala-Arciniega, L., Barrientos-Gutiérrez, I., & Reynales-Shigematsu, L. M. (2023). Consumo de tabaco y uso de cigarro electrónico en adolescentes y adultos mexicanos. Ensanut Continua 2022. Salud Publica De Mexico, 65, s65-s74. https://doi.org/10.21149/14830.
- ¹²⁸ Euromonitor International, 2021.
- 129 Jerzyński & Stimson, 2023.
- 130 Jerzyński & Stimson, 2023.
- ¹³¹ Lee, P. N., Abrams, D., Bachand, A., Baker, G., Black, R., Camacho, O., Curtin, G., Djurdjevic, S., Hill, A., Mendez, D., Muhammad-Kah, R. S., Murillo, J. L., Niaura, R., Pithawalla, Y. B., Poland, B., Sulsky, S., Wei, L., & Weitkunat, R. (2021). Estimating the Population Health Impact of Recently Introduced Modified Risk Tobacco Products: A Comparison of Different Approaches. Nicotine & Tobacco Research, 23(3), 426-437. https://doi.org/10.1093/ntr/ntaa102
- ¹³² Levy, D. T., Borland, R., Lindblom, E. N., Goniewicz, M. L., Meza, R., Holford, T. R., Yuan, Z., Luo, Y., O'Connor, R. J., Niaura, R., & Abrams, D. B. (2018). Potential deaths averted in USA by replacing cigarettes with e-cigarettes. *Tobacco Control*, 27(1), 18-25. https://doi.org/10.1136/tobaccocontrol-2017-053759.
- ¹³³ Levy, D. T., Borland, R., Villanti, A. C., Niaura, R., Yuan, Z., Zhang, Y., Meza, R., Holford, T. R., Fong, G. T., Cummings, K. M., & Abrams, D. B. (2017). The Application of a Decision-Theoretic Model to Estimate the Public Health Impact of Vaporized Nicotine Product Initiation in the United States. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, 19(2), 149-159. https://doi.org/10.1093/ntr/ntw158.
- ¹³⁴ Levy, D. T., Tam, J., Sanchez-Romero, L. M., Li, Y., Yuan, Z., Jeon, J., & Meza, R. (2021). Public health implications of vaping in the USA: The smoking and vaping simulation model. *Population Health Metrics*, 19, 19. https://doi.org/10.1186/s12963-021-00250-7.
- ¹³⁵ Levy, D. T., Sánchez-Romero, L. M., Li, Y., Yuan, Z., Travis, N., Jarvis, M. J., Brown, J., & McNeill, A. (2021). England SimSmoke: The impact of nicotine vaping on smoking prevalence and smoking-attributable deaths in England. Addiction (Abingdon, England), 116(5), 1196-1211. https://doi.org/10.1111/add.15269.
- Levy, D. T., Sánchez-Romero, L. M., Travis, N., Yuan, Z., Li, Y., Skolnick, S., Jeon, J., Tam, J., & Meza, R. (2021). US Nicotine Vaping Product SimSmoke Simulation Model: The Effect of Vaping and Tobacco Control Policies on Smoking Prevalence and Smoking-Attributable Deaths. *International Journal of Environmental Research and Public Health*, 18(9), 4876. https://doi.org/10.3390/ijerph18094876.
- ¹³⁷ Levy, D. T., Cadham, C. J., Yuan, Z., Li, Y., Gravely, S., & Cummings, K. M. (2023). Comparison of smoking prevalence in Canada before and after nicotine vaping product access using the SimSmoke model. *Canadian Journal of Public Health = Revue Canadianne De Sante Publique*. https://doi. org/10.17269/s41997-023-00792-3.
- ¹³⁸ Sánchez-Romero, L. M., Liber, A. C., Li, Y., Yuan, Z., Tam, J., Travis, N., Jeon, J., Issabakhsh, M., Meza, R., & Levy, D. T. (2023). The smoking and vaping model, A user-friendly model for examining the country-specific impact of nicotine VAPING product use: Application to Germany. *BMC Public Health*, 23(1), 2299. https://doi.org/10.1186/s12889-023-17152-y.
- 139 Mendez, D., & Warner, K. E. (2021). A Magic Bullet? The Potential Impact of E-Cigarettes on the Toll of Cigarette Smoking. *Nicotine & Tobacco Research*, 23(4), 654-661. https://doi.org/10.1093/ntr/ntaa160.
- ¹⁴⁰ Mzhavanadze, G., & Yanin, D. (2023). The Potential Impact of E-cigarettes on the Life-Years Lost from Conventional Smoking in the Russian Federation. *Journal of Consumer Policy*, 46(2), 253–274. https://doi.org/10.1007/s10603-023-09540-z.
- ¹⁴¹ Mzhavanadze, Giorgi. (2024). The Potential Impact of E-Cigarettes on the Life-Years Lost from Conventional Smoking in Georgia: A Replication Study. Journal of Health and Social Sciences (JHSS), 9(1). https://doi.org/10.19204/2024/THPT8.
- ¹⁴² Lives Saved: How the Swedish Model is Eliminating Smoking and Combating Smoking-Related Deaths. (2023). [Report by International and Local Tobacco Harm Reduction Experts]. Smoke-Free Sweden. https://smokefreesweden.org/lives-saved.pdf.
- ¹⁴³ Forey, B., Hamling, J., Hamling, J., Thornton, A., & Lee, P. (2011). *International Smoking Statistics (ISS): A Collection of Worldwide Data Sweden*. P.N. Lee Statistics and Computing Ltd. http://www.pnlee.co.uk/Downloads/ISS/ISS-Sweden_111024.pdf.
- 144 Användning av tobaks- och nikotinprodukter (självrapporterat) efter ålder, kön och år. Andel (procent). (n.d.). Folkhälsodata. Retrieved 18 September 2024, from http://fohm-app.folkhalsomyndigheten.se/FolkhalsodataFolkhalsodata/pxweb/sv/A_Folkhalsodata/A_Folkhalsodata_B_ HLV__aLevvanor__aagLevvanortobak/hlv1tobaald.px/.
- ¹⁴⁵ Forey, Hamling, Hamling, Thornton, & Lee, 2011.
- ¹⁴⁶ Death rate of malignant neoplasms (2018) by country and sex. (2018). [ECIR data tool]. ECIR European Cancer Inequalities Registry. https://cancer-inequalities.jrc.ec.europa.eu/data-tool-by-sex.
- ¹⁴⁷ Clarke, E., Thompson, K., Weaver, S., Thompson, J., & O'Connell, G. (2019). Snus: A compelling harm reduction alternative to cigarettes. *Harm Reduction Journal*, 16(1), 62. https://doi.org/10.1186/s12954-019-0335-1.
- ¹⁴⁸ Djurdjevic, S., Pecze, L., Weitkunat, R., Luedicke, F., Fry, J., & Lee, P. (2019). Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product. BMC Public Health, 19(1), 1411. https://doi.org/10.1186/s12889-019-7714-0.
- ¹⁴⁹ ECIS European Cancer Information System. (n.d.). Retrieved 18 September 2024, from https://ecis.jrc.ec.europa.eu/en.
- ¹⁵⁰ E-cigarettes and harm reduction: An evidence review. (2024). The Royal College of Physicians (RCP). https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review/.
- 151 Real people, real consequences: PMI's CEO Jacek Olczak warns government inaction on smoke-free products will only serve to prolong cigarettes. (2023, September 19). Philip Morris International. https://www.pmi.com/media-center/news/jacek-olczak-reuters-plus-2023-speech-real-people-real-consequences.
- ¹⁵² Tobacco Transformation Index 2022. (2023). Copyright © 2020 Idwala Research Ltd. (Company No. 12484940) All Rights Reserved. https://www.idwala.co.uk/publications/tobacco-transformation-index-2022.

- 153 PMI Integrated Report 2023. (2024). Philip Morris International. https://www.pmi.com/resources/docs/default-source/ir2023-documents/pmiintegrated-report-2023.pdf.
- 154 British American Tobacco Annual Review 2023. (2023). https://www.bat.com/ar/2023/index.html.
- 155 Reducing harm. (n.d.). British American Tobacco. Retrieved 18 September 2024, from https://www.bat.com/strategy-and-purpose/reducing-harm.
- 156 Full Year Results Announcement FY23. (2023). Imperial Brands PLC. https://www.imperialbrandsplc.com/content/dam/imperialbrands/corporate/ documents/investors/results/2023/2023-11-14-FY23-IMB-Full-Year-Results-Announcement.pdf.downloadasset.pdf.
- 157 Levy, D. T., Thirlway, F., Sweanor, D., Liber, A., Maria Sanchez-Romero, L., Meza, R., Douglas, C. E., & Michael Cummings, K. (2023). Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition. Nicotine & Tobacco Research, 25(12), 1810-1821. https://doi.org/10.1093/ntr/ntad014.
- 158 Role of the WHO FCTC in legal challenges. (n.d.). WHO FCTC. Retrieved 4 October 2024, from https://extranet.who.int/fctcapps/fctcapps/fctc/kh/ legalchallenges/role-who-fctc-legal-challenges.
- 159 World Health Organization. (2003). WHO Framework Convention on Tobacco Control, updated reprint 2004, 2005 (full text). World Health Organisation. https://apps.who.int/iris/bitstream/handle/10665/42811/9241591013.pdf;jsessionid=B3ED8F2675DC120D9C5E70F95D42F821?sequen ce=1.
- ¹⁶⁰ World Health Organization, 2003.
- 161 Tobacco: E-cigarettes. (2024, January 19). [Q&A]. WHO. https://www.who.int/news-room/questions-and-answers/item/tobacco-e-cigarettes.
- ¹⁶² World Health Organization, 2003.
- ¹⁶³ World Health Organization, 2003.
- 164 Elaboration of guidelines for implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control. (2008). Progress Report of the Working Group. Conference of the Parties to the WHO Framework Convention on Tobacco Control, Durban, South Africa. https://apps.who. int/gb/fctc/PDF/cop3/FCTC_COP3_6-en.pdf.
- 165 Resolução No 46, de 28 de Agosto de 2009. (2009, August 28). Ministério Da Saúde. Agência Nacional de Vigilância Sanitária. https://bvsms.saude. gov.br/bvs/saudelegis/anvisa/2009/res0046_28_08_2009.html.
- 166 Proteccion del Derecho al Medio Ambiente Libre de Humo de Tabaco y su Consumo, no. Decreto N° 534/009, El Presidente de la Republica actuando en Consejo de Ministros (2009). https://www.impo.com.uy/bases/decretos/534-2009.
- 187 Smoking, vaping, HTP, NRT and snus in Seychelles. (2023). Global State of Tobacco Harm Reduction. https://gsthr.org/countries/profile/syc/.
- 168 Draft guidelines for the implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control. (2010, November 18). Conference of the Parties to the WHO Framework Convention on Tobacco Control, Punta del Este, Uruguay. https://apps.who.int/gb/fctc/PDF/ cop4/FCTC_COP4_6Rev1-en.pdf.
- 169 Control and prevention of smokeless tobacco products and electronic cigarettes. (2010, September 15). Report by the Convention Secretariat. Conference of the Parties to the WHO Framework Convention on Tobacco Control, Punta del Este, Uruguay. https://apps.who.int/gb/fctc/PDF/ cop4/FCTC_COP4_12-en.pdf.
- 170 Electronic nicotine delivery systems, including electronic cigarettes: Report by the Convention Secretariat. (2012). Conference of the Parties to the WHO Framework Convention on Tobacco Control, fifth session, Seoul, Republic of Korea, 12-17 November 2012 WHO Framework Convention on Tobacco Control; WHO IRIS. https://apps.who.int/iris/handle/10665/75811.
- ¹⁷¹ Electronic nicotine delivery systems, including electronic cigarettes: Report by the Convention Secretariat, 2012.
- 172 Electronic nicotine delivery systems, including electronic cigarettes: Report by the Convention Secretariat, 2012.
- 173 WHO. (2014, September 1). Electronic nicotine delivery systems. Conference of the Parties to the WHO Framework Convention on Tobacco Control. Sixth session, Moscow, Russian Federation. https://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10Rev1-en.pdf.
- 174 WHO, 2014.
- 175 WHO, 2014.
- 176 WHO, 2014.
- 177 WHO. (2016). Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS) [Statement]. World Health Organization. https://www.who.int/fctc/cop/cop7/FCTC_COP_7_11_EN.pdf.
- 178 WHO, 2016.
- ¹⁷⁹ WHO, 2016.
- 180 WHO, 2016.
- 181 (Draft) FCTC/COP/7/A/R/2 Second report of Committee A, Conference of the Parties to the WHO Framework Convention on Tobacco Control, Seventh session. (2017, February 8). Conference of the Parties to the WHO Framework Convention on Tobacco Control, Delhi, India. https://fctc. who. int/publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-who-framework-publications/i/item/(draft)-fctc-cop-7-a-r-2-second-report-of-committee-a-conference-of-the-parties-to-the-parties-a-conference-of-the-parties-a-confereconvention-on-tobacco-control-seventh-session.
- 182 Progress report on regulatory and market developments on electronic nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS). (2018). [Report by the Convention Secretariat]. Conference of the Parties to the WHO Framework Convention on Tobacco Control. https://fctc.who.int/docs/librariesprovider12/meeting-reports/fctc_cop_8_10-en.pdf.
- 183 Beaglehole, R., & Bonita, R. (2024). Harnessing tobacco harm reduction. The Lancet, 403(10426), 512-514. https://doi.org/10.1016/S0140-6736(24)00140-5.
- 184 Robert Beaglehole. (2021, November 23). What will success look like? The E-Cigarette Summit. https://vimeo.com/649001613.
- 185 Beaglehole, R., & Bonita, R. (2022). Tobacco control: Getting to the finish line. The Lancet, 399(10338), 1865. https://doi.org/10.1016/S0140-6736(22)00835-2.
- 186 The FCTC COP10 Agenda and supporting documents: Implications for the future of tobacco harm reduction (Briefing Papers). (2023). Global State of Tobacco Harm Reduction (GSTHR). https://gsthr.org/resources/briefing-papers/the-fctc-cop10-agenda-and-supporting-documents/thefctc-cop10-agenda-and-supporting-documents-implications-for-the-future-of-tobacco-harm-reduction/.
- 187 Copwatch #COP10 summary COPWATCH: A Consumer Guide to FCTC COP. (2024, March 4). Copwatch.info. https://copwatch.info/copwatch-cop10summary/.
- 188 Interesting country statements made at #COP10 COPWATCH: A Consumer Guide to FCTC COP. (2024, February 8). Copwatch.Info. https://copwatch. info/interesting-country-statements-made-at-cop10/.
- 189 St-Kitts-and-Nevis-statement-at-COP10. (n.d.). Retrieved 4 October 2024, from https://copwatch.info/storage/2024/02/St-Kitts-and-Nevisstatement-at-COP10.png.
- ¹⁹⁰ St-Kitts-and-Nevis-statement-at-COP10, n.d.
- ¹⁹¹ The FCTC COP10 Agenda and supporting documents, 2023.
- 192 Implementation of Articles 9 and 10 of the WHO FCTC. (2023, June 21). Report by the Bureau. Conference of the Parties to the WHO Framework Convention on Tobacco Control, Panama City, Panama. https://iris.who.int/bitstream/handle/10665/377471/fctc-cop10-5-en.pdf?sequence=1.
- 193 Report of the Tenth session of the Conference of the Parties to the WHO Framework Convention on Tobacco Control. (2024). Conference of the Parties to the WHO Framework Convention on Tobacco Control. https://iris.who.int/bitstream/handle/10665/377610/fctc-cop10-26-en. pdf?sequence=1.
- 194 FCTC/COP/9/10 Challenges posed by and classification of novel and emerging tobacco products (Ninth session; Report by the Convention Secretariat). (2021). World Health Organization, Framework Convention on Tobacco Control. https://fctc.who.int/publications/i/item/fctc-cop9-10.
- 195 https://treaties.un.org/doc/source/RecentTexts/FCTC_en.pdf
- ¹⁹⁶ FCTC/COP/9/10 Challenges posed by and classification of novel and emerging tobacco products, 2021.
- 197 Philip Morris v. Public Health Agency of Sweden. (2022). Tobacco Control Laws. https://www.tobaccocontrollaws.org/litigation/decisions/philipmorris-v-public-health-agency-of-sweden.
- 198 Philip Morris GmbH v. Federal Republic of Germany. (2021). Tobacco Control Laws. https://www.tobaccocontrollaws.org/litigation/decisions/philipmorris-gmbh-v-federal-republic-of-germany.

- ¹⁹⁹ FCTC/COP/9/10 Challenges posed by and classification of novel and emerging tobacco products, 2021.
- ²⁰⁰ FCTC/COP/9/9 Comprehensive report on research and evidence on novel and emerging tobacco products, in particular heated tobacco products, in response to paragraphs 2(a)-(d) of decision FCTC/COP8(22). (2021). World Health Organization, Framework Convention on Tobacco Control. https://fctc.who.int/publications/i/item/fctc-cop9-9.
- ²⁰¹ Rossel, S. (2024, April 1). Mediocre Meeting. https://tobaccoreporter.com/2024/04/01/mediocre-meeting/.
- ²⁰² World Health Organization, 2003.
- ²⁰³ Shapiro, H. (2018). *No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018*. Knowledge-Action-Change. https://gsthr.org/resources/thr-reports/no-fire-no-smoke-global-state-tobacco-harm-reduction-2018/.
- ²⁰⁴ 200 countries: Smoking, vaping, snus, database. (n.d.). Global State of Tobacco Harm Reduction. Retrieved 4 October 2024, from https://gsthr.org/countries/.
- ²⁰⁵ Landry, R. L., Groom, A. L., Vu, T.-H. T., Stokes, A. C., Berry, K. M., Kesh, A., Hart, J. L., Walker, K. L., Giachello, A. L., Sears, C. G., McGlasson, K. L., Tompkins, L. K., Mattingly, D. T., Robertson, R. M., & Payne, T. J. (2019). The role of flavors in vaping initiation and satisfaction among U.S. adults. *Addictive Behaviors*, 99, 106077. https://doi.org/10.1016/j.addbeh.2019.106077.
- ²⁰⁶ Dauchy, E. P., & Fuss, C. (2023). Global Taxation of ENDS and ENNDS: A Cross-Country Evaluation and Recommendations for Taxation. Campaign for Tobacco-Free Kids. https://assets.tobaccofreekids.org/content/what_we_do/international_issues/Electronic-Cigarettes/Final_ENDSandENNDS_7.7.23.pdf.
- ²⁰⁷ Dauchy & Fuss, 2023.
- ²⁰⁸ Dauchy & Fuss, 2023.
- ²⁰⁹ Heated Tobacco Products Taxation & Price—Tax Burden HTP. (n.d.). Campaign for Tobacco-Free Kids. Retrieved 7 September 2024, from https://www.tobaccofreekids.org/what-we-do/global/taxation-price/tax-burden-htp.
- ²¹⁰ Heated Tobacco Products Taxation & Price—Tax Burden HTP, n.d.
- ²¹¹ Perucic, A.-M., Sandoval, R. C., Malik, S., & Morales-Zamora, G. (2022). Taxation of novel and emerging nicotine and tobacco products (HTPs, ENDS, and ENNDS) globally and in Latin America. *Revista Panamericana De Salud Publica = Pan American Journal of Public Health*, 46, e175. https://doi.org/10.26633/RPSP.2022.175.
- ²¹² Heated Tobacco Products Taxation & Price—Tax Burden HTP, n.d.
- ²¹³ Liber, A. C., Drope, J. M., & Stoklosa, M. (2017). Combustible cigarettes cost less to use than e-cigarettes: Global evidence and tax policy implications. *Tobacco Control*, 26(2), 158-163. https://doi.org/10.1136/tobaccocontrol-2015-052874.
- ²¹⁴ Liber, A. C. (2019). Heated tobacco products and combusted cigarettes: Comparing global prices and taxes. *Tobacco Control*, 28(6), 689-691. https://doi.org/10.1136/tobaccocontrol-2018-054602.
- ²¹⁵ Liber, 2019.
- ²¹⁶ Liber, Drope, & Stoklosa, 2017.
- ²¹⁷ Jakob, J., Joss, S., Meier, A., Tal, K., Schoeni, A., Marti, J., Diethelm, P., & Auer, R. (2022). The price of nicotine dependence: A comparison of the cost of nicotine across products in Switzerland, Germany, USA, Sweden, France and the UK, in 2019. *Tobacco Prevention & Cessation*, 8(November), 1–5. https://doi.org/10.18332/tpc/156052.
- ²¹⁸ Liber, 2019.
- ²¹⁹ Heated Tobacco Products Taxation & Price—Tax Burden HTP, n.d.
- ²²⁰ Heated Tobacco Products Taxation & Price—Tax Burden HTP, n.d.
- ²²¹ WHO Technical Manual on Tobacco Tax Policy and Administration. (2021). World Health Organization. https://www.who.int/publications/i/item/9789240019188.
- ²²² Yurekli, A. A. (2018). *Economics of Tobacco Taxation Toolkit*. World Bank Group. http://documents.worldbank.org/curated/en/238861522243274209/ Economics-of-Tobacco-Taxation-Toolkit.
- $^{\rm 223}$ WHO Technical Manual on Tobacco Tax Policy and Administration, 2021.
- ²²⁴ Yurekli, 2018.
- ²²⁵ Huang, J., Tauras, J., & Chaloupka, F. J. (2014). The impact of price and tobacco control policies on the demand for electronic nicotine delivery systems. *Tobacco Control*, *23 Suppl 3*(Suppl 3), iii41-47. https://doi.org/10.1136/tobaccocontrol-2013-051515.
- ²²⁶ Stoklosa, M., Drope, J., & Chaloupka, F. J. (2016). Prices and E-Cigarette Demand: Evidence From the European Union. *Nicotine & Tobacco Research*, 18(10), 1973–1980. https://doi.org/10.1093/ntr/ntw109.
- ²²⁷ Huang, J., Gwarnicki, C., Xu, X., Caraballo, R. S., Wada, R., & Chaloupka, F. J. (2018). A comprehensive examination of own- and cross-price elasticities of tobacco and nicotine replacement products in the U.S. *Preventive Medicine*, 117, 107–114. https://doi.org/10.1016/j.ypmed.2018.04.024.
- ²²⁸ Zheng, Y., Zhen, C., Dench, D., & Nonnemaker, J. M. (2017). U.S. Demand for Tobacco Products in a System Framework. *Health Economics*, 26(8), 1067–1086. https://doi.org/10.1002/hec.3384.
- ²²⁹ Cotti, C., Courtemanche, C., Maclean, J. C., Nesson, E., Pesko, M. F., & Tefft, N. W. (2022). The effects of e-cigarette taxes on e-cigarette prices and tobacco product sales: Evidence from retail panel data. *Journal of Health Economics*, 86, 102676. https://doi.org/10.1016/j.jhealeco.2022.102676.
- ²³⁰ Huang, Gwarnicki, Xu, Caraballo, Wada, & Chaloupka, 2018.
- $^{\rm 231}$ Zheng, Zhen, Dench, & Nonnemaker, 2017.
- ²³² Cotti, Courtemanche, Maclean, Nesson, Pesko, & Tefft, 2022.
- ²³³ Pesko, M. F., Courtemanche, C. J., & Maclean, J. C. (2020). The effects of traditional cigarette and e-cigarette tax rates on adult tobacco product use. *Journal of Risk and Uncertainty*, 60(3), 229-258. https://doi.org/10.1007/s11166-020-09330-9.
- ²²⁴ Kenkel, D. S., Mathios, A. D., Phillips, G. N., Suryanarayana, R., Wang, H., & Zeng, S. (2023). Fear or Knowledge The Impact of Graphic Cigarette Warnings on Tobacco Product Choices (Working Paper No. 31534). National Bureau of Economic Research. https://doi.org/10.3386/w31534.
- ²³⁵ Abouk, R., Courtemanche, C., Dave, D., Feng, B., Friedman, A. S., Maclean, J. C., Pesko, M. F., Sabia, J. J., & Safford, S. (2023). Intended and unintended effects of e-cigarette taxes on youth tobacco use. *Journal of Health Economics*, 87, 102720. https://doi.org/10.1016/j.jhealeco.2022.102720.
- ²³⁶ Chaloupka, F. J., & Tauras, J. (2022). Taxation of Emerging Tobacco Products: 2022 Update. 2020 Report Commissioned by the American Heart Association; 2022 Update Commissioned by the American Cancer Society Cancer Action Network, Inc. https://tobacconomics.org/research/taxation-of-emerging-tobacco-products-2022-update/.
- ²³⁷ Campus, B., Fafard, P., St. Pierre, J., & Hoffman, S. J. (2021). Comparing the regulation and incentivization of e-cigarettes across 97 countries. Social Science & Medicine, 291, 114187. https://doi.org/10.1016/j.socscimed.2021.114187.
- ²³⁸ VAT rates. (n.d.). GOV.UK. Retrieved 7 October 2024, from https://www.gov.uk/vat-rates.
- ²³⁹ Treloar, W. (2024, July 18). Statistics on NHS Stop Smoking Services in England. NHS England Digital. https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-nhs-stop-smoking-services-in-england.
- ²⁴⁰ Song, F., Elwell-Sutton, T., & Naughton, F. (2020). Impact of the NHS Stop Smoking Services on smoking prevalence in England: A simulation modelling evaluation. *Tobacco Control*, 29(2), 200–206. https://doi.org/10.1136/tobaccocontrol-2018-054879.
- ²⁴¹ Department of Health and Social Care & Neil O'Brien MP. (2023, April 11). Smokers urged to swap cigarettes for vapes in world first scheme [Press release]. GOV.UK. https://www.gov.uk/government/news/smokers-urged-to-swap-cigarettes-for-vapes-in-world-first-scheme.
- ²⁴² Gebreslassie, M., Galanti, M. R., Feldman, I., & Lager, A. (2023). Should Nicotine Replacement Therapy be Provided Free of Charge? A Cost-Utility Analysis in Sweden. Nicotine & Tobacco Research, 25(11), 1762-1769. https://doi.org/10.1093/ntr/ntad103.
- ²⁴³ Shapiro, H. (2018). No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018. Knowledge-Action-Change. https://gsthr.org/resources/thr-reports/no-fire-no-smoke-global-state-tobacco-harm-reduction-2018/.
- ²⁴⁴ WHO. (2016). Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS) [Statement]. World Health Organization. https://fctc.who.int/news-and-resources/publications/m/item/fctc-cop7(9)-electronic-nicotine-delivery-systems-and-electronic-nonnicotine-delivery-systems.
- ²⁴⁵ E-cigarettes and harm reduction: An evidence review. (2024). The Royal College of Physicians (RCP). https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review/.

- 246 PMI's approach to tobacco harm reduction. (n.d.). Retrieved 23 October 2024, from https://www.pmi.com/our-science/tobacco-harm-reduction. British American Tobacco-Reducing harm. (n.d.). Retrieved 23 October 2024, from https://www.bat.com/strategy-and-purpose/reducing-harm.
- ²⁴⁷ Fang, J., Lee, K., & Sejpal, N. (2016). The China National Tobacco Corporation: From domestic to global dragon? Global Public Health, 12(3), 315. https://doi.org/10.1080/17441692.2016.1241293.
- 248 King, B., Borland, R., Grande, M. L., Diaz, D., O'Connor, R., East, K., Taylor, E., Gartner, C., & Yong, H.-H. (2023). Associations between smokers' knowledge of causes of smoking harm and related beliefs and behaviors: Findings from the International Tobacco Control (ITC) Four Country Smoking and Vaping Survey. PLOS ONE, 18(10), e0292856. https://doi.org/10.1371/journal.pone.0292856.
- ²⁴⁹ Borrelli, B., & Novak, S. P. (2007). Nurses' Knowledge About the Risk of Light Cigarettes and Other Tobacco "Harm Reduction" Strategies. Nicotine & Tobacco Research, 9(6), 653-661. https://doi.org/10.1080/14622200701365202.
- 250 Steinberg, M. B., Bover Manderski, M. T., Wackowski, O. A., Singh, B., Strasser, A. A., & Delnevo, C. D. (2021). Nicotine Risk Misperception Among US Physicians. Journal of General Internal Medicine, 36(12), 3888-3890. https://doi.org/10.1007/s11606-020-06172-8.
- ²⁵¹ Doctors' Survey. (n.d.). Global Action to End Smoking. Retrieved 23 October 2024, from https://globalactiontoendsmoking.org/research/globalpolls-and-surveys/doctors-survey/.
- The Selection and Use of Essential Medicines (No. 958; WHO Technical Report Series). (2009). World Health Organization. https://www.who.int/ publications/i/item/9789241209588.
- 253 Schnoll, R. A., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F. T., Gariti, P., Wileyto, E. P., & Hitsman, B. (2015). Long-term Nicotine Replacement Therapy: A Randomized Clinical Trial. JAMA Internal Medicine, 175(4), 504. https://doi.org/10.1001/jamainternmed.2014.8313.
- 254 Royal College of Physicians. (2019). Nicotine without smoke: Tobacco harm reduction (RCP Policy: Public Health and Health Inequality). Royal College of Physicians. https://www.rcp.ac.uk/improving-care/resources/nicotine-without-smoke-tobacco-harm-reduction/.
- 255 Morphett, K., Puljević, C., Borland, R., Carter, A., Hall, W., & Gartner, C. (2021). Attitudes towards a hypothetical 'clean nicotine' product and harm reduction among smokers. International Journal of Drug Policy, 88, 103020. https://doi.org/10.1016/j.drugpo.2020.103020.
- 256 Hall, R., & Skopeliti, C. (2023, March 18). UK health expert raises alarm at vaping 'epidemic' among teenagers. The Guardian. https://www. theguardian.com/society/2023/mar/18/uk-health-expert-raises-alarm-at-epidemic-of-vaping-among-teenagers.
- The BMA urges Government to take action to stop a growing 'epidemic' of vaping. (2024, August 28). The British Medical Association Is the Trade Union and Professional Body for Doctors in the UK. https://www.bma.org.uk/bma-media-centre/the-bma-urges-government-to-take-action-tostop-a-growing-epidemic-of-vaping.
- ²⁵⁸ Chart compiled by Dr Colin Mendelsohn and reproduced with permission.
- 259 The data from Australia comes from the Australian Secondary School Alcohol and Drug survey (ASSAD), the largest national survey of adolescent substance use in Australia. The US National Youth Tobacco Survey is a cross-sectional, school-based, self-administered web-based survey of U.S. middle and high school students. ASH UK conduct an online survey for the GB data while the NHS conduct a secondary school survey for England. ASH NZ use a school-based survey. The Canadian Student Alcohol and Tobacco Survey is another school-based survey. The Canada Tobacco and Nicotine Survey targets "non-institutionalized people aged 15 years and older living in Canada's 10 provinces who do not live in collective dwellings or on reserves."
- 260 Juul E-Cigarettes: Fueling A Youth Epidemic. (n.d.). Campaign for Tobacco-Free Kids. Retrieved 23 October 2024, from https://www. tobaccofreekids.org/what-we-do/industry-watch/e-cigarettes.
- 261 Park-Lee, E., Ren, C., Cooper, M., Cornelius, M., Jamal, A., & Cullen, K. A. (2022). Tobacco Product Use Among Middle and High School Students— United States, 2022. MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7145a1.
- 262 Gentzke, A. S., Wang, T. W., Cornelius, M., Park-Lee, E., Ren, C., Sawdey, M. D., Cullen, K. A., Loretan, C., Jamal, A., & Homa, D. M. (2022). Tobacco Product Use and Associated Factors Among Middle and High School Students–National Youth Tobacco Survey, United States, 2021. Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C.: 2002), 71(5), 1-29. https://doi.org/10.15585/mmwr.ss7105a1.
- 263 Melchior, M., Nakamura, A., Bolze, C., Hausfater, F., Khoury, F. E., Mary-Krause, M., & Silva, M. A. D. (2019). Does liberalisation of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis. BMJ Open, 9(7), e025880. https://doi.org/10.1136/ bmjopen-2018-025880.
- 264 Midgette, G., & Reuter, P. (2020). Has cannabis use among youth increased after changes in its legal status? A commentary on use of Monitoring the Future for analyses of changes in state cannabis laws, Prevention Science: The Official Journal of the Society for Prevention Research, 21(1), 137. https://doi.org/10.1007/s11121-019-01068-4.
- 265 India e-cigarettes: Ban announced to prevent youth 'epidemio'. (2019, September 18). https://www.bbc.com/news/world-asia-india-49738381.
- 266 Gupte, H. A., Chatterjee, N., Mandal, G., & D'Costa, M. (2022). Adolescents and E-cigarettes in India: A Qualitative Study of Perceptions and Practices. Asian Pacific Journal of Cancer Prevention: APJCP, 23(9), 2991. https://doi.org/10.31557/APJCP.2022.23.9.2991.
- ²⁶⁷ Pan, L., Morton, J., Mbulo, L., Dean, A., & Ahluwalia, I. B. (2022). Electronic cigarette use among adults in 14 countries: A cross-sectional study. eClinicalMedicine, 47. https://doi.org/10.1016/j.eclinm.2022.101401.
- 288 Yadav, A., Singh, P. K., Yadav, N., Kaushik, R., Chandan, K., Chandra, A., Singh, S., Garg, S., Gupta, P. C., Sinha, D. N., & Mehrotra, R. (2020). Smokeless tobacco control in India: Policy review and lessons for high-burden countries. BMJ Global Health, 5(7), e002367. https://doi.org/10.1136/ bmigh-2020-002367.
- ²⁶⁹ Миронова, Л. (2023, May 10). Депутат предлагает запретить продажу вейпов в Казахстане. Bizmedia.kz. https://bizmedia.kz/2023-05-10-deputatpredlagaet-zapretit-prodazhu-vejpov-v-kazahstane/.
- ²⁷⁰ Kazakhstan. HBSC study. (n.d.). Retrieved 23 October 2024, from https://hbsc.org/network/countries/kazakhstan/.
- 271 Scheiby, K. (2023, July 24). Are disposable vapes bad for the environment? Greenpeace UK. https://www.greenpeace.org.uk/news/aredisposable-vapes-bad-for-the-environment/.
- ²⁷² Smith, L., & Sutherland, N. (2022). The environmental impact of disposable vapes. The House of Commons Library. https://researchbriefings.files. parliament.uk/documents/CDP-2022-0216/CDP-2022-0216.pdf.
- 273 Guide to Recycling your Vape. (n.d.). Vape Superstore. Retrieved 18 September 2024, from https://www.vapesuperstore.co.uk/pages/guide-torecycling-your-vape.
- 274 Vanapalli, K. R., Sharma, H. B., Anand, S., Ranjan, V. P., Singh, H., Dubey, B. K., & Mohanty, B. (2023). Cigarettes butt littering: The story of the world's most littered item from the perspective of pollution, remedial actions, and policy measures. Journal of Hazardous Materials, 453, 131387. https:// doi.org/10.1016/j.jhazmat.2023.131387.
- 275 Hajat, C., Stein, E., Selya, A., Polosa, R., Alaimo, S., Anfuso, C. D., Barbagallo, I., Basile, F., Battiato, S., Benhamou, B., Bertino, G., Bianchi, A., Biondi, A. G., Brandi, M. L., Cacciola, E., Cacciola, R. R., Cacopardo, B. S., Calogero, A. E., Cambria, M. T., ... The CoEHAR study group. (2022). Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research. Internal and Emergency Medicine, 17(3), 887-909. https://doi. org/10.1007/s11739-022-02967-1.
 - O'Donnell, J. (n.d.). A study claimed vaping doubles risk for heart attacks. It's been retracted for being 'unreliable'. USA TODAY. Retrieved 23 October 2024, from https://www.usatoday.com/story/news/health/2020/02/20/nyu-scientists-others-call-taxpayer-funded-ucsf-vaping-studyprobe/4805323002/.
 - Adlin, B. (2023, July 21). Journal Retracts Study That Linked Vaping to Liver Disease. Filter. https://filtermag.org/vaping-liver-disease-studyretracted/.
- 276 Bhatta, D. N., & Glantz, S. A. (2019). Electronic Cigarette Use and Myocardial Infarction Among Adults in the US Population Assessment of Tobacco and Health. Journal of the American Heart Association, 8(12), e012317. https://doi.org/10.1161/JAHA.119.012317.
- ²⁷⁷ Bates, C. (2023, January 2). Bad Science. *Tobacco Reporter*. https://tobaccoreporter.com/2023/01/02/bad-science/.
- The full version of this text can be accessed at: https://tobaccoreporter.com/2023/01/02/bad-science/ For more, visit The Counterfactual. https://clivebates.com/
- 279 Chalmers, V. (2024, April 29). Vaping teens risking metal exposure 'linked to brain damage'-Worst flavours. The Sun. https://www.thesun.co.uk/ health/27612827/vaping-teens-toxic-metal-brain-damage-worst-flavours-revealed/.

- ²⁸⁰ Kochvar, A., Hao, G., & Dai, H. D. (2024). Biomarkers of metal exposure in adolescent e-cigarette users: Correlations with vaping frequency and flavouring. *Tobacco Control*. https://doi.org/10.1136/tc-2023-058554.
- 281 Science Media Centre. (n.d.). The Science Media Centre. Retrieved 23 October 2024, from https://www.sciencemediacentre.org/about-us/.
- ²⁸² Expert reaction to observational study of lead and uranium levels in urine of teen vapers. (2024, April 29). Science Media Centre. https://www.sciencemediacentre.org/expert-reaction-to-observational-study-of-lead-and-uranium-levels-in-urine-of-teen-vapers/.
- 283 HIV and AIDS. (2024, July 30). [Q&A]. World Health Organization. https://www.who.int/news-room/questions-and-answers/item/hiv-aids.
- ²⁸⁴ Vaccines and immunization: Myths and misconceptions. (2020, October 19). [Q&A]. World Health Organization. https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-myths-and-misconceptions.
- ²⁸⁵ Coronavirus disease (COVID-19): Tobacco. (2022, May 25). [Q&A]. World Health Organization. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-tobacco.
- ²⁸⁶ Constitution of the World Health Organization. (n.d.). World Health Organization. Retrieved 31 May 2022, from https://www.who.int/about/governance/constitution.
- ²⁸⁷ World Health Organization. (2003). WHO Framework Convention on Tobacco Control, updated reprint 2004, 2005 (full text). World Health Organisation. https://iris.who.int/bitstream/handle/10665/42811/9241591013.pdf.
- ²⁸⁸ WHO Framework Convention on Tobacco Control. (2013). *Guidelines for implementation of Article 5.3*. https://fctc.who.int/publications/m/item/guidelines-for-implementation-of-article-5.3.
- Tobacco: E-cigarettes. (2024, January 19). [Q&A]. WHO. https://www.who.int/news-room/questions-and-answers/item/tobacco-e-cigarettes.
- ²⁹⁰ Lindson, N., Butler, A. R., McRobbie, H., Bullen, C., Hajek, P., Begh, R., Theodoulou, A., Notley, C., Rigotti, N. A., Turner, T., Livingstone-Banks, J., Morris, T., & Hartmann-Boyce, J. (2024). Electronic cigarettes for smoking cessation. *The Cochrane Database of Systematic Reviews*, 1(1), CD010216. https://doi.org/10.1002/14651858.CD010216.pub8.
- ²⁹¹ Expert reaction to World Health Organisation Q&A on electronic cigarettes. (2020, January 22). Science Media Centre. https://www.sciencemediacentre.org/expert-reaction-to-world-health-organisation-qa-on-electronic-cigarettes/.
- 292 For more on the GSTHR's proposed expansion of the MPOWER framework to the EMPOWERED framework, see Chapter One.
- ²⁸³ Shapiro, H. (2022). *The Right Side of History: The Global State of Tobacco Harm Reduction 2022* (No. 3; GSTHR Major Reports). Knowledge-Action-Change. https://gsthr.org/resources/thr-reports/the-right-side-of-history/.
- ²⁹⁴ Gunther, M. (2021, March 23). *Bloomberg's Millions Funded an Effective Campaign Against Vaping. Could It Do More Harm Than Good?* The Chronicle of Philanthropy. https://www.philanthropy.com/article/bloombergs-millions-funded-an-effective-campaign-against-vaping-could-it-do-more-harm-than-good.
- ²⁹⁵ For more information, see Shapiro, H. (2020). *Burning Issues: Global State of Tobacco Harm Reduction 2020. Chapter 5 Project fear: the war against nicotine*. Knowledge-Action-Change. https://gsthr.org/reports/burning-issues-2020/chapter-5/.
- ²⁹⁶ WHO Framework Convention on Tobacco Control, 2013.
- ²⁹⁷ Güell, O. (2023, February 12). Sanidad y la OMS ponen en jaque un gran congreso favorable a los cigarrillos electrónicos previsto en Madrid. El País. https://elpais.com/sociedad/2023-02-12/sanidad-y-la-oms-ponen-en-jaque-un-gran-congreso-favorable-a-los-cigarrillos-electronicos-previsto-en-madrid.html.
- ²⁹⁸ Tobacco Tactics. (n.d.). Tobacco Tactics. Retrieved 23 October 2024, from https://www.tobaccotactics.org/.
- ²⁹⁹ About Us. (n.d.). Tobacco Tactics. Retrieved 23 October 2024, from https://www.tobaccotactics.org/about/.
- 300 About Us, n.d
- ³⁰¹ See page 17, 'Our supporters': *TBIJ Annual Report 2021*. (n.d.). The Bureau of Investigative Journalism. Retrieved 23 October 2024, from https://s3.documentcloud.org/documents/23317837/annual-report-2021-finaldocx.pdf.
- 302 Allsop, J. (2023, September 6). *Q&A: Ben Hallman on the launch of The Examination*. Columbia Journalism Review. https://www.cjr.org/the_media_today/qa-ben-hallman-on-the-launch-of-the-examination.php.
- 303 Mayer, M. (2022, August 25). *Up to 60% of disposable vapes in the UK are illicit*. Tobacco Journal International. https://www.tobaccojournal.com/news/up-to-60-of-disposable-vapes-in-the-uk-are-illicit/.
- ³⁰⁴ Vaping: Trading standards detect rise in counterfeit vapes at Channel ports. (2022, December 27). BBC News. https://www.bbc.com/news/uk-england-kent-64052441.
- ³⁰⁵ Jewett, C. (2023, October 10). Illicit Vapes and E-Cigarettes Flood Stores as F.D.A. Struggles to Combat Imports-The New York Times. *The New York Times*. https://www.nytimes.com/2023/10/10/health/illegal-vapes-ecigarettes-fda.html#after-top.
- ³⁰⁶ Bright, D., & Martin, J. (2024, March 12). Australia's restrictive vaping and tobacco policies are fuelling a lucrative and dangerous black market. The Conversation. http://theconversation.com/australias-restrictive-vaping-and-tobacco-policies-are-fuelling-a-lucrative-and-dangerous-black-market-225279.
- ³⁰⁷ Addressing common myths about vaping: Putting the evidence in context. (2023). Action on Smoking and Health (ASH). https://ash.org.uk/resources/view/addressing-common-myths-about-vaping-putting-the-evidence-in-context.
- ³⁰⁸ Gendall, P., & Hoek, J. (2021). Role of flavours in vaping uptake and cessation among New Zealand smokers and non-smokers: A cross-sectional study. *Tobacco Control*, *30*(1), 108-110. https://doi.org/10.1136/tobaccocontrol-2019-055469.
- 309 Friedman, A. S. (2021). A Difference-in-Differences Analysis of Youth Smoking and a Ban on Sales of Flavored Tobacco Products in San Francisco, California. *JAMA Pediatrics*, 175(8), 863–865. https://doi.org/10.1001/jamapediatrics.2021.0922.
- ³¹⁰ Khouja, J. N., Dyer, M. L., Havill, M. A., Dockrell, M. J., Munafò, M. R., & Attwood, A. S. (2024). Exploring the opinions and potential impact of unflavoured e-liquid on smoking cessation among people who smoke and smoking relapse among people who previously smoked and now use e-cigarettes: Findings from a UK-based mixed methods study. *Harm Reduction Journal*, *21*(1), 90. https://doi.org/10.1186/s12954-024-01003-z.
- ³¹¹ Friedman, A., Liber, A. C., Crippen, A., & Pesko, M. (2024). *E-cigarette Flavor Restrictions' Effects on Tobacco Product Sales* (SSRN Scholarly Paper No. 4586701). Social Science Research Network. https://doi.org/10.2139/ssrn.4586701.
- ³¹² Smokefree Environments and Regulated Products Amendment Regulations 2023 (SL 2023/201) (as at 06 March 2024), New Zealand Legislation (2023), https://legislation.govt.nz/regulation/public/2023/0201/latest/whole.html#LMS878912.
- ³¹³ Tan, A. S., Lee, C., Nagler, R. H., & Bigman, C. A. (2017). To Vape or Not to Vape? Effects of Exposure to Conflicting News Headlines on Beliefs about Harms and Benefits of Electronic Cigarette Use: Results From a Randomized Controlled Experiment. *Preventive Medicine*, 105, 97. https://doi.org/10.1016/j.ypmed.2017.08.024.
- ³¹⁴ Morgan, J. C., Silver, N., & Cappella, J. N. (2021). How did beliefs and perceptions about e-cigarettes change after national news coverage of the EVALI outbreak? *PloS One*, 16(4), e0250908. https://doi.org/10.1371/journal.pone.0250908.
- 315 Tan, Lee, Nagler, & Bigman, 2017.
- ³¹⁶ Using e-cigarettes to stop smoking. (2021, November 24). NHS UK. https://www.nhs.uk/live-well/quit-smoking/using-e-cigarettes-to-stop-smoking/
- ³¹⁷ Smokers offered free support so they can Swap to Stop. (2024, September 24). City of Wolverhampton Council. https://www.wolverhampton.gov. uk/news/smokers-offered-free-support-so-they-can-swap-stop.
- ³¹⁸ Jones, A. (2024, July 24). Smokers urged to take up free vape starter kit initiative. Dorset Echo. https://www.dorsetecho.co.uk/news/24469884. dorset-council-swap2stop-vape-starter-kit-scheme/.
- ³¹⁹ Jackson, S. E., Tattan-Birch, H., East, K., Cox, S., Shahab, L., & Brown, J. (2024). Trends in Harm Perceptions of E-Cigarettes vs Cigarettes Among Adults Who Smoke in England, 2014-2023. *JAMA Network Open*, 7(2), e240582. https://doi.org/10.1001/jamanetworkopen.2024.0582.
- 320 Tobacco harm reduction consumer advocacy organisations (Briefing Papers). (2023). Global State of Tobacco Harm Reduction (GSTHR). https://gsthr.org/resources/briefing-papers/consumer-advocacy-organisations/consumer-advocacy-organisations/.
- ³²¹ Jerzyński, T., Harding, J., & Stimson, G. V. (2023). Global survey of consumer organizations advocating for safer nicotine products. *Public Health Challenges*, 2(1), e58. https://doi.org/10.1002/puh2.58.
- 322 Tobacco harm reduction consumer advocacy organisations, 2023.

SECTION ONE

A GLOBAL PERSPECTIVE 111



Nothing for us, without us: Opportunities for meaningful engagement of people living with NCDs. (2021). [Meeting report]. World Health Organization. https://www.who.int/publications/i/item/nothing-for-us-without-us-opportunities-for-meaningful-engagement-of-people-livingwith-ncds.

³²⁴ Nothing for us, without us, 2021.



GSTHR.ORG